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I    — „-T . Abstr a c t
In this thesis is presented a description of studies concerning the molecular modelling 
and biological evaluation of a set of novel antiviral agents for the helicase and 
polymerase proteins of Flaviviridae.
Viruses in this family are enveloped, have positive-sense RNA and are responsible for 
a variety of life threatening diseases. To date neither specific antiviral treatments exist 
nor are there any vaccines available for Flaviviridae infection. Thus there is an urgent 
need for new therapies.
The ultimate aim of this project was to design a coordinated in  silico & in  vitro 
protocol for the design and evaluation of novel Fla viviridae inhibitors.
That was achieved initially by establishing the three-dimensional structures of 
various Flaviviridae members by homology-based molecular modelling. In 
continuation, a set of small compound libraries was designed using a de novo 
structure-based drug design approach. Those compounds were screened in silico with 
the aid of molecular docking and a set of scoring algorithms. The best candidates were 
chosen to be chemically synthesised (not part of this thesis).
The genes of Hepatitis C and Dengue helicases as well as the Dengue NS3 domain 
(helicase and protease) were cloned in expression vectors and the proteins were 
produced and purified.
A novel biological assay was then established for the Hepatitis C helicase in order to 
evaluate the potency of the designed inhibitors in vitro. An attempt was finally made 
to feedback the computer model using the biological activity data of those 
compounds, in order to improve the cooperation levels between the in  silico and the 
in  vitro parts of this research.
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Chapter 1. Introduction
1.1 Flaviviridae.
Flaviviridae is a family of viruses that infect vertebrates m. Virions of the 
flaviviridae family are enveloped and slightly pleomorphic during their life cycle. 
They are spherical in shape and usually 40-60 nm in diameter. Their nucleocapsids 
are isometric and sometimes penetrated by stain. The usual size of the 
nucleocapsids is 25-30 nm in diameter and they have polyhedral symmetry [2].
Flaviviridae consists of three characterised genera and the unclassified ones [3]. The 
main representatives of each family are summarised below (Figure 1.1).
Flavivirus
Yellow fever virus [YFV] 
Dengue fever virus [DENV] 
Japanese encephalitis virus [JEV] 
Tick-borne encephalitis virus [TBEV]
s  X
Pestivirus
Bovine viral diarrhoea virus [BVDV] 
Classical swine fever virus [CSFV] 
Border disease virus [BDV]
Flaviviridae ^ ) y
\  /
Hepacivinis
hepatitis C virus [HCV]
Unclassified
Hepatitis G virus [HGV]
Figure 1.1. The Three genera that constitute the viral family of Flaviviridae. 
Hepatitis C virus was recently discriminated from the rest of the Flaviviridae, due 
to its distinct properties and clinical manifestations. More details about the most 
representative members of each family can be found in Appendices 1.1 to 1.4.
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It is remarkable that even though the above viruses are separated to different 
genera, and they do not have common biological properties and do not show 
serological cross-reactivity, they manage to retain high similarity in the 
morphology of the virion, the organisation of the viral genome, and the estimated 
life cycles and replication patterns that they follow w.
1.2 Epidemics of Flaviviridae
More than 170 million people worldwide are currently chronically infected with 
the Hepatitis C virus pj. They are all considered to be at risk of developing cirrhosis 
and some of them will develop liver cancer. Hepatitis C has spread all over the 
world and for every person who has the aids virus, 4 have the Hepatitis C Virus. 
Today, hepatitis C causes ten thousand deaths per year and is the main cause for 
more than half of the four thousand liver transplantations that are performed 
annually [6].
Infections that mosquitoes carry or more generally arthropod-borne flaviviridae 
have reached epidemic dimensions in some parts of the world. Dengue fever 
infects 50 million people per year in central Africa. According to the World 
Health Organisation (WHO) there are 6.5 billion inhabitants on this planet that 
live in areas of high risk of acquiring dengue. For example only for 2006 the 
Philippines reported 197 deaths and 14,738 cases of dengue fever [7]. Indonesia’s
Dimitrios Vlachakis, PhD 2006 14
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Dengue deaths reached 634 and Malaysia has already confirmed 74 deaths due to 
Dengue virus in the first 9 months. In Thailand more than 32,000 Thais have been 
infected with dengue fever and currently Singapore is going through its worst 
dengue fever outbreak ever on record, since the officially reported Dengue cases 
are nearing 11,000 m.
According to the WHO of South-East Asia since November 10*h, 2005, a total of 
5737 cases of Japanese Encephalitis with 1334 deaths (fatality rate of 23.3%) have 
been reported from Uttar in India since the outbreak started in July 2005. 
Moreover, since the 2nd of January 2006, a total of 2824 individuals have been 
infected with Japanese Encephalitis, 316 of these infections have already resulted 
in deaths (fatality rate of 11.2%). The Government in despair has employed both 
anti-larval and anti-adult measures by distributing 200,000 mosquito nets. The 
government after evaluating the situation decided to establish a law, by which all 
children between the ages of 1-12 years must be vaccinated and immunised 
against Japanese Encephalitis. The law will take action in January 2007, in schools 
and kindergartens [9].
West Nile Virus (WNV) first hit New York with 77 deaths in 1999. Moreover, the 
United States were alarmed and action was taken to stop the virus from spreading. 
But this year West Nile virus is again on the front covers of the newspapers. This 
year WNV has hit Illinois harder than any other state, with 399 cases so far, 21 of 
which resulted in death. The humid and full of swamps Louisiana comes second 
with 11 deaths in 2006 no].
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Farming and agriculture have both seriously suffered in the past from the impact 
that pestiviruses had on livestock. Many economies depend on primary production 
that comes from farming and agriculture and as a result most of these countries 
take preventative action against Pestiviruses [11-12].
Disproportionaly to the severity of an infection with almost all members of 
Flaviviridae, no specific antiviral therapy is available today. [13-14-15-16]
1.3.1 Hepaciviruses
Envelope Glycoprotein 
El
• • tapsid Protein
C
• • • Nudek Acid
• • * Envelope Lipid
••Envelope Glycoprotein 
12
FULL VIEW CUT-A-WAY
Figure 1.2. A model of the Human Hepatitis C Virus [in.
Before 1989, when the HCV agent was identified (Figure 1.2), all HCV infections 
were referred to as non-A, non-B hepatitis [isj. According to the World’s Health 
Organization more than 3% of the world's population is currently infected with 
HCV [i9]. Convert that in numbers and almost 170 million people are chronic
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carriers of the Hepatitis C virus (Figure 1.3) [20]. Without exceptions, they all 
belong to the high risk group for developing initially liver cirrhosis and potentially 
at a later stage, liver cancer [211. Statistics reveal that a great portion of the HCV 
carriers are using or have used in the past drugs intravenously. Another large 
portion of HCV carriers are those who needed blood transfusion at some stage in 
their life [22]. The latter is not a problem anymore in developed countries after the 
law for blood donor screening for HCV was introduced. The HCV infection of 
post-transfusion patients is under control and has eclipsed in the last few years. 
Other routes of transmission are needles, body piercing, tattooing, scarification 
and circumcision in some countries [23]. Still there is always a number of cases 
where the cause of the infection cannot be identified.
Upon infection with HCV the acute phase will follow. Twenty days later the 
copies of the Hepatitis C virus have already reached high levels that allow 
biochemists to detect the viral RNA. It is then that the first symptoms of the 
disease will become apparent [24]., although in some cases, the infection could be 
asymptomatic. Nine in ten acutely infected patients will develop chronic HCV 
infection [25] and eventually liver cirrhosis in 40% of the patients. [26].
If the transmission rate of the HCV infection remains as it is today, it is estimated 
that the number of patients with chronic hepatitis C will rise dramatically in the 
next ten years. Today, for example, the number of HCV victims only in the USA is 
estimated to be 8,800 annually. Statistics reveal that this number will rise to 
35,000 in 3 year’s time im.
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Hepatitis G virus (HGV) infections have not been so extensively studied as HCV 
infection. It has been found though that the GB viruses (GBV-A, GBV-B, and 
GBV-C) are related phylogenetically to the Hepatitis C virus. Humans are the 
natural host for GBV-C, whereas tamarins are the natural hosts for GBV-A and 
GBV-B. GBV-C is transmitted in a pattern similar to HCV and is quite often found 
in co-infection with HCV [28].
Figure 1.3. The world prevalence of the HCV infection per country
Anti HCV Prevalence
Red >5% High
1.1-5% Intermediate
Green 0 .2 -1% Low
Orange <0.1% Very Low
White Unknown
(Adapted from WHO, 1995 [29])
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1.3.2 Flaviviruses
Up to date the genera of flaviviruses 
counts more than seventy members in its 
ranks. Many of them are very dangerous 
human pathogens po]. Human flaviviruses 
are transmitted primarily with ticks and 
mosquitoes. This is making it very hard 
to deal with the disease, especially at 
some parts of the world, where 
eliminating mosquitoes is not possible
[31].
According to phylogenetic data, there 
are 72 species of flaviviruses, which have 
been further sub-divided into 14 groups. 
Those groups have been characterised 
and grouped into 3 main categories [32]. 
First is the mosquito-borne category,
Figure 1.4. The spread of the Dengue 
Virus from the 50’s until today. Even 
highly-developed areas of the planet are 
under threat (USA-EU).
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second is the tick-borne, and the final category is the no-vector one. Flaviviruses 
that affect humans are grouped in the first two categories [33]. A very dangerous 
and representative member of the Flaviviruses genera is the Yellow Fever Virus 
(YFV). Even though there is available vaccination against YFV, the fatality rates 
are very high [34].. YFV causes hemorrhagic fever upon infection and has a 
mortality rate that reaches fifty percent worldwide [34].
Dengue and dengue hemorrhagic fever (DHF) are caused by infection with one of 
four antigenically distinct, virus serotypes (DEN-1, DEN-2, DEN-3, and DEN4) [35]. 
Once infected with one of these serotypes, the individual develops specific 
immunity. However, cross-immunity does not develop. It is theoretically possible, 
therefore, for an individual to be infected four times, each time with a different 
serotype [35]. Dengue is mostly seen in tropical urban areas. As with other members 
of the Flaviviridae family, the virus is transmitted through mosquito bites, 
specifically Aedes aegypti, a domestic, day-biting mosquito that prefers to feed on 
humans [35]. Dengue is the most important mosquito-bome viral disease, affecting 
humans with a distribution comparable with that of malaria. Approximately 2.5 
billion people are living in areas at risk for epidemic transmission [36]. Tens of 
millions of cases of dengue fever occur annually along with up to hundreds of 
thousands of cases of DHF (Figure 1.4). DHF is the most serious manifestation of 
the disease, caused by an immunologic reaction that occurs for the most part in 
individuals already sensitized to the disease, either actively through infection or 
passively in infants through placental transfer of immunoglobulin from mother to
Dimitrios Vlachakis, PhD 2006 20
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child [37]. Initially, DHF appears the same as dengue but after several days the 
patient deteriorates with prostration, restlessness, signs of circulatory collapse 
(diaphoresis, cold extremities, dyspnea, circumoral and peripheral cyanosis, and 
hemorrhagic manifestations) [38]. Available laboratory tests cannot identify who 
will ultimately develop this manifestation [39].
Back in August 1999 an encephalitis outbreak in New York claimed the lives of 6 
humans, after 77 officially reported cases of infection m . Initially the outbreak was 
characterised serologically as St. Louis encephalitis virus. Further studies and 
sequence analysis revealed that the virus had higher similarity with the West Nile 
virus. West Nile virus is a mosquito-bome vims found most commonly in Africa, 
France, India, Indonesia, the Middle East, and Soviet countries [4i]. In 1999, a 
West-Nile-like vims was identified in patients living in the Northeast United 
States. The bird is the primary host and the principal vector is Culex univittatus [42] 
However, other mosquitoes are known to carry the vims, including Culex pipiens, 
Culex antennatus, and Culex tritaeniorhynchus (Asia). Other animal reservoirs are 
not part of the virus’s normal life cycle [43]. West Nile fever is common in the 
Middle East with most individuals exposed as children. Children experience a 
nondescript viral illness with fever that is rarely diagnosed. Neighbouring Israel 
also experiences infection although there, it is more likely to be the young adult 
than the child who becomes infected. Spread occurs primarily in the summer 
months when the mosquito population increases [44].
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Finally, another very important member of the Flavivirus genus is Japanese 
Encephalitis Virus (JEV) [45]. JEV is the major cause of viral encephalitis worldwide. 
Almost fifty thousand infections happen in Asia every year. JEV has a very high 
mortality rate that reaches thirty percent. Another thirty percent of the infected 
patients will develop long-lasting neurological conditions [46-t7].
Dimitrios Vlachakis, PhD 2006 22
Chapter 1. Introduction
1.3.3 Pestiviruses
Pestiviruses are mainly viruses that affect animals. The most representative 
members of the Pestivirus genera are the Classical Swine Fever Virus (CSFV), 
Bovine Viral Diarrhoea Virus (BVDV) and Border Diarrhoea Virus (BDV) [48]. 
There are two different routes of infection known today [49], the first is the nasal 
route and the second is the transplacental route. The transplacental route is very 
dangerous to livestock, since it retains the infection into the livestock and poses a 
constant thread to the rest of the animals. These viruses cause severe disease that 
will lead to death, but before that happens, it is very easy to cross species, infect 
and cause a milder version of the same disease to the other hosts [50-51-52]. Bovine 
Diarrhoea Virus causes a severe mucosal disease in cattle. Other species, such as 
swine and various ruminants have been found to be susceptible to the virus [53-54]. 
There are cytopathic and non-cytopathic biotypes according to their proliferation 
patterns in cell culture. Infection with BVDV has high morbidity and low 
mortality rates [55]. This mild disease is marked by ulceration of the nose, mouth, 
and gastrointestinal mucosa, which causes the virus to spread quickly because of 
continuous salivation, nasal discharge, coughing, or diarrhoea [56]. The major 
organs that the viruses attack and use for their replication are the lymphoid 
tissues, epithelial and all major lymphocyte cells. It has also been found that cells 
of the gastrointestinal tract, glands, and neurons can provide the host that viruses
Dimitrios Vlachakis, PhD 2006 23
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need to replicate [57 58]. Changing from the primary infecting non-cytopathic strain 
(or biotype) into the cytopathic strain is closely related to the mucosal disease. 
There are two scenarios to describe this conversion. The first one is that an 
insertion appears in a cleavage site in the NS2-3 protein. The second scenario is 
that there is duplication of the NS2-3 gene. As a result the NS3 protein will be 
expressed instead of the NS2-3 gene [59-60-61-62-63].
Humans are affected from Pestiviruses in an indirect way. Many countries base 
their economies on agriculture and farming. A Pestivirus infection can cause great 
damage to economies and as a result, especially in countries with weak economies, 
suffering to people m . The economic losses upon BVDV infection depends on the 
size of the epidemic [65].
CSFV or hog cholera virus is another important and extremely contagious 
pathogen of swine [66]. CSFV is transmitted by aerosols, clothes and direct contact 
[67-68]. This virus too, has shown in the past that it can lead to great economic losses 
[69]. Sheep and goat BDV will develop in a mild clinical disease that will then be 
followed by an acute postnatal infection m . Following the behaviours of BVDV 
and CSFV, BDV too, can be sub-divided into non-cytopathic and cytopathic 
biotypes. Here the cytopathic version is due to the production of the NS3 non- 
structural domain instead of the NS2-3 protein [7ij.
Upon pestivirus infection, the infected animal is isolated and slaughtered, which 
will eventually prevent further virus transmission. Killing the animal seems to be a 
much easier way to eradicate the infection rather than trying to cure it.
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Vaccination for BVDV is available and may lead to a much more controlled 
situation, where no animals have to be killed [72-73-74].
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Chapter 1. Introduction
1,4 Flaviviridae Genome.
Genus Flavivirus genomes consist of a single piece of linear, single-stranded, 
positive sense RNA [75], because the viral RNA has positive sense, the nucleic acid 
itself is capable of causing an infection in the appropriate host cells. The total 
genome can range from 10 to 12 kilobase (kb) pairs [76]. The 3' terminus of the viral 
genome is not polyadenylated and the 5' end has a methylated nucleotide cap, 
which allows the translation process to occur. Sometimes it is possible to have a 
genome-linked protein (VPg) in place of the methylated nucleotide cap.
The genome of the Pestivirus family, like the Flavivirus gene, is reported to be 
approximately 12.5 kb in length [77]. The Pestivirus family has no poly-A tail on the 
3' end of the RNA and also lack a 5' methylated nucleotide cap. In both genera, 
structural genes are located towards the 5' end of the RNA (Figure 1.5).
The Pestivirus and the Hepacivirus genus have internal ribosomal entry sites 
(IRES), which are responsible for providing a site for the initiation of the 
translation process for host ribosomes [78]. On the other hand the Flavivirus genus 
does not have IRES, but is capable of scanning the ribosomes to begin protein 
synthesis.
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Figure 1.5. Top (A): The organisation of the genetic material of the three genera 
that constitute Flaviviridae. This family of viruses carry a copy of a linear single­
stranded, positive sense RNA Bottom (B): The generic break down of the 
Flaviviridae genome and the function of each of the proteins that it encodes [79].
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1.5 Viral Replication
In order to identify targets for antivirals the life cycle of the Flaviviridae has to be 
thoroughly examined and understood. The replication process takes place in the 
cytoplasm and lasts approximately 20-30 hours for flaviviruses m . First the virus 
identifies the host cell by a set of special and unique for each virus membrane 
proteins. Only then is the virus capable of initiating its life cycle and reproducing. 
Very little is known about how the natural processes of hepatitis C virus infection 
develops, but with the limited data available the life cycle of Hepatitis C can be 
summarised in 5 different steps (also summarised in figure 1.6):
STEP 1: First the virus has to find and attach itself to a liver cell. Then the 
Hepatitis C virus will utilise special proteins present on its protective lipid coat in 
order to help it attach to a receptor site on the host liver cell [8i], For example HCV 
is looking for the CD81 (a tetraspanin, present on liver cells and lymphocytes) on 
cell membranes. Dengue virus is looking for heparan sulfate [82 83]. This will enable 
the virus to concentrate on the outer cell membrane.
STEP 2: The viral protein core will penetrate the host cell’s plasma membrane and 
will enter into the cytoplasm of the liver cell [8ij. In order to penetrate the host cell 
membrane HCV will make use of its protective lipid (fatty) coat [8i]. HCV will 
attempt to merge its lipid coat with the host’s outer membrane. As soon as the 
lipid coat has successfully fused to the plasma membrane, the membrane of the
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host will engulf the virus, a process identical to endocytosis, also known as 
receptor-mediated endocytosis. The difference in pH in the endosome of the cell 
will initiate the fusion between the envelope of the virus and the membrane of the 
endosome. The nucleocapsid will be left in the cytosol, where the viral genetic 
material, the positive single-strand of RNA will be uncoated [si]. When the virus is 
inside the host its protein coat dissolves. As a result the viral RNA is now released 
into the cell. It is not clear yet if the virus first enters the host and then 
dissociation of its protein coat occurs or if during penetration of the cell 
membrane the protein coat is broken open (after fusion with the liver host cell) 
and then the contents of the virus are released into the cytoplasm. There is the 
possibility that there may be enzymes on the liver cells cell membrane that the 
HCV may utilise to dissolve its protein coat.
STEP 3: Now that the viral RNA is in the cytoplasm it will find the cell’s 
ribosomes and it will begin the process of the production of materials necessary for 
viral reproduction [si]. Hepatitis C has a positive strand of RNA, so the nucleic acid 
can be directly read by the host cell's ribosomes -  as if it was normal mRNA. It is 
the 5’ untranslated region (5'UTR) of the viral genome that will find its way to the 
ribosomes, where translation will take place. The viral genome is firstly translated 
as a single polyprotein, which is later cleaved into individual-mature proteins by 
viral and host enzymes (signalases [85]). Flaviviruses have a short 5’ UTP with a 
type I m7GpppNlmpN2 cap structure [86]. On the other hand Pestiviruses [87] and 
Hepaciviruses (HCV [88] and HGV [89]) carry with them an IRES, which will take
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the ribosome to the first coding triplet in order to express the viral polyprotein. 
During this process two things take place simultaneously. First the virus begins to 
produce the materials coded in its RNA, and second it also influences most of the 
normal functions of the cell, in an attempt to disorganise the host cell cycle. 
Another interesting feature of HCV is that it will also try to push the host cell to 
reproduce, in an attempt to create a new host for viral reproduction m. This may 
be why HCV infection is directly associated with hepatocellular carcinoma. The 
first product of the viral RNA is the RNA transcriptase that it will use for 
reproduction [8ij.
STEP 4: As soon as the RNA transcriptase is made, it will make the negative strand 
of the viral RNA, to be used later on as a template for the generation of new viral 
RNA [8i]. The complementary negative strand of the RNA is synthesised by non 
structural proteins, the RNA-dependent RNA polymerase, with the aid of various 
cofactors poj. This strand is then used, again by the RNA-dependent RNA 
polymerase, as a template for the synthesis of the genomic HCV RNA. Viral RNA 
will be copied thousands of times in order to make genetic material for new 
viruses and it is certain that this new RNA will contain various point mutations
[90]. This is a powerful weapon of the HCV to escape from the host’s immune 
system response. The viral RNA will drive the production of protein-based 
capsomeres to be used for the new viruses’ protein coats. As soon as replication is 
over, the viral RNA is encapsidated and moves towards the endoplasmic reticulum 
of the host cell. The final product is known as nucleocapsid.
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STEP 5: The viral assembly takes place during budding, into cytoplasmic vacuoles 
and not as it was until recently thought in the cell surface as occurs with its 
arbovirus relative, the togavirus [si]. The new viruses go to the inside of the plasma 
membrane, where they interact, attach and finally establish a bud. The plasma 
membrane surrounds the virus and releases it on the outside of the cell. During 
the release the virus will take with it a lipid coat from the host’s cell membrane. 
When the virus is about to be ejected from the host cell, the envelope protein will 
become glycosylated, and the virus will leave the host towards the extracellular 
matrix m. This will help the virus to attach to another liver cell further down. 
This process will continue until complete lysis of the host cell occurs.
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THE VIRAL LIFE CYCLE OF FLAVIVIRIDAE
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Figure 1.6. The life cycle of the members of Flaviviridae, starts with the 
adsorption (1) then the receptor-mediated endocytosis (2) takes place. The 
difference in pH in the cytoplasm will trigger the low-pH fusion in lysosomes 
(3), which will be followed by the uncoating of the genetic material of the 
virus (4). The linear piece of +ve sense ssRNA will move to the ribosomes to 
initiate translation (5). Translation will produce the polyprotein the viral 
genome codes for (6). The polyprotein is going through some proteolytic phases 
using both viral and host proteases. Eventually a set of structural and non- 
structural viral proteins is available (7). In the mean time, under the host’s cell 
membrane, the synthesis of copies of -ve sense RNA takes place, followed by 
+ve sense progeny ssRNA synthesis (8). The nucleocapsid is assembled (9) and 
the virions bud in the endoplasmatic reticulum (10). They are soon transported 
to the Endoplasmatic Reticulum (ER) and to the Goldgi Apparatus (GA), where 
they mature (11). Eventually the mature virions are released (12).
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1.6 Targets for Antiviral Research
Significant Research has taken place during the last few years in the area of new 
antivirals against flaviviruses. New targets have been identified and various 
experiments have been conducted in the area of drug development, in pursuit of a 
new and efficient cure to the diseases that flaviviruses are responsible for.
1.6.1 Vaccination
Prevention of the disease is always the best option. Preventing a harmful 
condition, such as a viral infection, is much more preferred than trying to cure it
[9i]. Epidemiologically, immunising people against a virus would reduce the 
number of carriers and therefore the spread of the disease would dramatically 
decrease after a few generations. The drawback for vaccine development against 
Flaviviridae is that those viruses are highly mutagenic. [92]. Another problem is to 
which viral strain the vaccine is aimed for. An example here is Dengue virus, 
where all tested vaccines so far are against a particular serotype and not against all. 
Efficient broad-spectrum vaccines do not exist, and administering limited 
vaccination can be even more catastrophic, since any infections will another 
serotype different to the one that host is immune, could yield a much worse 
infection [8ij. A great number of HCV and Dengue II broad-spectrum formulas 
have been tested so far, with no much success [93].
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1.6.2 Viral IRES Blocking
The replication of the Hepatitis C virus depends on the IRES. IRES will direct the 
ribosomes to the RNA material of the virus in order for translation to take place 
and the viral polyprotein to be produced [94]. If the IRES area on the viral RNA was 
blocked then the process of translation would not be feasible. Merck and Roche 
have joined in a common attempt to develop an approach of blocking the viral 
IRES site. Many inhibitory compounds have been suggested and a few very 
promising antisense oligonucleotides have been produced [95]. Characteristic 
examples are the peptide nucleic acids that are capable of inhibiting translation at 
ECso of 50 nM [95]. Biaryl guanidines have been shown to inhibit translation with a 
dose of 2 pM [95].
1.6.3 Viral Proteases
Viral proteases are employed by the virus for parts of the polyprotein processing 
[96]. The protease that codes in the NS3 region of the viral genome has been 
identified as a major target for antiviral research [96]. Flaviviridae protease belongs 
to the chemotrypsin superfamily of proteases. It has a heterodimeric structure and 
complexes with NS4a proteins in order to be activated [96]. Serine protease activity 
at four different sites of the viral genome and its crucial contribution to the 
formation of the viral polymerase give the viral protease high importance and
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priority in the list of targets for antiviral agents. Small molecules and peptides 
have been tested as potential inhibitors of this enzyme. The most promishing have 
been reported to exhibit activities in pM or nM concentrations [97].
1.6.4 Capping Inhibition
Another promising antiviral target is capping inhibition [98]. Flaviviridae do not 
have a terminal IRES site on their genome. As a result they must achieve 5’ 
capping in order to retain activity. After RNA triphosphorilation (by an RNA 
triphosphatase), guanylyl transferase adds a guanine base on the last phosphate 
group. In the next step the site will be methylated by an enzyme called methyl- 
transferase [99]. Unfortunately, even though capping inhibition is a promising 
approach, no inhibitor has been reported to date.
1.6.5 Inhibition of the Viral Polymerase
Inhibition of the RNA-dependant RNA-polymerase (RdRp) is a very popular 
approach that many scientists choose for their research [100]. Viral polymerase is an 
enzyme whose structure is very common to all Flaviviridae members [101]. The 
RNA-dependant RNA-polymerase is coded in the NS5B region of the viral
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genome. Research has produced a few active compounds against the HCV RNA- 
dependant RNA-polymerase.
Ribavirin, which is one of the oldest ones, works via the 5’ triphosphate 
formation; 5-ethynyl-l-p-dribofuranosylimidazole-4-carboxamide (El CAR) is 
another active derivative of Ribavirin [102].
The 2 ’-C-methyloadenosine and 2 ’-C-methyloguanosine ribonucleosides are also 
two potent inhibitors of the HCV RNA replication in vitro [103]. Their inhibitory 
potency (IGo) was determined to be 1.9 pM and 0.13 pM respectively, in the HCV 
NS5B enzymatic assay. Unfortunately, 2-C-methyloadenosine is not orally 
bioavailable in rats [104].
In an attempt to improve the bioavailability of both 2’-C-methyloadenosine and 
2’-C-methyloguanosine a series of nucleosides modified in the purine heterobase 
were synthesised and biologically evaluated, achieving IGo values as low as 0.12
p M  [103].
Figure 1.7. The chemical structures of Ribavirin (A), 2’-C-methyloadenosine (B) 
and 2’-C-methyloguanosine (C).
HO
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1.6.6 Inhibition of the Viral Helicase
Inhibition of the viral helicase is a very promising approach that is becoming 
increasingly popular [iosj. Helicases are capable of unwinding double stranded DNA 
and RNA to single strands by breaking the series of hydrogen bonds that keep the 
two strands together. The unwinding activity of the viral helicase is essential to 
the virus during its replication process. Mutated inactive helicases in Dengue and 
Bovine Diarrhea viruses led to reduced proliferation of the virus [106]. It is believed 
that inhibition of the viral helicase will be an effective tool for the reduction of 
the replication rates of the Flaviviridae viruses. The viral Helicase is coded in the 
NS3B region of the viral genome next to the NS3A gene, which codes for the viral 
Protease. A summary of the Flaviviridae Helicase inhibitors is reported below.
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1.7 Current Research & Known Inhibitors for Flaviviridae Helicases
Virofarma reported a series of compounds with benzimidazole derivatives with 
ICso values within 0.7 to 10 pM (Table 1) [107]. The mechanism of action of these 
drugs is unclear, but based on their shape one could assume that they should act in 
the RNA biding site of the helicase, competing with the single-stranded RNA for 
binding to the protein.
Table 1. The 7 compounds reported by Virofarma and their activities.___________
H
Compound Linker (R) Linker (R) Name ICso
1 H,C---^  ---CHj Benzene 10
2 A 0.7
3 C2 0.7
4 C4 0.7
5 C8 0.7
6 CIO 0.7
7 C12 0.7
The aminophenylbenzoxazole- and the aminophenylbenzothiazole- containing 
compounds showed no inhibitory effect, whereas the aminobenzimidazole- 
derived diamides produced a rather moderate 13% inhibition. The
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aminophenylbenzimidazole derived diureas showed inhibition in the range 
between 20 and 28%. In general it was noted that there is significant decrease of 
potency when the benzimidazole moiety is removed and substituted with 
benzoxazole or benzothiazole moieties. The same is observed for the removal of 
the benzene ring. Activity drops when the benzene ring is removed.
Figure 1.8. Some of the compounds suggested by Virofarma as Hepatitis CHelicase 
Inhibitors.
A series of nucleotide compounds were suggested as potential inhibitors of the 
helicase of Hepatitis C  mainly targeting the ATP site on the protein [no]. The 
theory is that since the unwinding process is energy-dependent, even competition 
for the ATP, induced by any compound, would result in less energy being 
available for the system and as a result reduced unwinding function of the 
helicase. So, a wide range of competitive NTPase inhibitors was suggested. These 
include ribavirin-5 triphosphate (RTP), ribavirin-5 diphosphate (RDP), adenosine- 
5-thiotriphosphate (ATP-S) or ADP. These compounds were all tested against
R = C4 or C6 R = C2, C4, C6, C7
R = C4 or C6
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Hepatitis C helicase and were found to be moderate inhibitors of the unwinding 
activity of the HCV Helicase enzyme (summarized in figure 1.9).
Structure Inhibition Potency
ATPase Helicase
HO-
RTP IC50= 40 pM IC = 180mM
Competitive
NM* ROP ICcn = 90 pM IC™ = 250hM
Competitive 50
Paclitaxel ICi-q = 17 pM 
Competitive
IC50 > 1 mM
„CHi
‘"V
< ' 2*0 Trifluoperazine IC ^ = 105 pM IC ^ = 0.6-0.7 mM 
Noncompetitive
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Figure 1.9. The series of compounds suggested by Borowski tin]
The effect of N7-chloroethylguanine and N9-chloroethylguanine in the helicase 
activity of the WNV was investigated. These compounds were found to be 
activators of the helicase activity by 850 and 220% respectively [iu]. Similar 
patterns in activation were observed with the Hepatitis C  helicase as well (Figure
1.10).
Structure Activator? Potency 
He^caseATPase
C!
ED20P > 1 mM ED/0v « 18 jiM
Nr-cMo*cethylguanir?e
0
H
-chtoroethylguantne
Figure 1.10. N7 chloroethyl guanine and N9-chloroethyl guanine
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A series of ring-expanded (“fat”) nucleoside analogues with the 6-aminoimidazo 
[4,5] [1,3] diazepine-4,8-dione ring system was synthesised and tested against the 
NTPase/helicase WNV (Table 2) [nsj. Some compounds were found to be potent 
inhibitors of the NTPase/helicase of the WNV. It was also found that the same 
compound that was active against the helicase activity of the protein was inactive 
against the NTPase activity. It was supposed that this series of compounds binds to 
the major or minor groove of dsDNA or dsRNA, affecting the stability of the 
double helix.
NH
HO
HO OH OHHO
NH
\
CH 2-Ph-O M e
Table 2. The IGo values of the above compounds
Compound Number WNV - ICso (pM)
1 10
2 1.5
3 1-3
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Two series of ring-expanded (“fat”) heterocycles, nucleoside and nucleotide 
analogues were prepared and tested against the NTPase/helicase activity of the 
Flaviviridae family of viruses. The first series contained the imidazo [4, 5-e][l,3J 
diazepine ring system and the other series contained the imidazo [4,5-e][l,2,4] 
triazepine ring system. They were tested against the helicases of WNV, HCV and 
JEV, with some of these compounds quite potent inhibitors of the helicases (Table 
3). Their inhibitory effect is mainly exerted on the ATPase activity of the enzymes 
[116].
NH
NH
OH1
NH
2
Table 3. The IC50 values of the above compounds
Compound
Number
WNV 
ICso (pM)
WNV 
ICso (pM)
WNV 
ICso (pM)
1 5.7 >500 2
2 3.3 5.5 >500
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1.8 Aims and Objectives
The main objective of this project is to develop a research methodology to 
facilitate the design and the discovery of novel antiviral agents. The strategy 
followed can be broken down into the following steps:
• The first step is the identification of a suitable target. The helicase and the 
polymerase proteins of Flaviviridae were chosen.
• The three-dimensional structures of the new targets were modelled by 
homology based molecular modelling techniques.
• Then using de novo structure -  based drug design algorithms a series of 
lead compounds was generated.
-> At  this stage som e of  those  lead c o m p o u n d s  will  he c h e im c a l h  svnihesisee.  
by o t h e r  m e m b e r s  of t h e  group.
• The genes of Hepatitis C helicase, Dengue helicase and Dengue NS3 
(helicase + protease) domain were cloned into expression vectors and the 
proteins were produced and purified.
• Finally an enzymatic assay was developed in order to biologically evaluate 
the potency of the designed inhibitors. The experimental results obtained 
from the biological assay were fed back to the computer in order to refine 
and improve the in silico model.
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2.1 Molecular Modelling
Molecular modelling is very useful for investigating, comparing, analysing and 
visualizing chemical structures and for giving qualitative and quantitative 
information about biological systems [117].
^  S tenc^
Figure 2.1. Steric hinderance of a small organic compound
Figure 2.1 shows a characteristic example of steric hinderance. Two dimensional 
models like this only contain qualitative information. Quantitative information 
can arise through molecular mechanics and in conjunction with a computer, 
where the physical properties of the molecules can be evaluated and analysed 
based on a set of predefined criteria concerning various chemical properties (such 
as bonding, charges, steric hinderance...) ms]. Molecular Modelling can be used to 
study the geometry, the energy and the chemical properties in  silico so efficiently 
that nowadays it is possible to predict the outcome of chemical reactions, design 
reactions, determine the unknown three dimensional structures of proteins, screen 
and design new and effective drugs [nsj. In this part, the basic principles and 
theory of the methods that have been used in this chapter will be presented.
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2.1.1 Molecular Properties
The geometry and the overall structure of a molecule are described by its bond 
distances, dihedral angles and bond angle [119]. This unique set of angles and 
distances create a set of coordinates that define the positioning of each atom in 
that molecular structure in three dimensional (3D) space. The energy condition of 
this molecule can also be assessed and evaluated. The energy of a molecule 
includes all forms of energies, such as kinetic motion (described by vibration, 
rotation and translation) and forms of the potential energy of the molecule [120]. 
The potential energy of a molecule can be defined by the analysis of the 
electrostatic interaction between charges, the magnetic interactions between 
spinning charges and finally the potential energy of the bonds of the molecule. 
The total energy is indicative of the reactivity and stability of that a molecule or a 
system. Below is a reaction coordinate diagram that indicates the energy changes 
during the course of a chemical reaction [1213.
Transition State
Energy
Kinetics
Reactant
x
i
Thermodynamics
Product
Reaction Coodinate
Figure 2.2. Energy changes during the course of a chemical reaction.
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Here the products are in the lowest or global minimum, the transition state is at 
energy maximum and the reactants are at an energy minimum. The dotted lines in 
the above diagram are indicative of the reactivity of the system (its kinetics) and 
the thermodynamic stability of the system. Through molecular modelling it is 
possible to quantify the above characteristics of the system and, for example, 
predict its reactivity. There are two fields in molecular modelling that attempt to 
do this: molecular mechanics and quantum mechanics [122].
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2.1.2 Molecular Mechanics 8c Forcefields
Molecular mechanics are based on the ball and spring representation of molecular 
systems. Here, the atoms are considered to be little balls, with varying properties 
according to the element, and the bonds are considered to be the springs that 
make the two interconnecting balls interact with each other. The ball and spring 
model is described by Hook's law, which evaluates and quantifies the energy of 
the stretching of the spring [123].
The force constant is the constant k. The energy that is contained in the spring 
and the restoring force of the spring are proportional to the force constant. The 
force constant will determine the strength of the bond that the spring represents 
[124]. The vibrational frequency of the spring is described as:
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The vibrational frequency (n) has been estimated to be proportional to the square 
root of the force constant (k) and inversely proportional to the reduced mass of the 
atoms that participate in a bond [125].
All of the above can be combined and through potential energy functions of 
various structural features, such as bond lengths, bond angles and non-bonded 
interactions, can describe a forcefield (figure 2.3) [1263. There are many different 
ways to set a forcefield depending on the needs of the system under investigation. 
Usually the factors affecting the energy of a molecular system (bonds, angles, 
dihedrals, non-bonded, etc), are evaluated separately and they will contribute to 
the value of the total energy of the system [127]. The most popular forcefields are 
the MM2, which is suitable for small molecules, hydrocarbons and some simple 
heteroatom functional groups, AMBER or CHARMM, which are parameterised to 
be used for peptides, nucleic acids and generic macromodels [128].
H3C
Figure 2.3. Total energy is affected by bond distances, bond angles, dihedral angles 
and finally non-bonded interactions
Bond Angle
(Dihedral Angle
H ^  ►CH3
non-bonded interaction
CH3
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Overall through molecular mechanics the total energy of a molecule is described 
as a sum of all the contributions that may arise from loss of equilibrium in bond 
distances, also known as stretching contribution, bond angles, known as bending 
contribution, dihedral angles, the torsion contribution and finally non-bonded 
interaction contributions [129].
The energy that is stored in chemical bonds of a molecule can describe the stretch, 
bend, and torsion energy whereas it is the steric attraction or repulsion that 
represents the non-bonded energy [130]. The latter is broken down to two different 
categories: the van der Waals (VDW) and electrostatic interactions [131].
bonds
stretch
+
dihedral angles non-bonded atoms
V   ^ torsion V  '  V  "*• non-bonded
van der Waals radius
E VDW
0
where,
rij° is the distance at the minimum 
eij is the energy at the minimum 
s =  2 -1/6 rij° is the van der Waals radius
8 . .
1J
Figure 2.4. The van der Waals interactions plot and formula.
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A very steep energy barrier is generated at the van der Waals radius of each atom. 
Moreover a very shallow energy well is produced at larger separations (figure 2.4). 
The inherent steric size of atoms and elements is dictated by their VDW radii. The 
same metric is used to describe weak attractive forces between atoms in close 
proximity [132]. A trivial example of the weak van der Waals attractive forces is the 
condensation of a gas into liquids. Furthermore it is the van der Waals radii of 
each element that is used for its visualisation purposes in space filling models of 
the molecule they participate. Steric repulsion takes place only in the case where 
two atoms come closer than the sum distance of their VDW radii [133].
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2.1.3 Energy Minimisation
As soon as the set of the internal coordinates of a molecular system has been 
determined, computer algorithms can be used to help find those coordinates 
which will account for the lowest energy of the system [134]. All bond angles, 
lengths, dihedral angles and the relative energy between various different 
conformations of a given system will be evaluated in order to determine the 
minimum energy conformation [135]. It is crucial to understand that reducing the 
strain energy of a given molecular system does not mean that the system will 
reach energy minimum (also known as global minimum). An example is the 
following figure (figure 2.5) with two different conformations of butane:
HsC Global H3C Local
Figure 2.5. Two different conformations of butane
An energy minimisation algorithm will allow the rotation of groups, when their 
bonding allows. The rotation of the groups will give the molecule the opportunity 
to explore different conformations that will account for different energy values, 
thus allowing the compound to move towards its global minimum conformation
[136].
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2.1.4 Quantum Mechanics
Quantum mechanics are useful for the evaluation of electronic properties that may 
influence physical and chemical reactions between different groups of a biological 
system [137]. The estimation of energy conformational profiles and that of 
intermolecular interactions in various cases can be achieved through quantum 
mechanical calculations. The quantum mechanics arise from the Schroendinger 
equation [i38j. In a very simplistic representation the latter equation can be 
described as:
H p s i  — E p s i
Where: H is the Hamiltonian operator,
Psi is the wave function 
E is the total energy of the system
Using the Schroendinger equation and the above operators a complete description 
of any molecular system can be achieved.
At a given molecular system the Schroendinger equation can be solved in two 
different ways [139]. First is the no approximation or ab initio  approach [i40]. 
Secondly, the Schroendinger equation could be solved by the introduction of some 
approximations, which is a method also known as semi-empirical approach [i4 i].  
The main advantages of ab initio  methods is that all electrons are explicitly 
included and they do not requiring any specific parameterization, thus making ab 
initio  calculations a universal tool for all molecular systems [142]. On the other hand 
in semi-empirical calculations it is the valence electrons that are explicitly
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included. Here most of the integrals are neglected or approximated by a set of 
parameters that arose from experimental work [i43j. Choosing the most suitable 
approach to investigate a given system does not solely depend on the size of the 
molecular system, but on the type of unique parameters and molecular properties 
of the system. For example, the conformation, electrostatic potential and, electron 
density of the given molecular system.
The most popular semi-empirical calculation algorithms are the AMI, MNDO, 
CNDO and MINDO, whereas for ab initio  calculations the Gaussian program is 
very representative. AMPAC and MOPAC on the other hand are very widely used 
for ab initio  calculations [143].
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2,1,5 Molecular D ynam o
Molecular dynamics simulations are used to describe the patterns, strength 
and properties of drug-receptor interactions, the solvation of molecules, the 
conformational changes that a molecule may undergo under various conditions 
and other events that require the systematic evaluation of molecular properties in 
dynamic molecular systems [i**]. Molecular dynamics are concerned with the 
motion of atoms and molecules [145]. An example is the normal mode analysis, 
where the dynamic motion of a molecular system is evaluated from its total 
energy. According to Hook’s law, the total energy of a small and simple diatomic 
molecule should be given by:
E(r) = \  k(r - i°)2 € F(r) = - ^  = -k (r - r°)
Where: E = energy, F = force, r = distance, r° = initial distance, k = Hook’s constant
Here, the forces on the atoms are estimated by the derivative of the energy [146]. 
When the forces have been assigned the Newton law of motion can be used to 
solve the molecular motion (F = m x a, force = mass x acceleration). In the case of 
the small and simple diatomic molecule the displacement from the equilibrium 
bond length (x) will be given by the formula:
me mo
x = r - r° and u =r  m e + m o
Where: p is the effective mass of the vibrating diatomic molecule.
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In molecular dynamics simulations the kinetic energy of the system will depend 
on the temperature of the system [U7]. The total energy will be the sum of the 
kinetic and potential components of the system. The acceleration of each atom is 
estimated from the set of forces it accepts, under the given forcefield. The results 
generated can be used to estimate the configurational and momentum information 
for each atom of the system (i.e. energy, pressure). Molecular mechanics therefore 
can be used to further optimise a model generated by homology modelling as well 
as docking results, where the protein / ligand interactions can be analysed for their 
stability during a specific time [i4sj.
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2.1.6 Homology Modelling
Homology modelling is used in order to predict the 3 dimensional structures of 
proteins with unknown 3D structure, using solved homologous proteins as 
templates im .
Homology modelling claims that the biological structure of a protein is more 
related to its biological properties and function than its sequence [iso]. A 
homologous protein is a protein that belongs to the same family, has the same 
function and shares more than thirty percent similarity with the protein of 
interest.
The first step of a homology modelling algorithm is to set up and optimise the 
sequence alignment between the query protein and its template. Sequence 
alignment is broken down into four steps usij. Firstly, it uses rapid alignment 
methods to calculate all pairwise similarity scores. The second step is the 
generation of a similarity matrix. Then the sequences are clustered according to 
the generated similarity matrix with the aid of an algorithm. The next step is the 
generation of a cluster alignment using a consensus method and finally a multiple- 
progressive alignment is generated. The groups of the sequences are aligned 
according to their cluster branch order.
After that the algorithm will perform an initial partial geometry alignment for the 
sequence of the template protein with the unknown structure [152]. The initial
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geometry will be copied from various regions of one or more template proteins. If 
there is residue identity, between the alignments, then all coordinates are copied. 
That includes backbone and sidechain. If there is not residue identity but still 
residue similarity is retained, only the coordinates from the backbone atoms will 
be passed on. In cases of zero identity or similarity a gap will be left on the model, 
which is also known as loop. A loop will be modelled by borrowing coordinates 
from any protein (from the Protein Data Bank) that matches the required 
sequence. The sidechain is generated automatically using a build-in rotamer 
explorer module fisai-
Finally, the new models must adequately meet and satisfy a scoring function that 
ensures that the degrees of the non-polar sidechain groups that are buried are 
within range and that all hydrogen bonding capabilities have been explored [i54].
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2.1.7 Model Evaluation
The N-Ca and the Ca-C bonds in a protein are capable of rotating. The rotation of 
these bonds can be described by the phi and psi torsion angles (figure 2.6 -  bottom 
right) [155]. The values of these angles define the secondary element that each set of 
residues will form. To visualise phi and psi angles in a protein a Ramachandran 
plot is constructed. Psi angles are found in the YY* axis, whereas phi angles are 
found in the XX’ axis (figure 2.6).
The Ramachandran Plot.
180
Beta-sheet.
+psi Left
handed
alpha-helix.
Right handed 
alpha-helix.
—  c-psi
+ phi- phi
Figure 2.6 The layout of a generic Ramachandran plot. Indicating the major 
secondary element areas of a protein. Bottom-right: a typical residue with the phi, 
psi and omega angles designated.
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The white space on the diagram above describes the pairs or groups of atoms that 
have distance smaller than the sum of their van der Waals radii, because of the 
conformation of the backbone. As a result a sterically unreal conformation will be 
generated, thus making the combination of those atoms disallowed. The area with 
no steric clashes is represented in red color. The residues in the red area are 
considered to be in the allowed regions and this is where the alpha helices and 
beta sheet conformations are usually found. The yellow areas include the pairs or 
groups of atoms with radii a fraction less than the sum of their van der Waals 
radii. This is the area that the motif of the left handed alpha helix would be found, 
where the atoms are allowed to come a little closer. The generously allowed areas 
of the Ramachandran plot are areas with pairs or groups of atoms with radii quite 
less than the sum of their van der Waals radii, but not significantly clashing with 
each other. Glycine is a versatile amino acid, because it does not have a side chain. 
Glycine can take phi/psi angles in each of the four quadrants in the Ramachandran 
plot. As a result glycines are usually encountered in loop regions in the protein, 
where it would be impossible for any other residue to be, because of the steric 
hindrance.
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2.1.8 Molecular Docking
Molecular Modelling
The last molecular modelling technique that is extensively used in this project is 
molecular docking [i56]. The docking algorithm is basically split into two main 
parts: the searching algorithm and the scoring algorithm [157].
The searching algorithm will explore all conformations of the ligand within the 
space available [is#]. Practically, it is impossible to perform all these calculations for 
every compound so most of the rotational and translational states of each 
compound will be explored within a given threshold of identical conformations. 
Each compound is not a rigid body, but is a dynamic structure that exists in an 
ensemble of different conformations. The user can define how fine the docking 
algorithm will be by altering the various parameters of the task. Very fine 
calculations are much more accurate, but also much more time consuming. The 
most popular docking algorithm approaches can involve a coarse grained 
molecular dynamics simulation or a linear combination of many structures or a 
genetic algorithm that generates new conformations as it moves along.
The second feature of the docking algorithm is its scoring function [159]. The 
scoring function must be able to accurately evaluate each different conformation 
using certain forcefields and rules from physics, and return a value that will 
describe the energy of the system at the given conformation. Low energies 
indicate better, more stable interactions.
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2 X 9 Ping design
In the last few years the number of biological targets suitable for drug discovery 
has increased enormously and, at the same time, computer-aided drug design 
techniques are becoming more popular everyday, sustained by the need to 
accelerate the drug discovery process [i60]. Structure-based methodologies are now 
widely used to design and optimise new potential drugs and, in particular, de novo 
approaches (structure based novel inhibitor design) remain very attractive to 
researchers as a time and cost efficient methods to design novel entities, despite 
the challenges associated with them [i6i].
Basically, three questions have to be addressed by a de novo design program: how 
to assemble the candidate compounds; how to evaluate their potential quality; and 
how to sample the search space effectively.
In answering the first of these questions, we can consider two main approaches to 
build the desired structures [i6i]. The first (figure 2.7-top) is the linking procedure, 
where the algorithm selects the most suitable moieties to interact with the active 
site of the protein and then starts to link them together in a chemically 
appropriate way. The second approach is the growing procedure (figure 2.7), 
which involves the determination of a group as a starting point and then the 
growing of a larger compound that would fit in the active site and that would be 
capable of establishing interactions with it. The first approach requires that the
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user must supply the docking/interaction points of the moieties that will be used 
as anchors to the final structure.
HO,
HN
The linking approach
\H
N-
HO,
N“
The growing appoach 
Figure 2.7. LigBuilder’s approaches to structure-based drug design.
The second approach requires that the user selects a suitable “seed” as a starting 
point, and that the user directs the growing process. The best results will be 
obtained from the combination of these two procedures.
Evaluation of the results obtained could be done by different methods [i62i: 
receptor-based scoring functions: explicit force-field methods; empirical scoring 
functions; and knowledge-based scoring functions. All of these approaches attempt
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to approximate the binding free energy. Force fields are computationally more 
costly than the other two types of scoring functions.
The last issue related to the de novo drug design methods is the sampling of the 
chemical space associated with the growing compounds [i«]. There are many 
different search algorithms implemented in the variety of software programs 
available, and new ones are continuously developed.
It is also important to mention the nature of the “building blocks” used to 
construct the structures: some programs connect single atoms, others use a library 
of chemical fragments. The size and the diversity of the fragment library is 
fundamental for a broad search of the chemical space [164]. The main problem 
associated with the de novo methodologies is represented by the chemical 
feasibility of the structures generated: unfortunately, computers do not know 
organic chemistry, yet.
In our project, we have used a de novo approach for the design of some helicase 
inhibitors using a software called LigBuider. This package can use both the “link” 
and the “grow” approaches and implements a genetic algoritmm based search for 
the determination of the best structures. Once the compounds are drawn from the 
population, the new population is formed by combining the information from 
groups of selected individuals. This is done by randomly splitting the 
representative strings of the parents and recombining them to form new entities. 
This operation is called Crossover [i65]. Because the parents have been selected for 
their fitness, the children of these parents will, statistically, be more fit than the
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parents. This is done until a new population has been built from the old one. The 
final step is the evaluation of the new population, which may result in starting the 
whole process over again by changing a single or groups of parameters. The cycle 
described in figure 2 . 8  is continued until a solution that is good enough for the 
experiment’s criteria has been obtained.
Build, initial 
population 
(often random)
Stop looping and. 
cluster results Evaluate
population
members
Repeat for the 
given number o f 
generations
Perform  fitness 
based selection
Form new 
population with 
crossover operator
Figure 2.8 The steps of the genetic algorithm of LigBuilder
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2.2 Introduction to the Homology Modelling Project
The aim of this project was to design the 3D models of the Helicase and 
Polymerase enzymes of the Dengue, Yellow Fever, West Nile and Japanese 
Encephalitis virus using homologous proteins as templates, all members of the 
flaviviridae viral family. The models are to be used for structure based drug design, 
in order to design inhibitors for these enzymes. However, priority was given to 
the HCV helicase, firstly due to the available X-ray solved structure (co­
crystallised with ssRNA [166]), and secondly due to the availability of the HCV 
helicase gene in the molecular biology lab.
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2,2,1 Homology Modelling of the Flaymridag H elices
The initial DNA sequences of the genes encoding for the Dengue-type II, West 
Nile, Yellow Fever and Japanese Encephalitis Viral Helicase proteins were 
downloaded from GenBank [i»j. The DNA sequences were translated on the on­
line Expasy DNA/Protein translator [167].
The on-line Blast-P search revealed that the best template for the homology 
modelling experiments was the corresponding Hepatitis C Helicase, which has 
been solved by X-ray crystallography (PDB entries: 1A1V & 80HM).
The sequence alignment was performed with the multiple alignment program 
ClustalW [168]. It revealed an average 30% homology identity between the HCV 
Helicase and the model sequences. The percentage identity between the Dengue 
Primary sequence and the HCV sequence was 31.2%, the West Nile virus 29.8%, 
the Japanese Encephalitis 30% and the Yellow Fever 31%. The sequence 
alignments are shown in figure 2.9.
The Helicase Homology Experiments were performed by a traditional homology 
modelling approach (i.e. using a single protein template only), since the 30 % 
homology identity is marginally acceptable by the algorithm. The homology 
modelling algorithm would divide the sequence into Structurally Conserved 
Regions (SCRs) and Structurally Variable Regions (SVRs).
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Figure 2.9. Multiple sequence alignment among the 5 Flaviviridae Helicases. The 
four known motifs to the Flaviviridae helicases are colour coded and enclosed in 
boxes. Key residues to homology modelling are also highlighted.
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The SCRs are obtained from the coordinates of the template and the SVRs are 
obtained from direct access of the algorithm to its built-in PDB database. The 
initial models were obtained from COMPOSER [169], a module of the Tripos Sybyl 
[170] suite running on a SGI workstation [m]. The primary sequence of each of the 
unknown structures was imported in COMPOSER and the structure of the 
corresponding HCV template protein was added in the database of the software. 
The database of COMPOSER at that time numbered 1850 structures. In order to 
assist the database of COMPOSER to become more efficient with the two 
helicases, a group of 125 helicases was downloaded from the PDB web site and 
were imported into COMPOSER’S database. All loops were eliminated and the 
four models for the four flaviviridae virus members were built. To further 
optimise the models, the DNA from the template was added to the structures and 
the resulting complexes were initially energetically minimised and then subjected 
to short molecular dynamics simulations.
Energy minimisation was done in MOE (Molecular Operating Environment suite 
[172]) initially using the Amber forcefield implemented into the same package, up to 
a RMSd gradient of 0.0001. Molecular dynamics were performed after that at 
300K, 1 atm for 1000 picoseconds with 2 fsecond step size, using the NVT 
ensemble in a canonical environment. NVT stands for Number of atoms, Volume 
and Temperature that remain constant throughout the calculation. The results of 
the molecular dynamics simulation were collected into a database by MOE and 
can be further analysed.
Dimitrios Vlachakis, PhD 2006 70
Chapter 2 Molecular Modelling
Dengue Helicase Model West Nile Helicase Model
Jap. Encephalitis Helicase Model Yellow Fever Helicase Model
Figure 2.10. The four Helicase Models: the Dengue virus (top left), the West Nile 
virus (top right), the Japanese Encephalitis virus (bottom left) and the Yellow 
Fever virus (bottom right). The above conformations were obtained after the 1 
nanosecond molecular dynamics simulation.
In order to assess and evaluate in more detail the quality of the four Helicase 
models they were initially superimposed with the HCV template and the 
coordinates of the ssRNA were copied to the models and subjected to another 
course of molecular dynamics for 1000 picoseconds with the oligonucleotide
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present. This way the cooperativity between each model and the ssRNA would be 
assessed. After the MD simulation, the ssRNA fragment of all four models did not 
move significantly (low RMSD < 0.5 A). Indicating that the ssRNA fragments 
established interactions with each model, which stabilised them in the same 
pattern as in their template.
Figure 2.11. The superimposition of the final helicase models with the HCV + 
ssRNA structure (top -  left) and that of the ssRNA conformation in each of the 
models upon MD simulation (top -  right). Red is the HCV, in Yellow the Dengue, 
in Blue the Yellow Fever, in Magenta the West Nile and in Orange the Japanese 
encephalitis. Their corresponding RMSd (all atoms) with HCV are 1.9, 2.2, 1.1 and 
1.4. In Green is the ssRNA from the HCV helicase. The ssRNA interacting residues 
have been conserved from the template to the model (bottom -  left/right).
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2.2.2 Evaluation of the Helicase Models
In a homology modelling experiment the fact that structure is more conserved 
than sequence is always an assumption that has to be taken into consideration. 
Here, the structural elements of the models are not significantly different to those 
of HCV helicase. The quality of the models was tested with PROCHECK [173]. The 
templates 1A1V and 8 OHM were found to have 100% and 99.7% of their residues 
in the allowed regions of the Ramachandran plot, respectively.
Ramachandran plot results for the Dengue model before minimisation and 
molecular dynamics showed that 82.2 % of its amino acids were in the allowed 
area of the Ramachandran plot (RP), 13.9% were in the additionally allowed 
regions and 2.5% were in the generously allowed regions, whereas 1.4% of the 
residues of the model were found to be in the disallowed area of the 
Ramachandran Plot (table 2.1). The Procheck evaluation was repeated after the 
molecular dynamics and in this case the percentage of residues in the allowed area 
of the RP was increased to 92.5%. Moreover 5.3% were in the additional allowed 
regions and 2.2% in the generously allowed area. There were no residues in the 
disallowed area (table 2 .1 ).
The results for the accuracy of the model of the WNV showed that 80.9% of the 
model's residues were found in the core region of the RP, 13.6% were in the 
additional allowed regions, 3.7% of the residues were found in the generously
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allowed area of the RP and 1.8% of the model's residues were located in the 
disallowed region (table 2.1). After Molecular Dynamics the Ramachandran 
statistics for the WNV model were 86.1% of residues in the core area of the RP, 
1 1 .3 % of residues in the additional allowed areas, 2 .6 % in the generously area and 
again the number of residues in the disallowed area was eliminated.
In the same way the Ramachandran statistics for the Japanese Encephalitis 
helicase were improved from 79.9% of residues in the core region (rough model) 
to 94.2% in the model after molecular dynamics. The percentage was also 
decreased from 15.1% to 5.1% in the allowed regions, from 3.3% to 0.7% in the 
generously allowed regions of the RP and from 1.6% to 0% in the disallowed 
region.
Finally, the Ramachandran statistics for the Yellow Fever helicase were improved 
from 81.5% of residues in the core region (initial model) to 96.7% in the model 
after molecular dynamics. The percentage was also decreased from 13.4% to 3.2% 
in the allowed regions, from 3.2% to 0.1% in the generously allowed regions of the 
RP and from 1.9% to 0% in the disallowed region.
Table 2.1. The Ramachandran plot values of the each model after homology and 
after optimization and re-evaluation.
After Homology
After Energy M inimisation & Model 
Optimisation
Project Model Core Allowed Generous Disallowed Core Allowed Generous Disallowed
H
el
ic
as
e
Pr
oj
ec
t DenV 82.2 13.9 2.5 1.4 92.5 5.3 2.2 0
W NV 80.9 13.6 3.7 1.8 86.1 11.3 2.6 0
JEV 79.9 15.1 3.3 1.6 94.2 5.1 0.7 0
YF 81.5 13.4 3.2 1.9 96.7 3.2 0.1 0
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2.2.3 Discussion of the Helicase Models
Ramachandran plot evaluation is not enough to confirm the practical quality of 
the model. Even if the geometry, phi, psi and omega angles of a model are perfect, 
the model could be unreliable if it does not satisfy the known functional criteria of 
the family of proteins it comes from. All of the known functional motifs of the 
flaviviridae helicases are present in the HCV template and have been inherited by 
all models (see sequence alignment - figure 2.9).
There are certain motifs conserved among the different helicases of the 
flaviviridae family. The Hepatitis C, Dengue, West Nile, Yellow Fever and 
Japanese Encephalitis helicases belong to the superfamily II of helicases and share 
seven common motifs within their domains. RNA binds to the helicase at the 
Arginine-rich site of the 2nd domain. There are two supposed mechanisms of 
action for the flaviviridae helicases. The “sliding theory”, suggests that the enzyme 
binds to the edge of the double stranded RNA of the virus and slides along, 
separating the two strands, by breaking all the hydrogen bonds between 
corresponding bases [i74]. According to this theory the helicase is using its leading 
edge for unwinding. On the other hand another theory suggests that the helicase 
may be using its trailing edge [175]. Movement of the helicase along RNA takes 
place from 3’ to 5’ and is described by its periodicity (i.e. unwinding is not 
continuous, but occurs between brakes). The flexibility of the enzyme allows it to 
undergo significant conformational changes that are essential for its motion. The
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energy requirement for the motion of the helicase is supplied by the hydrolysis of 
ATP. The ATP binding site is located between domains I & II, where it initiates an 
allosteric effect that will eventually change the conformation of the helicase thus 
allowing it to move on the viral RNA. ATP must complex with a divalent cation in 
order to produce its effect. The extreme importance of the helicase enzymes in the 
survival of the viruses was demonstrated by mutagenesis experiments that led to 
inactive helicases. No virus that was carrying an inactive helicase survived [175-176].
Figure 2.12. The HCV Helicase co-crystallised with a ssRNA fragment [177]
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The flaviviridae helicases have three domains in total, which are separated by two 
channels (Figure 2.13). The first and third domains are interacting much more 
together than they do with domain two. The outcome of this is that the channel 
between domains 1-2 and 2-3 is larger than the channel between domains 1-3 and 
2-3. Domain two is supposed to undergo significant movements compared to the 
other two domains, during the unwinding of double-stranded nucleic acids.
Figure 2.13. The NS3 Helicase domain from HCV complexes with ssRNA. There 
are two suggested channels for the ssRNA.
So, the positioning of domain two is very flexible relative to that of the other two 
domains. As a result the Helicase acquires the form of a dynamic “hinge” that 
moves according to the needs of the protein and the process it is involved in [vm. 
The topology of the first and the second domains is very similar. These two 
domains contain the structurally conserved regions of helicases of this family. This
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is confirmed by the superimposition of the two domains, which gives an RMSd of 
2.0 A for 76 Ca atoms.
Domain 3 includes a 40 amino-acid long region, just before the helix in the C 
terminus that does not contain any secondary structures This may contribute 
to the flexibility required by the protein during its cleavage from the NS4A 
domain during polyprotein processing. On the other hand towards the N-terminus 
of the protein there is the highly conserved “Walker A box” or “P-loop” motif. 
This motif is very often found among helicases and consists of a glycine rich 
region of the protein that provides a quite flexible loop between strands and 
helices [in]. The “Walker A box” has phosphate-binding properties and is found in 
most ATPases. In the HCV helicase crystal structure the sulphate ion interacts 
with the nitrogens Gly207 and Gly209, and the side-chains of Ser208, Lys210 and 
Ser211. Lys210 establishes a H2O mediated interaction with As290 of the DExH 
motif (Asp-Glu-x-His). The position of the sulphate ion was found to be very 
similar to the position that the (3-phosphate of ADP would take in the PcrA 
helicase-ADP complex. So, it is suggested that this is the space that p-phosphate 
should take when NTP or nucleotide diphosphate (NDP) is bound to the HCV 
helicase. The residues Gln460, Arg464 and Arg467 are highly conserved residues 
from domain 2 that are exposed to solvent in the major channel of the Helicase. 
Arg461 and Arg462 are buried amino-acids in the core of the 2nd domain \ \ t t \-
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Figure 2.14. The residues Gln460, Arg464 and Arg467, which are highly conserved 
residues from domain 2.
The single strand of RNA is located in the main channel of the helicase between 
domains 3 and 1-2 (figure 2.15). The size of the channel is approximately 16 A in 
diameter. The 5' end of the oligonucleotide is towards the part of the channel 
between domains 2 and 3 and the 3' end of the oligonucleotide is towards the part 
of the channel between domains 1 and 3 [i78].The ssRNA and the Helicase 
interaction occur mainly between the backbone of the RNA, since it is a non­
specific protein-RNA interaction. The 
majority of the established interactions are 
located towards the two ends of the ssRNA. 
Most interactions arise from regions lacking 
secondary structures in domains one and 
two. The positioning of the interaction- 
participating amino acids is symmetric and 
as a result it appears to be a symmetric
Figure2.15. The size available for 
the ssRNA in the HCV helicase is 
approx. 16 A.
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distribution of the interactions between the RNA and the protein. Quick 
superimposition of the first and the second domains revealed that the residues 
involved in the phosphate contacts are structurally equivalent. Furthermore the 
phosphate-binding amino acid series of Ser231, Thr269, Ser370 and Thr411 are 
conserved in NS3 domains and this is evidence that these two domains may be 
derived from a gene duplication event. Val432 and Trp501 are also highly 
conserved residues among HCV NS3 sequences, nevertheless neither seems to play 
any role in nucleic acid binding or duplex unwinding 1177].
The second domain has two extended antiparallel strands (residues 430-452), 
which interact with the 5’ of the oligonucleotide. This is also known as the L-45 
loop and it belongs to the family of nucleic-acid binding motifs. The positioning of 
the domains that make the channel for the RNA in the helicase is very similar to 
that of the domains in the replication protein A (RPA) [177]. In both cases 
interactions are better formed towards the ends of the oligonucleotide and only 
minor interactions occur with the nucleotides in the middle.
There are no sequence-specific interactions with the RNA bases and the helicase. 
This was anticipated from the biological activity of the helicase and its behavior 
during enzymatic assays 1177J. Any differences in the binding affinity between 
different nucleotides may be due to differences in RNA distortion and base 
stacking.
HCV strains appear to have very high sequence conservation among them. The 
percentage identity of the sequence alignments is calculated to be greater than
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eighty percent. Comparison of the sequences of Bacillus stearothermophilus [179] 
and Escherichia coli DNA helicase [iso] showed that there is an overall structure 
similarity between the domains 1A-2A of the above strains and 1-2 domains on 
the HepC helicase. The alignment of the primary amino-acid sequence may not be 
identical, but the alignment of the motifs is evidence that the arrangement of 
these different proteins in space and function must be similar to each other [isi]. 
Site-specific mutagenesis has revealed that the function of the residues in these 
motifs of various helicases (including HepC) is crucial to the function of the 
helicases. Any change of these amino-acids will result in a protein mutant with 
lower affinity in unwinding dsRNA and dsDNA [1823.
The fold of domain 1 is very similar structurally to that of common ATP 
transphosphorylases (for example adenylate and thymidine kinases).
Figure 2.16. The GSGKST motif in domain 1 is conserved in kinases.
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The GSGKST motif in domain 1 is conserved to the same loop in kinases, where its 
role involves binding of the p-phosphate of ATP [i83i. Site mutagenesis studies of 
that motif have reported that the mutant protein is inactive.
Another crucial motif for the helicase is the DExH motif (motif II). The DExH 
motif is responsible for the binding of the Mg2+-ATP substrate. Studies in 
adenylate and thymidine kinases revealed that an aspartate binds the Mg2+ and 
helps to establish the optimum orientation of ATP for nucleophilic attack [i«i. 
Mutating this aspartate to any other amino acid will produce a helicase incapable 
of hydrolysing ATP. Also His293 is involved in the hydrolysis of ATP. Mutation of 
His293 will lead to an inactive helicase, but still capable of hydrolysing ATP. It is 
suggested that this residue plays a key role between the ATP hydrolysis and
nucleotide binding process [i85].
Figure 2.17. The DExH motif, which is responsible for the binding of the Mg2+-  
ATP substrate.
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The role of the QRxGRxGR motif is not clear yet, but this motif appears in most of 
the helicases of this family. Site mutagenesis studies revealed that mutation of this 
motif in vaccinia virus helicase will produce a helicase that posses much less 
ATPase activity [i87].
Motif VI consists of three conserved arginines [iss]. All three arginines are involved 
in the binding of ssRNA in the helicase’s channel between domains 1 and 2. Kim 
suggested that Arg461 is hydrogen bonded to Asp412 and Asp412 interacts with 
ssRNA. So, there is an indirect importance of the Arg461, which is to keep the 
Asp412 in the correct orientation for the RNA to be able to interact with it. 
Mutagenesis studies of the arginines revealed that the resulting helicase has 
decreased RNA binding affinity [i77j.
Arg464 and Arg467 are expected to interact with ATP from mutation studies. 
Mutating the arginines to alanine or glutamine in vaccinia NPH-II or eIF-4A 
reduced the ATPase activity by 20% [i89]. Arg467 is found to be conserved among 
all the superfamilies of helicases [i9o].
Motif III is located in-between the first and the second domains. Its role is to 
operate as a “hinge” offering the all important flexibility to the helicase protein 
ti9i]. The la motif constitutes part of the beta sheet in the 1st domain, while 
interacting with the oligonucleotide too. Motif V is also in contact with the 
oligonucleotide. Thr411 hydrogen bonds to a phosphate of an oligonucleotide. The 
usually conserved motif IV (from known helicases) is absent from the HepC 
helicase though.
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There has been extensive work done on the motif IV of the superfamily I and II of 
helicases, but it was either done using weak criteria for the alignments or the 
HepC helicase evolved in a different fashion than the rest of the members of the 
two superfamilies. In the rest, of the DNA helicases of these superfamilies of 
helicases, motif IV is involved in the binding of ATP [192].
Residues in the HepC helicase that would be expected to constitute part of motif 
IV are the residues Ser370 and Lys371. Ser370 interacts with the oligonucleotide 
via a water-mediated hydrogen bond and Lys371 establishes a backbone 
interaction [193].
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2.2.4 The Proposed function of the HCV Helicase
The conserved motif VI is found across the inner part of the channel in 
flaviviridae helicases and it extends into the ATP site. The same pattern is seen in 
the structures of the adenylate kinases [imj. In the group of adenylate kinases the 
conserved motif starts from the channel, where the oligonucleotide binds and 
extends into the ATP binding site. The purpose for this is that the binding of ATP 
or ATP analogues will have an immediate and direct allosteric effect on the 
helicase [i«]. So, the energy of the hydrolysis of ATP is utilised directly for the 
purposes of the enzyme, without losing any of it in exchanges between different 
motifs or “loose connections” [i96].
The binding of the ATP (or its analogues) will result in a conformational change in 
the structure of the enzyme. The most significant movements include the burial of 
the phosphates that were exposed to the solvent. Mutation studies on the ATP 
interacting residues, which lead to helicases incapable of ATP hydrolysis, have 
resulted in a wider configuration of the helicase molecule with much lower 
affinity for unwinding double stranded nucleotides [197].
Upon ATP binding, the domains one and two get together by the conformational 
change initiated originally in motif VI. This pattern would be expected to be 
common in all superfamily I and II members due to the consistency of the 
conserved motif VI [i98].
The residues Gln460 and His293 belong to the motif VI and stand on opposite sites
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in the oligonucleotide-binding channel. These two residues may be the ones 
responsible for regulating the equilibrium between the “tense” and “relaxed” states 
upon binding of the polynucleotide. The importance of these two amino acids was 
suspected by the fact that helicases with the DExH motif II often have a glutamine 
residue in motif VI, whereas helicases that have a DEAD motif often come with a 
histidine residue in this position [i98].
ATP
ADP
Figure 2.18. The schematic mechanism of RNA unwinding with the HepC 
Helicase. The binding of ATP will initiate the movement of domains one and two 
and the opening of the RNA binding channel, so that the ssRNA can translocate in 
the 5’ to 3’ direction
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The suspicion that the 2nd domain is flexibly linked to the rest of the protein was 
confirmed from the work of Yao et al{\99\. The 2nd domain of the hepatitis C virus 
interacts directly with the polynucleotide. The movement of the above domain 
could influence a relative movement of the polynucleotide as well (compared to 
the rest of the protein). The residues Val432 and Thr448 may interact with the 
nucleotide bases at the 5' end of the single-stranded nucleic acid, and this can 
result in a movement of the polynucleotide from the 5’ towards the 3’ direction -  
during the closure of the 2nd domain [200]. Trp501 helps the single stranded nucleic 
acid to give up on its interaction with its surrounding residues. The positioning of 
Trp501 will only help the movement of the polynucleotide towards the 5’ 
direction. The hydrolysis of ATP and the release of ADP will result in a slight 
opening of the polynucleotide channel and a coordinated movement of the whole 
domain 2 of the helicase towards the 5’ direction [201].
So the hydrolysis of ATP will result in the movement of the polynucleotide 
relative to the rest of the helicase. Apparently, it has been found that helicases are 
capable of moving several bases from the polynucleotide per ATP molecule that is 
hydrolysed to ADP [202].
As mentioned before, the HepC helicase is very similar to other helicase 
(structurally), from superfamilies I and II [203]. So, instead of just sharing sequence 
similarities amongst them, the HCV helicase shares many conserved common 
motifs in its structure. There are two motifs that have been found to be extremely 
vital for the winding of the double stranded nucleic acids in the helicases [204]. The
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first motif is the YRGADV structurally conserved motif and the second one is the 
DFSLDPTF structurally conserved motif. The YRGADV motif is the link between 
the IV and the V motifs in the superfamily II helicases. At the end of this loop lies 
the residue Arg393. Mutagenesis studies have shown that upon mutation of the 
residue of Arg393 to Ala, the recombinant protein is incapable of unwinding 
double stranded polynucleotides [205]. Combined with the fact that this arginine 
residue (Arg393) is fully exposed to the solvent and the nature of the arginine 
amino acid, makes it a very good target for drug design experiments in an attempt 
to design compounds that will inhibit the function of the HCV helicase. The 
affinity of RNA winding is not completely lost to the mutant helicase, but it is 
extensively reduced pt*].
Motif DFSLDPTF is the link of the two anti-parallel beta sheets between the V 
and VI motifs. Mutagenesis studies for this motif involve the manipulation and 
mutation of the residue Phe444. Mutating Phe444 to Ala will produce a protein 
that is capable of hydrolysing ATP, but incapable of unwinding dsRNA. The 
affinity for unwinding dsDNA has dropped to half compared to the original 
helicase [207].
These two motifs are known as Arg-clamp and Phe-loop respectively among all 
helicases of HCV (including various genotypes and quasispecies). What makes 
these two motifs unique, is the fact that they only appear on HepC helicases and 
not on the other helicases of the superfamily I and II [208].
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ssRNA
Figure 2.19. The HepC helicase with the Arg393 residue shown in stick 
representation. It can be seen that the function of this Arginine residue is to hold 
the oligonucleotide in place.
This characteristic gives these two motifs special value, since they constitute ideal 
drug targets for structure-based drug design. The position of the two key residues 
(Arg393 and Phe444) is shown in figure 2.19. The side chain of the residues 
Arg393 is only 2.5 A away from the phosphate backbone of the RNA. On the 
other hand the distance of Phe444 is almost 15 A away from the phosphate 
backbone of the RNA. It was not clear whether the RNA strand that is located in 
the channel of the HepC helicase (figure 2.19) was the translocating or the 
complementary strand. The interactions between the Arg393 residue and the 
oligonucleotide (figure 2.19) reveal that the binding is too tight and this implies 
that the strand in the channel of the helicase is probably the translocating one [209]. 
The helicase in figure 2.20 is in its ground-state configuration with the single­
stranded oligonucleotide located in the major channel of the helicase protein. The 
oligonucleotide is picking many interactions from the protein and this does not 
seem to favour the unwinding process.
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Figure 2.20. A and B show the locations of the Arg-clamp and the Phe loop in the 
helicase structure of HCV. C is another attempt to explain the mechanism of 
action of the HCV helicase (Domain 1 is red, domain 2 is blue and domain 3 is 
gray). When ATP is not present the helicase is interacting with the 
oligonucleotide so strongly that it is impossible for it to slide through. After ATP 
binding though, Domains 1 and 2 come closer and the channel between domains 
1-2 and 3 becomes bigger and this allows the oligonucleotide to slide towards the 
3’ direction p u g .
The problem is that the residues of the surrounding amino acids are too close to 
the ssRNA and this probably stabilises it in the protein p i n .  The loosening of the 
interactions between the protein and the ssRNA is achieved by the contribution of 
ATP. ATP or any ATP analogues bind to the ATP binding site, which is on the 
same motif with the RNA binding site, the energy released by the hydrolysis to
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ADP will initiate an allosteric effect in the helicase that will eventually result in 
the movement of the second domain and the loosening of the interaction with the 
oligonucleotide. This will last until the effect from the hydrolysis of the ATP is 
finished. Then the helicase will go back to its “closed” or “ground” state. To sum 
up it appears that offering energy to the helicase drives the protein to its “excited” 
state, and enables it to slide along the polynucleotide chain [212].
The structures of x-ray data of two helicases, one with the bound oligonucleotide 
and the other without it, were compared. Both structures came from the same 
HCV genotype and the sequence alignment proved that they are identical. It was 
proven that the channel of the helicase without the bound oligonucleotide is 
tighter than the one with the oligo. Moreover it was found that in the helicase 
with the bound oligonucleotide, Arg393 is further away from the ssRNA and the 
Trp501 is further too. This proves that there is a coordinated action and movement 
of amino acids in the helicase during the oligonucleotide binding with a general 
loosening of interactions during the sliding of the helicases [213].
It is demonstrated in figure 2.19 that the Arg393 residue interacts with the bound 
ssRNA molecule both when ATP is present and not. It has also been shown that 
the AG of the RNA binding to the helicase in the presence of ADP is weaker when 
Arg393 is absent (mutated to Ala). Focusing on residue 393 in the wild type 
helicase and in the mutated one (Arg393 to Ala393), the AG contribution of the 
393 residue was found to be ten times stronger in the wild type one when the
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Arg393 is present. That is another proof of the fact that the Arg393 is an excellent 
target for drug design experiments puj.
The Phe loop is basically focused on the amino acids Phe438 and Phe444, but it 
also involves the following four amino acids, which are located in close proximity: 
His528, Phe531, Trp532 and Phe536. The vitality of the existence of these amino 
acids is confirmed by mutagenesis studies on the helicase. The mutation of any of 
these residues will lead to a mutant with no helicase unwinding capabilities [215]. 
Neighbouring amino acids should also be considered. For example Arg393 next to 
the conserved Tyr392, which is thought to work in a similar function with Trp501 
[2i6]. Tyr392 is thought to hold nucleotide chain from backsliding towards the 3’ 
direction. Mutating Tyr392 to Ala though does not change the unwinding 
capabilities of the helicase at all [216].
Another vital amino acid that was found after examining the binding mode of 
ssRNA in the HepC helicase is the Cys431. This amino acid was shown to have 
bonded with a small molecule, probably from the crystallisation process. The 
capability of this residue to interact with a molecule alien to the protein-ssRNA 
complex is proof that Cys431 is a good target for drug design. Furthermore the 
accessible area of the residue (to the solvent) is large (~75%) and the position of 
the residue in the helicase’s channel is strategic. As will be described later on, the 
positions of residues Arg393 and Cys431 will be exploited by structure-based drug 
design experiments.
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2.2.5 De novo drug design for the HCV helicase
Cys431 has established a S-S bond with a mercaptoethanol (HS-CH2-CH2-OH) in 
the HCV helicase x-ray structure. That can only mean that the Cys431 is accessible 
to the solvent, even when ssRNA is present, and could potentially establish 
interactions with a future inhibitor. Cys431 is located in a very strategic position 
for the blocking of the passage of the ssRNA through the helicase (figure 2.21).
Figure 2.21. Choosing the right starting point for the growing algorithm is a very 
crucial step. Here the seed was included in the PDB file (1A1V).
Further examination of the helicase for exposed to the solvent residues revealed 
two arginine residues (Arg393 and Arg481), positioned in such a way that the 
ssRNA was crossing the space between them. These residues were set to define a 
possible active site of the helicase that could be targeted for the design of novel 
inhibitors: the arginine residues could establish H-bonds, whereas the Cys431
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residue could possibly react with the compound, maybe establishing a S-S or a 
Hydrogen bond. Ideally, such an inhibitor would interact with the two Arg393, 
Arg481 and the Cys431, thus forming a bridge in the middle of the RNA channel 
in the helicase. If the compound covalently bonds to the receptor, then it is 
expected to be strong enough to block the passage of the ssRNA thus inhibiting 
the helicase.
A variety of different seeds was tested, the most suitable one was a small 
compound attached to the Cys431. First the S-S bond was broken and missing 
hydrogens were restored on both sulphur atoms (one of the compound and the 
other of the Cys431 residue). Then the oxygen was removed, since its existence 
would significantly reduce the number of fragments suitable for that seed-receptor 
arrangement. The remaining compound was used as a starting point for the 
“growing” algorithm of LigBuilder.
kWKKKmm
Figure 2.22. The co-crystallised fragment was firstly released from Cys431 by 
breaking the S-S bond and then the p-mercaptoethanol OH was removed, since an 
-OH group would dramatically limit the diversity of the generated compounds.
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The complex was energetically minimised using a molecular mechanics algorithm, 
having fixed the backbone of the protein. The detached compound was entered as 
the starting point of the drug design algorithm and thus it was expected that this 
moiety would be present in this position on all the new compounds.
Figure 2.23. The Active site analysis of LigBuilder prior to the analysis of the seed. 
The receptor is examined and probable (predicted) electron-donating regions are 
coloured blue whereas probable electron-accepting regions are coloured red. In 
the next steps the algorithm will position the “seed” in space and depending on the 
area that it falls in, the algorithm will attempt to combine the suitable fragments 
from its database, trying to satisfy all user and built-in criteria.
The algorithm used the small compound as a starting point and started to grow 
structures by combining different chemical fragments that it stores in its database. 
The criteria are to optimally utilise the available space of the receptor and to
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establish the maximum amount of interactions with the adjacent residues of the 
helicase (Figure 2.23). All the different compounds that were designed were 
deposited in a folder for further investigation. A similarity cut-off of 90% was used 
in order to make sure that structurally all the different compounds in that folder 
would be at least 90% different. The space available (Figure 2.24) was filled with 
newly designed compounds, with the only size-limiting parameter being the pre­
defined molecular weight of the compound. For all drug design experiments the 
Lipinsky’s drug-likeness rules were applied [217].
Figure 2.24. Distances and the available space in the Helicase’s active site
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After many iterations of the genetic algorithm of LigBuilder a possible lead was 
obtained, which had all the moieties that could interact with the given active site 
on the helicase and met all algorithm’s criteria, but, unfortunately, it cannot be 
considered a suitable drug. The lead compound from LigBuilder had 16 chiral 
centres and would not be feasible to synthesise (Figure 2.25).
,OH
HOj
Figure 2.25. The lead compound generated by LigBuilder docked into the helicase
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From the observation of the ligand/protein complex it is evident that the computer 
program tried to fill all available space and, in order to obtain useful results, we 
had to force the software to use only the space defined by the three target 
residues. That was achieved by physically incorporating a tube-like structure that 
encloses all key residues and restricts considerably the search space (figure 2.26). 
The tube was originally made from carbon atoms and the PDB file pw] was edited 
converting the carbon atoms to “Dummy” atoms (Du). Du atoms do not have any 
atomic properties, they are incapable of establishing interactions of any nature and 
they have no charge. In this way the tube acts as an inert wall, limiting noticeably 
the search space.
Figure 2.26. The application of the tube simplified the task of LigBuilder.
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The structures that LigBuilder generated (Figure 2.27) proved to be considerably 
simpler and more drug-like. The novel structure was isolated and then docked 
again into the original receptor, where it originated from. Only this time the 
“tube” was not present and the full receptor was available to be explored by the 
docking algorithm.
The result of the docking confirmed that this compound, that had been 
specifically designed for the particular area (between Arg481-Cys431-Arg393) on 
the helicase found its way to the suggested site and managed to establish the 
interactions that it was supposed to (figure 2.27). The second best lead from 
LigBuilder was the same compound with an extra CH3 substitution on one of the 
phenyl rings. That C H 3  was able to interact with the sulphur of the Cys431 and 
further stabilise the docking.
It is obvious that the presence of the extra carbon has pushed the compound a bit 
lower, which is evidence that the extra carbon successfully established an 
interaction with the nearby available sulphur from the Cys431 residue.
Following these promising results, we decide to use this structure as our basic 
scaffold for the design of a potential inhibitor capable of reacting with the desired 
cysteine (figure 2.27). To achieve this, our initial step was to include a chemical 
moiety able to react with the sulphur atom of Cys431. Michael acceptors, like the 
vinyl ketone, are known to react quickly with thiols and we decide to include this 
moiety in our compound replacing one of the acid groups (Figure 2.27b). The
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ketone should be still able to form the hydrogen bond with Arg481 while the 
cysteine should be close enough to react with the double bond.
Figure 2.27. The new lead compounds using LigBuilder and the “tube”
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We were not able to dock successfully compound B (Figure 2.28) into the active 
site, simply because the structure was now too big to fit between the two 
arginines, but a simple change in the position of the vinyl ketone to the meta 
position led to compound C which was able to dock in the desired position. 
Although the obtained molecule has all the desired properties, we have further 
modified the structure by replacing one of the carbon atoms of the linking double 
bond with a nitrogen atom, to simplify the synthetic procedure (Figure 2.29).
A
HO
OH
OH
OH
OH
o
// \
\  //
Figure 2.28. Route followed for the design of the final compound. 
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Compound D can be further functionalised by adding a side chain that could 
stabilise the ligand / protein complex by establishing new interactions with the 
enzyme. Those interactions mainly involve new hydrogen bonds, possibly with 
Cys431. It is important to mention that the last two modifications were “chemistry 
driven” and an already established synthetic methodology could be applied to 
obtain compound E in 3 steps [219-221]. (figure 2.29) .
D M S O
M e O N a
Figure 2.29. Proposed synthetic scheme.
Observing the minimised docking result of the compound E/helicase complex 
(figure 2.30), we can appreciate how the carboxylic acid moiety nicely interacts 
with Arg393 while the ketone forms a hydrogen bond with Arg482. The sulphur 
atom is just 4A  away from the carbon atom and it should react with it, since it is 
correctly placed for a nucleophilic attack to the double bond of the vinyl ketone 
moiety (Figure 2.30).
Di mi trios Vlachakis, PhD 2006 102
Chapter 2 Molecular Modelling
Figure 2.30. The combined lead from all different LigBuilder Experiments.
In conclusion, we have designed a series of compounds (figure 2.28) as potential 
inhibitors of the HCV helicase. These molecules have all the desired properties: 
they interact with the proposed key residues (Arg393, Cys431 and Arg481) and 
their structural simplicity should allow a simple synthesis. At this point, all 
compounds in figure 2.28 are currently being prepared by other members of the 
group.
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2.2.6 A Comparison between two X-ray Resolved Polymerases
The HCV and BVDV polymerases have both been resolved by x-ray 
crystallography, and their 3D coordinates have been deposited at the PDB web 
site. Initially, the obtaining homology models for the Dengue, West Nile, Japanese 
Encephalitis and Yellow Fever viruses seemed impossible due to the low sequence 
identity between the available templates and the model sequences, which is 
approximately 17% with both HCV and BVDV as templates (Figure 2.31). 
Generally, such low identity does not allow homology modelling but considering 
that our aim is to design models that could be used later on as templates for the 
drug design experiments, the overall accuracy of the generated structures is not as 
significant as the local reliability of the RNA-binding site, which is going to be 
used as the target area for the inhibitor design experiments. Furthermore, 
structural comparison between the HCV and BVDV polymerase proteins revealed 
that even though their overall sequence alignment score is very low (11% 
homology), the area around the co-crystallised oligonucleotide is very much 
conserved (figure 2.32). Structural superimposition between the polymerases of 
HCV and BVDV reveals that structure is more conserved than sequence. This also 
means that even though the overall alignment score is not satisfactory, the HCV 
and BVDV could be used as templates for the rest of the Flaviviridae models 
focusing on an accurate modelling of the active site area and the conservation of 
all known structural motifs vital for the function of the Flaviviridae polymerases.
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Figure 2.32. The 3D structures of the HCV and BVDV polymerases. Green is 
the HCV and Red the BVDV polymerase. Blue is the RNA oligonucleotide. 
Both structures have been resolved by x-ray crystallography. Although they 
only share 10% sequence identity, their structure, and structural elements are 
much more conserved. Superimposition of the two structures yields an RMSD 
of 1.9 A. It becomes apparent that it is not the alignment score that mostly 
influences the accuracy of the homology models, but the conservation of the 
vital motifs for the enzyme to be functional. Here is can be seen that the RNA 
interacting residues are conserved between the HCV and BVDV polymerases. 
The RNA binding site should be conserved to all new models.
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The theoretical structure of the polymerase proteins for each of the species of 
Dengue, West Nile virus, Japanese Encephalitis and Yellow Fever were modelled 
using the HCV and BVDV polymerases as a template structures. The alignment 
identity of the models against the template was calculated to be approximately 
17%. It can be seen from the structural alignment of figure 2.31 that even though 
the sequence alignment between Dengue, West Nile Virus, Japanese encephalitis, 
yellow fever and either of the HCV or BVDV templates is very low, the alignment 
score between the four sequences to be modeled exceeds 50%.
All four polymerase models were expected to bind the ssRNA oligonucleotide in 
the same way that HCV polymerase does. In order to ensure that the models will 
have by default a properly shaped active site and to further provide a scaffold to 
the algorithm, the ssRNA fragment found in the HepC X-Ray file was 
incorporated as part of the template structure during the building of the homology 
model.
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2.2.7 The ligand supported homology modelling using MODELLER
The design of the initial model was done using MODELLER [222], which is a 
complete homology modelling software package that generates 3D structures of 
models based on the information from the initial sequence alignment. Spatial 
restraints are attempted to be satisfied according to the rules imposed by the 
CHARMM22 built-in forcefield. The 3D protein model is obtained by optimising 
the molecular probability density function while simultaneously minimising input 
restraint violations [222]. To guarantee sufficient conformational sampling of each 
active-site residue, several homology models are generated in this step. 
Preliminary tests showed that a number between 10 and 100 models provides a 
satisfactory sampling. To optimise the local interactions, all models obtained are 
subjected to a crude simulated annealing refinement protocol available in 
MODELLER (Figure 2.33). Positioning the “ligand” ssRNA into the homology 
model was done from the information obtained from the Hepatitis C template 
polymerase. Here it is assumed that ssRNA will bind the model in a mode similar 
to the one in the template protein. As a result, the ssRNA fragment was copied and 
moved into the resulting model whilst keeping its orientation and initial 
conformation to be used as a restraint for the model building process (Figure 2.34). 
The ssRNA fragment was kept fixed in all steps of the homology modelling 
experiment using user-defined restraints (Figure 2.35).
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The Dengue Virus Polymerase The West Nile Virus Polymerase
The Jap. Encephalitis Polymerase The Yellow Fever Polymerase
Figure 2.33. The four Helicase Models: the Dengue virus (top left), the West Nile 
virus (top right), the Japanese Encephalitis virus (bottom left) and the Yellow 
Fever virus (bottom right).
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Figure 2.34. (a) The three dimensional structure of HepC polymerase determined 
by X-ray crystallography (pdb code: 1HB7). (b) The predicted three dimensional 
structure of the dengue polymerase by homology modelling and (c) the 
superimposition of (a) and (b). 1HB7 is in Green and the dengue model is in Red.
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I
Figure 2.35. The superimposifion of the key residues that interact with the ssRNA. 
For example this Arg (Si) residue is located at the exact same position, with the 
exact same geometry and orientation on all 4 models as in the template protein. 
The key residues of a Flaviviridae polymerase have been highlighted in circles. 
Those ssRNA interacting residues have been conserved during homology 
modelling from template to models.
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2.2.8 Model Evaluation for the Polymerase
The models were initially checked with the built-in model evaluation function of 
the MOE package and was found to be perfect in dihedrals, angles and bond 
lengths. Minor atom-atom proximity contact errors were reported, but none of 
them was disturbing the 3D structure of the model or was contributing to an 
elevation of the overall energy of the complex, thus destabilising it. The 
polymerase models were then checked with a Ramachandran plot evaluation. The 
same energy minimisation and molecular dynamics process as in the Helicases 
section was performed. The results are summarised in the table below (table 2.2):
Table 2.2. The Procheck values of the polymerase models after homology and after 
optimization and re-evaluation.
After Homology After Energy Minimization & Model 
Optimization
Project Model Gore Allowed Generous Disallowed Gore Allowed Generous Disallowed
V
DenV 79.7 16.9 2.0 1.4 80.9 16.7 2.4 0
g% WNV 68.2 24.6 6.1 1.0 89.8 8.4 1.8 0t
3 JEV 68.7 24.1 6.4 0.8 92.1 4.9 3.0 0
YF 67.5 25.3 6.6 0.6 89.4 8.5 3.1 0
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2.2.9 Homology Modeling of the Dengue Polymerase using MQE
The homology modelling of the Dengue polymerase was also performed using the 
homology function of MOE. MOE homology algorithm allows the incorporation 
of multiple templates and this time both BVDV and HCV templates were used. 
Figure 2.36 shows the new alignment from MOE
Figure 2.36. The sequence Alignment of Dengue, HCV and BVDV used in MOE:
DENGUE ESETPNLDIIGKRIEKIKQEHETSWHY DQDHPY KTWAY HGSY ETKQTGSAS SMVNGWRL
HCV- H C V -1 NB --------------------------------------------------------------------SM SYTW T-GALITPCAAEESKLPINPLSNS
B V D V -IS  4 F VIREHNKW IL-KKI -RFQGNLNTK KMLNPGKLSE-QLDREGRKRNIYNHQIGTIMSS
DENGUE LTKPWDIIFMVTQMAMTDTTPFGQQRVFKEKVDTRTQEPKEGTKKIJHKITAEWLWKELGK
H C V -1N B 7 LLRHHNMV-YAT— TSRSASLR-QKKVTF DRLQVLDDHYRDVLKEMKAKAS--------------
B V D V -1 S 4 F  AG IR LEK LPIVR— AQT DTKTF- HEAIRDKIDKSENRQN PELHNKLLEIFHTIAQPTL—
DENGUE KKTPRMCTREEFTRKVRS-NAALGAIF-TDENKWKSAREAVEDSGFWELVDKERNLHLEG
H C V -1N B7 TVKAKLLSIEEACKLTPPHSAKSKFGYGAKDVRNLSSRAVNHIRSVWEDLLEDTETPIDT
B V D V -1S 4 F KHTYGEVTWEQLEAGVNR-KGAAGFLEKKNIGEVLDSEKHLVEQLVRDLKAGRKIKYYET
DENGUE KCETCVYNMMGKREKKLGEFGKAKGSRAIWYMWLGARFLEFEALGFLNEDHWFSRENSLS
H C V -1N B7 TIMAKSEVFC VQPEKGGRKP-ARLIVFPDLGVRVCEKMALYDWSTLPQAVMGSSY
B V D V -IS  4 F AIPKNEKRDVSD-DWQAGDLWEKRPRVIQY PEAKTRLAITKVMYNWVKQQPWIP— GY
DENGUE GVEGE GLHKLGYILRDVSKKEGGAMYADDTAGWDTRITLEDLKNEEMVTNHMEGEHKKLA
H C V -1N B7 GFQYSPKQRVEFLVNTWKSKKCPMGFSYDTRCFDSTVTESDIRVEESIYQCCD— LAPEA
B V D V -1 S 4 F  EGKTPLFNIFDKVRKEWDSFNEPVAVSFDTKAWDTQVTSKDLQLIGEIQKYYY— KKEWH
DENGUE EAIFKLTY QNKWRVQRPTPRGTVMDIISRRDQRGSGQWTY GLNTFTNMEAQLIRQMEG
H C V -1N B7 RQAIRSLTERLYIGGPLTNSKG QNCGYRRCRASGVLTTSCGNTLTCYLKATAACRAA
BVDV- 1 S 4 F  KFIDTITDHM TEVPVI TAD— G EVYIRNGQRGSGQPDTSAGNSMLNVLTMMYAFCES
DENGUE EG V- FKSIQH LTVTE EIAVKNWLVRVGRERLSRMAIS GDDCW  KPL DDRFASAL
H C V -1N B 7 KLQ------------------------------------------------------------- DCTMLVNGDDLWICE SAGTQEDAAALRAF
B V D V -1 S 4 F TGVPY KS FN---------------------------------------------RVAR IH VCGDDGFLITEKGL------- GLKFANKG
DENGUE T -  ALNDMGKVRKDIQQWE PS RGWNDWTQ VP FCS HH FHE LIMKDGRVL W PCRNQDE LIGR
H C V -1N B7 TEAMTRY SAPPGDP PQPEY-DLELITSCSSNVSVAHDASGKRVYYLTRDPTTPLAR
B V D V -IS  4 F MQILHEAGKPQKITEGEKMKVAY -R  FED IE  FCS HT PVPVRWS DNT S SHMAGRDTAVILSK
DENGUE A R IS  QGAGWS LRETACLGKSYAQMWS LMY FHRRDLRLAANAICS A -V P S  HWVPT SR
H C V -1N B7 AAWETARHTPINS-------------------------WLGNIIMYAPTLWARMILMTHFFSILLAQEQLEKAL
B V D V -1S 4 F MATR LDSSGE-RGTTAYEKAVAFSFLLMYSWNPLVRRICLLVLS— QQPETDPSKH
DENGUE TTWSIHATHEWMTTEIMLTVWNRVWIQENPVJMEDKTPVESWEEIPY LGKREDQWCG— SL
H C V -1N B7 D C Q IYG ACYS-IEPLDLPQ IIERL-H G LSAFTLH SYSPG EINRVASCLR KLGVPPL
B V D V -1S  4 F ATY------------------Y Y KGDPI GAY KDV-1GRNLSELKRTGFEKLANLNLSLSTLGVWTKHT SK
DENGUE IGLT S RATWAKNIQTAINQVRS LIGNEE Y T DYMPSMKR FR REE E E1AGVL---------- W------------
HCV- 1NB7 RTWRHRARSVRAKLLSQGGRAATCGRYLFNWAVRT-KLKLTPIPAASQLDLSGWFVAGYS
B V D V -1 S 4 F  RIIQDCVAIGKEEGNWLVKPDRLISSKTGHLYIPD-KGFTLQGKHY--------------------------------
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In yellow are the conserved residues among the Dengue, HCV and BVDV. The 
main template for the homology experiment is the BVDV and the HCV template 
has only been used for the RNA binding site alignment (HCV residues: 218-226 
corresponding to BVDV residues: 532-540). The Mn++ atoms were pasted from the 
HCV template into the model. The same was done with the ssRNA 
oligonucleotide. MOE generated a series of possible conformations for the model, 
which was saved in a database, and then averages were saved in a single pdb file. 
The best model as ranked by the algorithm was chosen to be further optimized by 
molecular dynamics.
The molecular dynamics calculations were done using GROMACS 3.2 
[www.gromacs.com]. There are two important parameters that define the molecular 
system in a dynamics simulation. Those are the coordinates and the topology of 
the system. The coordinates are the ensemble of the Cartesian (x, y, z) position of 
each atom in the system. The topology of the system contains all the atomic 
parameters, such as charges, bond lengths, bond angles and dihedrals. The 
GROMACS suite contains a database with all amino acid and nucleotide 
topologies. In this study, not only the topology of the protein residues had to be 
defined, but the RNA too. The ssRNA of the template consists of four uridines and 
although GROMACS has the residue “URA” (a standard uridine) already defined 
in its database, two new residues had to be defined: the “URD”, which is the first 
uridine and the “URF”, which is the last one. “URD” is a uridine without its 
phosphate group at the 5’ position and “URF” is a uridine monophosphate, but
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with a hydrogen in the position of the 3’ -OH. In GROMACS the URA nucleotide 
is defined as N-0-Uridine-P03*N, where N is the next heterocyclic base of the 
RNA It means that there is no clear topology for terminal bases, but only for those 
in the middle of the nucleic acid strain.
Another issue was that after defining the URD and URF nucleotides the molecular 
dynamics program would not connect the 4 bases, but position them as individual 
nucleotides in space (URD URA URA URF). The topology was edited again and 
the correct type of bonds, angles and dihedrals were defined. Finally the four 
nucleotides were bonded together forming a small oligonucleotide chain (URD- 
URA-URA-URF), corresponding to the ssRNA taken from the template. 
Furthermore, the correct parameters for Mn++ where not included in GROMACS. 
Thus the ions where substituted with Mg++ ions, which are correctly parameterised 
by GROMACS. Having defined everything in the molecular system, the latter was 
ready to proceed to a geometry and energy optimisation by molecular dynamics. 
The molecular dynamics were initiated by generating a periodic box enclosing the 
system, which was then filled with water and the system was neutralised, by 
exchanging water molecules with the appropriate ions. The system was 
energetically minimised using the steepest descent algorithm, in an attempt to give 
the system the opportunity to optimise its conformation in the ssRNA area. The 
molecular dynamics simulation was run having constrained all the bond lengths of 
the molecular system for 1 nanosecond in an NVT environment. After that time, 
the water was removed and the system was energetically minimised using a
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Figure 2.37. The three Aspartic Acids 
coordinated around the Mn++ atoms in the 
Dengue Polymerase Model.
an attempt to allow the 
system to improve its 
geometry without moving 
too far away from its original conformation. Figure 2.37 shows the two models and 
the 3 Asp residues coordinated against the two Mg+t atoms. Figure 2.38 shows the 
Dengue polymerase model and the ssRNA (in Green) in very close proximity to 
the three Asp residues (in spacefill representation).
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steepest descent initially 
and a conjugate gradient 
algorithm later from
within GROMACS.
The restrains were used in
Figure 2.38. The model of the Dengue Polymerase by GROMACS (in green is 
ssrna and in spacefill representation are the three Asp residues.
the
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2.2.10 Discussion of the Helicase Models
There are 5 conserved motifs that are highly conserved in all Flaviviridae 
Polymerases [223]. Those motifs are found in the two x-ray resolved models and 
were also inherited by the four models.
Motif I is used for Magnesium coordination or sugar selection. There are three 
highly conserved ASPs in this motif. Motif II is supposed to participate in the 
sugar selection process with the sequence GxxxTxxxNTxT. Motif III is used to 
coordinate the magnesium atoms as well, and is made of GDD. Motif IV completes 
the palm structure and must contain either an R or a K. Motif V establishes 
hydrophobic interaction with the thumb and is made of a conserved CS and an 
overall hydrophobic patch around it.
The function of the Flaviviridae polymerase N-terminal domain is not known. The 
C-terminal residues are highly hydrophobic and predicted to be membrane- 
anchoring region. The Flaviviridae polymerases present a deep cleft in the middle 
with the palm at the base. The fingers and thumb domains are both important for 
correctly positioning the substrates for catalysis by the palm domain. Like 
poliovirus polymerase and calicivirus RNA polymerase, their structure shows an 
elaborate arrangement of polymerase domains that have been termed “fingers,” 
“palm,” and “thumb,” on the basis of its resemblance to a right hand. The overall 
topology of the flaviviridae polymerase models has a typical ’right hand' 
polymerase structure, with catalytic sites in the base of the palm domain,
Dimitrios Vlachakis, PhD 2006 117
Chapter 2 __________________________________________ Molecular Modelling
surrounded by thumb and finger domains (Figure 2.39). These latter domains fully 
encircle the active site, creating a channel for binding to a ssRNA template. In 
addition, a &-hairpin structure protrudes from the thumb toward the active site 
and is likely to be involved in correct positioning of the template. The overall 
structure of NS5B is remarkably similar to the RNA dependent RNA polymerases 
(RdRp) of bacteriophage PHI 6. NS5B also has a low-affinity GTP-binding site, 
distal from the active site, which is thought to be an allosteric regulator of the 
finger-thumb interaction (Figure 2.40). NS5B is tethered to membranes by a C- 
terminal peptide anchor and interacts with itself to form higher-order RdRP 
complexes.
PALM
FINGERS
THUMB
Figure 2.39. Ribbon diagram of predicted three dimensional structure of Dengue 
polymerase showing the conserved fingers, palm and thumb domains common to 
all Flaviviridae polymerases.
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The fingers domain contributes to binding both the incoming NTP and the 
template-strand. The fingers domain of the flaviviridae polymerases can be divided 
into a palm-proximal region that is an a-helix-rich subdomain called a  fingers, 
and a distal region that is a ^-strand-rich subdomain, which we have named the 
“fingertips” or p fingers. The fingertips subdomain is composed of seven p-strands 
and three a-helices. There are three conserved sequence motifs (F-H) shared by 
all RdRps in the fingers domain that play an important functional roles in the 
mechanism of polymerization [223]. Motif F contains several conserved positively 
charged residues (KxxRxxxxxxxxxR). It forms a p-strand and two a-helixes, and 
combines the fingers and the thumb to help build the nucleotide import tunnel 
and help position the incoming templates. Motif G also contains several conserved 
positively charged residues (xxxKxExxx). Motif H contains an a-helix and a p- 
strand in Dengue RdRp, while in most RdRp structures, the motif H forms a loop 
and an a-helix. This structural element lies at the gate of the template tunnel, and 
is also predicted to be involved in orientation of incoming template [223].
The palm is the catalytic domain and contains a folding motif that is highly 
conversed among polymerases. It consists of a three-stranded antiparallel p-sheet, 
a small helix, three supporting a-helices and a p-strand. The antiparallel p-sheet 
exists in all RdRps and is the catalytic core of the palm domain. At the interface 
with the thumb domain, a long loop followed by the pair of p-strands belonging to 
the thumb domain completes the palm domain. This pair of p-strands region is 
similar in all RdRps and in HIV-1 Reverse Transcriptase (RT). The palm domain,
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the catalytic domain of RdRp, contains the four-amino acid sequence motifs found 
in all classes of polymerases, named A-D, plus a fifth motif, E. The A-D motifs are 
highly conversed in RdRp, and motif A and C are also found in the DNA 
polymerase, whereas motif D, like motif B, is conserved in sequence only in the 
RNA-directed polymerases. Motif E occurs only in RdRps and RTs. Motif A 
contains three aspartic acid residues (DTxxxDxxxTxxDxxxxxxx), which are 
responsible for binding the catalytic metal ions. The Aspartic acid near the end of 
the p-strand is completely conserved in all classes of polymerases. Motif C contains 
the highly conserved GDD motif that coordinates the catalytic metal ions (Figure 
2.40). This structure is very similar in all classes of polymerases and positions the 
two aspartates (xxxxxGDDxxx) close to the conserved aspartate of motif A. In 
motif E, the hydrophobic residues are important for the interactions with the palm 
core structure and account for the conservation of several hydrophobic residues in 
motifs A, C and D of RNA-dependent polymerases.
The thumb domain of the flaviviridae RNA-dependent RNA polymerases contain 
motif I, consisting of an a-helix and a p-strand. An arginine is a strictly conserved 
residue in the motif, and is essential for enzymatic efficiency. The corresponding 
thumb region in HCV is mainly a-helical, containing eight a-helices and four p- 
strands. In Dengue RdRp there is a long loop rich in positively charged residues 
near the gate of the template tunnel. Moreover, Dengue RdRp, similar to HCV 
RdRp, has a long p-hairpin connecting two a-helices and occluding the active site 
cleft. This hairpin acts as a discriminator for distinguishing the single-stranded
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RNA templates from double-stranded RNA. Without the p-hairpin structure, 
calicivirus, poliovirus and 0 6  enzymes are consistent with the ability of these 
enzymes to utilise double-stranded RNA as templates [223]. Another function of this 
domain is to form a hydrophobic binding pocket near the domain core with the 
help of the palm domain and two long loops of the fingers domain [223].
Figure 2.40. Catalytic residues (drawn in ball and stick conformation) of predicted 
three-dimensional structure of Dengue Polymerase and crystal structure of HCV 
Polymerase.
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3.1 Introduction
The genes encoding for the HCV helicase protein, Dengue type 2 NS3 domain (full 
length -  1.8kb) and helicase protein (alone -  1.3kb) were obtained from a cDNA 
library, from the Pasteur Institute in Paris, in order to produce the corresponding 
recombinant proteins. The cDNA product was amplified by PCR and ligated into the 
pGEM-T plasmid [224] and later on the pET28a and pET23b+c plasmids [225], which 
encode ampicillin resistance. The plasmid was transformed into E. Coli bacteria (DH5- 
a) strain [226] and the bacteria were plated out on ampicillin containing plates. The 
only surviving bacteria the next day should be those carrying the pGEM-T plasmid. 
Single colonies were picked and cultured overnight in liquid suspensions. Then the 
cells were lysed and their plasmid was extracted (mini-prep). The molecular weight of 
the plasmids was confirmed by gel electrophoresis. The DNA was then purified and 
concentrated to be sequenced with custom-made primers that had to be designed for 
complete sequencing of the insert. Then the inserts were re-cloned into the 
expression vectors pET28a and pET23b+c, in order to prepare for protein expression.
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3.1.1 Polymerase Chain Reaction
The sequences encoding (i) the full length NS3 and (ii) the helicase domain alone 
were amplified by PCR. Gene specific (custom-made) forward and reverse primers 
were used:
NS3F: AAGCTTGCCGGAGTATTGTGGGATG
NS3R: AAGCTTCTACTTT CTTCCGGCT GC AAATT C
HELF: AAGCTTAGTGCTATAGCCCAGACTG
NS3F > HELF >
<  NS3R
Figure 3.1. The annealing of the custom-made primers for the two genes in PCR.
The two primers annealed at each end on the NS3 & the helicase genes and the PCR 
reaction went on for 30 cycles. The cycle used was the default one involving the 
denaturing of DNA at 95 °C for one minute then the temperature was decreased to 58 
°C for one minute in order to initiate primer annealing and then increased to 72 °C for 
five minutes to allow the DNA polymerase to extend the DNA (Figure 3.2).
npevtedfcr 30 cycles
72 “C
Figure 3.2. The PCR conditions for the amplification of the NS3 & Helicase Domains.
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3.1.2 Plasmid Preparation & Phosphatase Reaction
Restriction enzymes are the main tools used for cloning. These enzymes are able to 
cut DNA at specific recognition sites. Here, the plasmid of pET23b was cut at its 
unique Hind III [227].
Hind  III Hind III
5’XXAAGC TTXXXXXXXXXXXXXXXXXXXX \GCTTXX 
3 XXTTCGA AXXXXXXXXXXXXXXXXXXXX f XGA \XXf
XXA
XXTTCGA
DNA igase AGCTTXX
AXX
XXAAGCTTXX 
XXTTCGA AXX
To stop the plasmid religating to its original circular form a phosphatase reaction was 
performed straight after digestion. The phosphatase reaction removed the phosphate 
groups from the 5’ ends of the restricted plasmid so that the overhanging ends could 
not get back together. The insert has phosphate groups at both of its ends and this 
way when the insert was applied there was no problem for it to ligate to the plasmid. 
The insert was capable of ligating to the vector, since it was carrying its own 
phosphate groups at both its 5’ ends. Self-ligation of the insert is possible, but since it 
would not encode Amp resistance it will not be able to survive the antibiotics.
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3.1.3 Gene Insertion - Ligation
The process of joining DNA fragments together with covalent bonds is known as 
ligation. In a ligation reaction a phosphodiester bond is formed between the 3' 
hydroxyl end of one nucleotide chain and the 51 phosphate end of another. The 
enzyme used in the experiment was the T4 DNA ligase (from T4 bacteriophage [228]). 
The plasmid and the inserts were digested with the appropriate restriction 
endonucleases. Gel electrophoresis was used to separate the fragments and they were 
isolated by gel purification (Figure 3.3). The mix of the ligation reaction was 1:4 
molar ratio (vector : insert). The mixture contained 1 x DNA ligase buffer (Promega 
Ltd., Southampton, UK) in a final reaction volume of lOpL and 3 units of DNA ligase 
(Promega Ltd., Southampton, UK). The ligation mixture was incubated for 16 hours at 
17°C.
Initially the PCR products of the genes were ligated into the pGEM-T vector 
(Promega Ltd, Southampton, UK.). The pGEM-T vector is a linearised vector with a 
5’ thymidine overhang at each end. The 5’ thymidine overhangs will improve the 
efficacy and success of ligation experiment. This is achieved firstly by preventing the 
re-circularisation of the vector and secondly, by providing an overhang that is 
compatible for the ligation of PCR products, that have been made by thermostable 
polymerases.
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M
Kb
5.8
4 ----
2
1.8  -
1.8 NS3 gene M V V (V+NS3)
Figure 3.3. Gel electrophoresis of the NS3 gene before and after ligation. The plasmid 
was also run in a lane to confirm its size (M=Marker, V=Vector).
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3.1.4 Transformation -  mini prep
Bacterial transformation is the process where competent bacteria take up DNA 
(usually in the form of plasmids) from their environment (Figure 3.4). The term 
competent means that bacteria have been treated and their cell membranes are more 
permeable to genetic material than before. Here the E. Coli strain DH5-a was used, 
because of its versatility, short replication times, that it can sustain a high plasmid
content and most importantly for its 
compatibility with the chosen plasmids. 
The transformation was done by the “heat 
shock” method [229]- According to this 
method the plasmid is added to thawed 
cells (4 °C) and they are kept on ice for 45
minutes, and then they are heat-shocked 
for 2 minutes at 42 °C. This will permealize 
their membranes and will allow to the plasmids to enter the cytoplasm. Finally, LB 
medium is added and the cells are placed in a 37 °C waterbath for approximately sixty 
minutes. After a short incubation the cells are inoculated overnight on a petri dish 
with LB agar and ampicillin antibiotic (at 100 pg/mL). The cells were lysed and their 
plasmids were isolated.
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3.1.5 DNA Purification & Concentration
For the purification and cleaning of the isolated plasmid DNA, the DNA /  plasmid 
purification kit from Qiagen was used (see experimental). The DNA precipitant is a 
combination of phenol chloroform and isoamyl alcohol. After the addition of a 
solution of phenol-chloroform the DNA solution was centrifuged at 13000 rpm for 10 
minutes. Cell debris should stay at the bottom of the centrifuge tube, while pure DNA 
will be in the supernatant fraction.
For the concentration of the DNA a combination of isopropanol and sodium acetate 
was used. DNA is left at 4 °C for a few hours in a solution containing the above 
reagents (reagents will help it precipitate faster). Then it is spinned at 13000 for 20 
minutes and subsequently 70% ethanol is added and the solution is spinned for 
another 5 minutes. The eppendorf is heated in a PCR block to evaporate ethanol at 52 
°C.
M: (k)  (<p) V B A
► pGEM-T
► 1,8 (A )
* 1,3 (B)
V=vector
B=helicase
A=NS3
Figure 3.5. Gel Electrophoresis 
of the pGEM-T plasmid, the 
helicase protein and the full 
NS3 domain after isolation and 
concentration.
V is the pGEM-T vector at 4 
A is the full NS3 domain at 1,8 
B is the helicase protein at 1,3
(all above are in kb)
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3.1.6 Cloning
NS3F
HELF
- r e W - i .y
/ PCR with High Fidelity Taq Polymerase(<- 1st PCR: NS3F -  NS3R)(2nd PCR: HELF -  NS3R -») \
HCVNS3 Domain
NS3R
c z z u r
Clone into pGEM-T
pGEM-T
agctt
i ttcga 
la
Hind ID
pGEM-T
Digest with Hind III
ttcga
agctt
ttcga
agctt
pET23b
ttcga
agctt
pET23b
ILigation \# h  T4 ligase Ligation wwi T4 ligase
pET23b
NS3 domain
Helicase and full NS3 
genes are ready to 
transform an 
expression vector
Figure 3.6. Illustration of the method of cloning the Dengue genes in pET23b.
pET23b
Helicase
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The genes for the Dengue helicase and Dengue NS3 domain were cloned into the
pGEM-T vector using the single cut Hind III restriction site. As a result, orientation of
the insert had to be 
confirmed by a PCR screen 
(Figure 3.7). The PCR was 
setup using 50 pL of lOx 
Taq buffer, 50 pL MgCh, 20 
pi dNTPs, 5 pi of each 
primer, 365 pi of H2O and 
5 pi of Taq polymerase. 
The PCR mix was enough 
for 20 different PCR 
reactions. The PCR cycles 
were set as: an initial 95 °C 
denaturing step for 5 min 
and then 95 °C for 1 min, 
58 °C for 1 min and 72 °C 
for 2 min. Each cycle was 
repeated 30 times. Final 
temperature was set to 4°C.
M I—helicase gene—
1.3 k b
1 iNS3 domain-----------
helicase gene
Figure 3.7. Electrophoresis gels of the Dengue helicase and 
Dengue NS3 domains after PCR -  screening for positive 
colonies.
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3.1.7 Primer Design
The sequencing reactions are only accurate for 400-500 bases one way. There are two
available primers for both genes:
NS3F = AAGCTTGCCGGAGTATTGTGGGATG
HelF = AAGCTTAGTGCTATAGCCCAGACTG
NS3R -  AAGCTTCTACTTTCTTCCGGCTGCAAATTC
The full NS3 gene that is 1.8 kb long requires an internal primer for its sequencing.
The region of interest was identified and the primer was designed using the 
approximation: Tm = [4 (G + C) + 2 (A + T)] and making sure that there is a C=G base 
pair at the 3’ end. The annealing temperature of the newly designed primer was 
estimated to be 60 °C.
T h e d esig n ed  prim er se q u e n c e  w as: gcagagacccatttcctcag
Figure 3.7. The primer setup for the NS3 gene used for cloning (in red). The primer in 
green is the primer that was manually designed to allow the sequencing of the centre 
of the helicase gene.
| NS3F
----
v.
|
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3.1.8 Site Directed Mutagenesis (Quick Exchange)
Sequencing of the transformed pET vector revealed that both the NS3 domain and the
helicase genes contain a stop codon at the end. There is a TAG triplet in frame that
stops the transcription machinery prematurely (see below). By that it is assumed that
the inserts were not prepared having protein isolation in mind. Site Directed
Mutagenesis was used to mutate the T base of the TAG triplet to A. This way the
specific triplet would not code for a stop codon anymore, but for a lysine. The choice
for lysine was made because of the existence of the two neighbouring lysines on
either side of the TAG triplet, thinking that a third lysine would not change
significantly the amino-acid environment of the area.
The original seq: cagccggaagaaagTagaagcttgcggcc
The mutated seq: cagccggaagaaagAagaagcttgcggcc
In red are the gene’s bases before the stop codon
In blue are the stop codon triplets (top) and the mutated one (bottom)
In green are the vector’s bases after the stop codon
The side-directed mutagenesis was performed following the quick-change approach 
as described by Nelson and McClelland [230]- Specific oligonucleotide primers were 
designed in a manner that they encoded the desired mutation, along with 14 
nucleotides complementary to the region around the desired mutation point. These 
oligonucleotide primers (or cassettes) should not exceed 20 nucleotides on either side 
of the mutation point. The oligonucleotides will amplify DNA around the desired 
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location and will induce the desired mutation. About lOOng of the NS3 domain gene 
in pGEM-T vector was used as a template for the PCR reaction (Figure 3.8). The 
reaction mix contained lpg of each oligonucleotide primer, and 0.1 mM dNTPs in a 
final reaction volume of 50pL. The reaction was performed in l x  Pfu Turbo reaction 
buffer (containing lOmM MgCh) with 1 unit of Pfu Turbo DNA polymerase 
(Stratagene, La Jolla, CA, USA).
l94°C )  3°seconds^> 55 °C 30 seconds£>i 68 °C
repeated for 22 cycles
Figure 3.8. The conditions for the Polymerase Chain Reaction for the site directed 
mutagenesis experiment
After PCR, the sample was finally used to transform competent DH5oc cells. Positive 
clones were isolated by sequencing after mini-prep. Site directed mutagenesis is a 
PCR based application that involves the extension of a mismatched oligonucleotide, 
thus incorporating a mutation. The primer designed for SDM was prepared with the 
criteria that its melting temperature would be well above the 76 °C, that it would span 
at least 12 bases either way of the base to be replaced and finally that there would be 
a CCG base pair rather than an A=T.
SDM primer 1 = AAGCTTAGTGCTATAGCCCAGACAG 
SDM primer2 = GGATCCAGTGCTATAGCCCAGACAG
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3.1.9 Re-Cloning of the stop-free genes
The new genes were digested with Hind III and then re-ligated in phosphatase- 
treated pGEM-T vector. The mixture of the overnight ligation at 17 °C was then used 
to transform DH5a E.Coli cells using the heat-shock method. The colonies that grew 
on ampicillin (100 pg/mL) plates were PCR screened for the existence and the 
directionality of the insert (see gel below). Positive colonies were picked up and 
inoculated for overnight cultures with 10 mL LB. The cells were then lysed and their 
plasmids were isolated (mini-prep). Sequencing results confirm the correct mutation 
to lysine and the removal of the stop codon. The genes were then restricted out of the 
pGEM-T vector with Hind III and ligated into the pET23b vector. The ligation was 
used to transform BL21 DE3 plysS E.Coli that were screened for insert-directionality 
using vector-forward and gene -reverse primers.
Figure 3.9. The following figure shows the electrophoresis gel of the final screen for 
directionally correct insert of the full NS3 domain on pET23b in BL21 DE3 plysS 
E.Coli cells. The helicase gene can be extracted by PCR from any of the above positive 
colonies. Then the amplified helicase genes are re-ligated into the pET23b vector and 
re-transformed into BL21 DE3 plysS E.Coli cells. (Experimental Data in Appendix)
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3.2 Protein Expression
Protein expression is a general term to describe how information encoded in a 
segment of DNA (a gene) is converted into a functioning protein in a cell. As such, 
protein expression covers the processes of transcription (converting the DNA 
sequence of a gene into a messenger RNA molecule) and translation (converting the 
information in the messenger RNA into an amino acid sequence) as well as all of the 
methods a cell uses to regulate these processes.
A very common and representative protein expression system in E. coli is the pET 
vector system [231]. The pET system is based on the T7 phage promoter (T7 RNA 
polymerase expression system). T7 polymerase has the unique characteristic that it is 
specific for T7 promoters and will not recognise any other promoters within the cell. 
The latter combined with the facts that those T7 promoters are very rare and that 
termination sequences for T7 promoters are also rare, make it possible to have very 
long transcripts with no interruption. Finally it has been found that the T7 RNA 
polymerase is roughly five times faster than the host {E.Coli) RNA polymerase. As a 
result, genes controlled by the T7 RNA polymerase can be overexpressed.
Special E.Coli strains have been developed that contain the T7 RNA polymerase. 
Responsible for the operation of the T7 RNA polymerase gene is the lacUV5 
promoter. This promoter can be induced by the addition of isopropyl beta D
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thiogalactopyranoside (IPTG) [232].
So, if the system was perfect the insert (gene of interest) should only be expressed in 
the presence of IPTG, by the induction of the lacUV5 promoter that will initiate the 
production of the T7 RNA polymerase.
Figure 3.10. 750 ml cultures in 2 L flasks were used at 280 rpm in expression flasks. A 
lot of different expression conditions were tested in order to achieve the optimal 
expression conditions and establish an expression protocol.
3.2.1 Cloning and expression vectors
The pGEM-T vector that was purchased from Promega Ltd (Southampton, UK), was 
used for cloning. For the expression part of the Dengue proteins, pET23b vector was 
purchased from Novagen (AMS Biotechnology, Milton Keynes, UK). The vector 
pET28a, was a kind gift from Dr Klump, Roche Biosciences, Palo Alto, USA.
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3.2.2 Preparation of competent E  c o li cells
A glycerol stock of each of the BL21 (DE3) plysS and C41 (DE3) plysS E. coli strains 
were used to inoculate lOmL of LB medium with and without the corresponding 
antibiotics. The culture was grown overnight in a shaking incubator at 250 rpm, at 
37°C for 16 hours. A 1:200 fold dilution was made in fresh LB medium and that was 
grown too in a shaking incubator at 250 rpm at 37°C. This time the culture was grown 
until its optical attenuance at 600nm reached 0.4. Cells were centrifuged at 2000 g for 
10 minutes and the pellets were re-suspended in half the culture-volume of lOOmM 
CaCIV 15 % (v/v) glycerol. After that they were incubated on ice for 30 minutes. The 
cells were centrifuged as before, only this time they were re-suspended in 1/10th 
culture-volume of a mixture of CaClz/glycerol. The cell suspension was aliquoted and 
snap frozen in liquid nitrogen. The frozen aliquots were stored at -80°C.
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3.2.3 SDS-polvacrvlamidg gel electrophoresis (SDS-PAGE)
The SDS-PAGE protocol is described by Laemmli [233]. The mix for the running gel is 
12.5% (w/v) acrylamide solution (acrylamide and N, N’- methylene bisacrylamide in a 
ratio of 37:1 (w/w)). Moreover, the gel contains 375mM Tris-HCl buffer, pH8.8, 0.1% 
(w/v) SDS, 0.225% (w/v) ammonium persulphate, 13.2 mM TEMED and water so that 
the final volume is adjusted to lOmL. On the other hand the stacking gel contains 5% 
(w/v) acrylamide, 0.14% (w/v) N-N’ methylene bisacrylamide, 0.1% (w/v) SDS in 
125mM Tris-HCl buffer, pH 6.8, 0.45% (w/v) ammonium persulphate, 13.2mM 
TEMED and was made to a final volume of 5 mL. The electrolyte running buffer 
contains 0.1% (w/v) SDS, 192mM glycine and 25mM Tris-HCl at pH 8.3.
The protein sample buffer consists of 80mM Tris-HCl buffer at pH 6.8. It also 
contains 0.2% SDS, 8% glycerol, 0.003% (w/v) Bromophenol Blue, 10% v/v 
(3-mercaptoethanol. p-mercaptoethanol must be added freshly just before use. The 
gels were run at 200 V. Coomassie Blue stain solution was used (0.03% w/v in 50% 
v/v methanol and 10% v/v acetic acid). The stain phase lasts for 1—2 hours and the de­
stain phase follows in a wash solution containing methanol (25% v/v) and acetic acid 
(7% v/v). Pre-stained protein markers (New England BioLabs) were used in 
electrophoresis along with the samples in order to determine molecular weights of 
samples.
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3.2.4 Recombinant protein immunological detection (Western blotting)
After SDS-PAGE, the resolved proteins were transferred to a moistened nitrocellulose 
membrane (Amersham International pic, Bucks, UK) [235]. The protein transfer was 
done by electro-blotting the membrane at 145mA for 45 minutes using a semi-dry 
blotter (Sartorius Ltd, Epsom, Surrey, UK). After the completion of the transfer, the 
membrane was blocked in tris buffer solution (TBS), (20mM Tris-HCl, pH 8.0, 50mM 
NaCl), containing 1% (w/v) skimmed milk powder for over an hour at room 
temperature. Then the membrane was washed 3 times for 5 minutes each in TTBS 
(TBS with 0.05% (v/v) Tween 20). After that they were left shaking for 1 hour at 
room temperature in 5ml of TTBS containing 1% (w/v) skimmed milk powder and 
the primary antibody. The membrane was washed 3 times for 5 minutes each in 
TTBS and then agitated for 1 hour with TTBS containing 1% (w/v) skimmed milk 
powder and the second antibody. The second antibody is an alkaline phosphatase 
conjugate (Sigma Chemical Company, Poole, UK) that is applied at a dilution of 
1/5000. The membrane was washed 3 times for 5 minutes each in TTBS and was 
stained with Nitro blue tetrazolium and 5-bromo-4-chloro-3-indoyl phosphate (Bio- 
Rad Laboratories, Watford, Herts, UK). Continuous shaking will initiate the colour 
reaction (usually within 2-5 minutes). Washing the developed membrane with 
distilled water will stop the colour reaction.
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The immunological detection of proteins the anti hexa-histidine conjugated 
antibody, requires washing 3 times for 10 minutes each in TBS (lOmM Tris-HCl pH 
7.5, 150mM NaCI) of the membrane after transfer. The membrane is then blocked for 
1 hour in TBS-His containing 3% BSA. It is then washed 3 times for 10 minutes each 
in TTBS-His (20mM Tris-HCl pH 7.5, 500mM NaCI, 0.05% Tween 20). Then the anti 
hexa-histidine conjugated antibody (Qiagen Ltd., Crawley, West Sussex, UK) is added 
for 1 hour at a 1:1000 dilution (in TTBS-His). Excess antibody is removed by washing 
3 times for 10 minutes in TTBS-His after the one-hour incubation. The membrane is 
stained as before using nitro blue tetrazolium and 5-bromo-4-chloro-3-indoyl 
phosphate.
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3.2.5 The Expression of the Dengue full NS3 protein
The full-length Dengue NS3 domain (including the helicase and protease coding 
regions) was incorporated into the pET23b vector (Novagen, Madison, WI, USA). The 
difference between this recombinant protein and the native HCV NS3 protein 
consists of the presence of the six-histidine residues at the C-terminus of the 
expressed protein. The nucleotide sequence was verified prior to protein production. 
The primers used for PCR in order to amplify the NS3 domain of the Dengue vims 
were:
NS3F: AAGCTTGCCGGAGTATTGTGGGATG 
NS3R: AAGCTTCTACTTTCTTCCGGCTGCAAATTC.
The recombinant E. Coli strain BL21 (DE3) plysS (Novagen) was used for protein ex­
pression. Cultures were induced at an attenuance (600 nm) of 0.4, upon addition of 
isopropyl-(3-D-thiogalactopyranoside (IPTG, Sigma, St-Louis, MO, USA) at a 
concentration of 0.25 mM in Luria Bertani medium containing 100 pg ampicillin / ml 
and 34 pg chloramphenicol / mL. Protein expression was allowed to proceed for 5 h at 
16°C. All subsequent steps were performed at 4°C. The total pellet from a 750 mL 
culture was resuspended in 10 mL of 20 mM sodium phosphate pH 7.5, 300 mM NaCI, 
100 pg/mL lysozyme and Triton X-100 was added to 0.1% final concentration. 
Following a 60-min incubation on ice, the suspension was sonicated four times for 10
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s with 30 s intervals (Branson sonifier 450, Branson Ultrasonics, Danbury, CT, USA). 
Then it was centrifuged at 17 000 x  g for 20 min.
The Dengue NS3 
protein at 79 kDalton
Figure 3.11. The expression of the full-length Dengue NS3 domain after elution. The 
Left gel is coomasie stained whereas the right one is a western blot. Lanes represent 
hours after induction with IPTG.
M In. Sol. lh 2h 3h 4h
Figure 3.12. Dengue NS3 domain (at 78 kDalton). First lane is the marker, second 
the insoluble fraction, third the soluble fraction and forth-seventh lanes are the 1st 
to 4th hours of incubation after the addition of IPTG (0.5 mM) at 16 °C
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3.2.6 The Expression of the Dengue helicase
0.5M IPTG 
M lh 2h 3h 4h
The Dengue helicase coding region was incorporated into the pET23c vector 
(Novagen, Madison, WI, USA). The difference between this recombinant protein and 
the native Dengue NS3 protein consists of the presence of the six-histidine residues at 
the C-terminus of the expressed protein. The insert was copied from the previous 
Dengue full NS3 domain using the primers: AAGCTTAGTGCTATAGCCCAGACTG 
and AAGCTTCTACTTTCTTCCGGCTGCAAATTC. The recombinant E. Coli strain 
BL21 (DE3) (plysS) (Novagen) was used for protein expression. Luria Bertani medium 
was prepared containing 100 pg/mL ampicillin and 34 pg/mL chloramphenicol. The 
inoculated cultures (from overnights 1:50 v/v) were induced with 0.5 mM IPTG at an 
attenuance (600 nm) of 0.4. The protein expression was allowed to proceed for 4 h at 
18°C. Then the culture was centrifuged at 8000 rpm for lOmin and the cell pellet was 
resuspended in phosphate buffer.
Figure 3.13. The SDS gel from the expression of the Dengue helicase. Here the hours 
are reported after inoculation of IPTG.
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3.2.7 The Expression and purification of HCV helicase
The full-length HCV helicase coding region was incorporated into the pET28a vector 
(Novagen, Madison, WI, USA). The difference between this recombinant protein and 
the native HCV NS3 protein consists of the presence of the six-histidine residues at 
the N-terminus of the expressed protein. The nucleotide sequence was verified prior 
to protein production. The HCV helicase gene was generously provided by Roche 
laboratories in Palo Alto, USA (through dr Klump).
750 mL cultures containing LB, chloramphenicol 34 pg/mL and kanamycin 25 pg/mL 
were prepared. The initial inoculation was taken from an overnight culture with a 
1/50 ratio. The recombinant E. Coli strain C41 (DE3 - plysS) (Novagen) was used for 
protein expression. Cultures were induced at an attenuance (600 nm) of 0.45 with 
0.5mM IPTG. The culture was allowed to grow for 3 hours upon induction at 18 °C. 
The total pellet from 4 x 750 mL cultures was resuspended in 30 mL of 20 mM sodium 
phosphate pH 7.5, 300 mM NaCI, 100 pg/mL lysozyme and Triton X-100 was added to 
0.1% final concentration. Following a 30-min incubation on ice, the suspension was 
sonicated four times for 20 s with 15 s intervals (Branson sonifier). Then it was 
centrifuged at 15 000 x g for 20 min. Clarified homogenates were adjusted to 10 mM 
imidazole (Sigma), filtered through a 0.45 pm membrane and loaded twice on a nickel 
affinity column. After washing the column with five column volumes of buffer S (20
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mM sodium phosphate pH 7.4, 500 mM NaCI) containing 10 mM imidazole, NS3 was 
eluted with buffer S containing 300 mM imidazole. To avoid precipitation, and 
immediately after elution, the buffer in helicase-containing fractions was exchanged 
for 25 mM Tris-HCl pH 7.5, 0.05% CHAPS (3-[(3-cholamidopropyl)-
dimethylammonio]-l-propane sulphonate), 20% glycerol, 5 mM DTT (dithiothreitol) 
(buffer P). Protein concentration was evaluated using the Bradford protein assay (Bio- 
Rad Laboratories, Hercules, CA, USA) with bovine serum albumin (BSA) as standard.
- 4 -  175 
83
4 -  62 
47
4 -  32 
"
Figure 3.14. The SDS (gel on the left) with the HCV helicase after a quick binding 
experiment in order to run a western blot (gel on the right) to confirm the existence 
of the His-tagged protein
Purified NS3 protein was aliquoted and stored at -  80°C. This protein preparation was 
estimated to be greater than 75% pure by sodium dodecyl sulphate-polyacrylamide 
gel electrophoresis and Coomassie blue staining. The purification procedure yields 
approximately 1.6 mg of HCV NS3 per 3 litres of E. Coli cultures.
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la elution with pH (3.5) 2^  elution (imidazole)
M 1st 2nd 3rd M 1st 2nd 3rd
graph of volume eluted v s  A280nm
volume eluted (mil
Figure 3.15. The SDS gels from the first and second elutions for the HCV helicase. 
Only the 2nd tube of the 2nd elution contains the HCV helicase. The contamination 
could not be removed and it was decided to proceed with the assay
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3.3 The Enzymatic Assay
A novel assay for measurement of Hepatitis C virus (HCV) NS3 helicase activity was 
developed using modified Flashplate™ technology [236]. This assay involves the use of a 
DNA duplex substrate and recombinant HCV NS3 produced in E. Coli. The DNA 
duplex consisted of a pair of oligonucleotides, one biotinylated, the other DIG- 
labelled at their respective 5’ termini. This DNA duplex was immobilised, via the 
biotin molecule, on the surface of a neutravidin-coated 96 well plate (Pierce) 
Helicase activity results in the release of the DIG labelled oligonucleotide, which 
translates in signal (luminescence) reduction with respect to control wells. 
Biochemical characterisation of the HCV NS3 helicase activity was performed using 
this assay. It was demonstrated that the NS3-mediated unwinding is proportional to 
both the amount of DNA substrate in the well, and to the NS3 concentration in the 
reaction. Most of the NS3-mediated unwinding was achieved in the initial 60 min of 
incubation. As expected the reactions were ATP-dependent. We found this assay to 
be highly reproducible since only slight variation was observed when a total of 98 
helicase reactions (including controls) were performed on one plate. Therefore, this 
Flashplate™ helicase assay is fast, convenient and reproducible. These criteria make it 
suitable for high throughput screening of potential NS3 helicase inhibitors.
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Double stranded DNA. 
One strand is DIG 
labelled [D] & the other 
Biotin Labelled [B]
R eleased  strand 
caries the DIG label 
and can be 
detected  
and quantified
Biotin will bind to the 
plate, immobilising the 
DNA fragment
The fDl labelled strand is now released
m i
Helicase will unwind 
the dsDNA to ssDNA
Figure 3.16. The enzymatic Assay setup for testing the activities of novel compounds 
against the HCV helicase.
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3.3.1 The HCV Helicase Assay
Two DNA oligonucleotides were prepared. The S’-biotin-GCTGA- 
CCCTGCTCCCAATCGTAATCTATAGTGTCACCTA (39-mer template strand) and 
the 5’-DIG-CGATTGGGAGCAGGGTCAGC (20-mer release strand). The release 
strand was DIG-labelled at the 5-end.
The helicase substrate was prepared by annealing the template to the release strands. 
Both strands were mixed in a 1:1 molar ratio in 2 mM HEPES (N-[2-hydroxyethyl] 
piperazine-Ar-[2-ethanesulphonic acid]), 0.05 M NaCl, 0.1 mM EDTA, and 0.01% SDS 
(w/v) and subjected to a denaturation-renaturation process in which the 
oligonucleotides were heated at 100°C for 5 min., followed by a 30 min incubation at 
65°C and then a slow renaturation step at 22°C for 4 h. The hybridised NS3 helicase 
substrate was kept at -  20°C. A stock solution of neutravidin (Pierce, Rockford, IL, 
USA) was prepared at a final concentration of 1 mg/mL in phosphate buffered saline 
(PBS). The Flash-plate™ (NEN Life Science Products Inc., Boston, MA, USA) was 
coated overnight at 4°C with 100-pL/well of a 5-pg/mL neutravidin solution in a 0.5- 
M sodium carbonate buffer pH 9.3. Wells were subsequently blocked upon addition 
of 100 pL of a 0.1% (w/v) BSA solution followed by an incubation at 22°C for 2 h. 
Plates were then washed three times with 200 pL/well of PBS, air-dried at room 
temperature and stored at 4°C with desiccant. For standard assays, 75 pL of 1 M phos­
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phate buffer pH 7.0, containing 1 M NaCl and 2.5 ng of the partially annealed DNA 
duplex was applied to each well, followed by an incubation at 22°C for 4 h. The wells 
were then washed twice with 200 pL PBS and once with 200 pL of 50 mM Tris HC1 
pH 7.5, 50 mM NaCl solution, pre-warmed at 37°C.
Helicase reactions were initiated upon addition of 90 pL of a reaction mix consisting 
of 11 nM of purified full-length HCV NS3 protein, 25 mM 4-morpholine- 
propanesulphonic acid (MOPS) pH 7.0, 5 mM ATP, 2 mM DTT, 3 mM MnCh, and 
100 pg/mL of BSA to the wells in which 2.5 ng of DNA substrate was previously 
applied. For negative controls, the reaction mix contained no ATP. Moreover, in 
experiments where the effect of metal cations was investigated, either MgCh or 
MnCh was used as the metal co-factor. Reactions were allowed to proceed for 60 min 
at 37°C. Wells were then washed twice with 200 pL of a 150-mM NaCl solution and 
dried at room temperature for 15 min.
The wells of the multi-well plate were washed for 5 min with detection washing
buffer (0.1 M maleic acid, 0.15 M NaCl, pH 7.5, 0.3% tween20). Then each well was
incubated in 100 pi of Blocking Solution (Blocking reagent: 10% BSA (w/v) in Maleic
acid buffer -same as washing buffer without tween20) for 30 min followed by a 30
min incubation in 20 pL Antibody solution (1:10000 solution of the antibody -75
mU/mL- in Blocking solution). The wells were washed twice with 100 pL of
detection washing buffer (0.1 M Tris-HCl, 0.1 M NaCl, pH 9.5). Then 20 pL of
detection buffer were applied for equilibration. 1 pL of chemiluminescence substrate 
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(CSPD) working solution was applied to each well and the plates were incubated for 5 
minutes at 17 °C. The wells were drained and after a quick incubation at 37 °C, in 
order to dry the wells completely, the plate was exposed to a luminescent imager for 
10 minutes. The luminescence continues for almost 48 hours. The constant-intensity 
phase lasts for the first 24 hours.
Remaining DIG label in each well of the 96 well-plate was counted against controls 
(one with no protein and one with no ATP) in a luminescence multi-well plate reader 
(luci II).
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3.3.2 Results from the Assay & Compounds Tested
Each activity test was repeated three times on different plates (different batches of 
coating). The results were then all averaged and the average luminescence reading is 
used as an indication of the inhibitory action of each compound. The following table 
summarises the results only from the active compounds.
Table 3.1 The results from the enzymatic assay are summarised in the following table 
Here, active compounds are considered to be all compounds that have at least slightly 
blocked the unwinding efficiency of the HCV helicase.:
STRUCTURE NAME M.W.
A MeOOC. COOMe
“ O u u j U X
H
CF-AB
14
398.41
B ^ ^ \^ ^ C O O M e
M e O O C ^ ^ ^ ^ CF-AB
2 1
384.38
C
CF-AB
23
412.44
D
HOOC COOH
X u u j u c r
H CF-AB
25
370.36
E
^ \ ^ C O O H
HOOC
CF-AB
26
356.33
I F
r^ Y c o o oH
^ ^ h n ^ C ^ ^ y ' n h -y ^ .
CF-AB
27
384.38
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A
1 st 2 nd 3** Average % inhibition
10 mM 0.168 0.169 0.175 0.171 3.2
1 mM 0.164 0.165 0.171 0.167 2 . 6
No Inhibitor 0.152 0.153 0.154 0.153 —
B
1 st 2 nd 3* Average % inhibition
10 mM 0.218 0.208 0.207 0 . 2 1 1 8.4
1 mM 0.175 0.171 0.170 0.172 1 .1
No Inhibitor 0.165 0.166 0.166 0.166 —
C
1 st 2 nd 3rd Average % inhibition
10 mM 0.247 0.247 0.253 0.249 16.2
1 mM 0.217 0.223 0.218 0.219 1 0 . 6
No Inhibitor 0.165 0.159 0.164 0.163 —
D
1 st 2 nd 3rd Average % inhibition
10 mM 0.371 0.360 0.361 0.364 36.1
1 mM 0.240 0.241 0.235 0.239 1 2 . 6
lpM 0.182 0.187 0.185 0.185 2.5
No Inhibitor 0.173 0.168 0.175 0.172 —
E
1 st 2 nd 3rd Average % inhibition
10 mM 0.401 0.388 0.406 0.398 47.3
1 mM 0.264 0.255 0.276 0.265 22.3
1 |iM 0.165 0.167 0.169 0.167 3.9
No Inhibitor 0.148 0.144 0.147 0.146 —
F
1 st 2 nd 3rd Average % inhibition
10 mM 0.455 0.446 0.461 0.454 56.7
1 mM 0.305 0.309 0.311 0.308 29.3
1 |iM 0.169 0.171 0.172 0.171 3.6
No Inhibitor 0.154 0.151 0.152 0.152 —
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The % inhibition for each compound is produced by the equation:
(a -b )  * 1 0 0
% inhibition = ----------------------------
c
where, a = Average luminescence at given concentration
b = Average luminescence without compound 
c = Average luminescence without protein (lumi-max)
The above luminescence values are correlated to the calibration runs of the 
luminecensce plate reader before the assay. So, maximum luminescence averages 
0.532 (0.525-0.537) over lOwells. Wells without DNA substrate have an average of 
0.048 (0.047-0.05), wells without ATP substrate have an average of 0.052 (0.045- 
0.056) and wells without anything else but the neutravidin coating have an average 
luminescence of 0.039 (0.037-0.041). All compounds were subjected to a 60-min 
assay.
The following table summarises all compounds that were tested against the HCV 
helicase in comparison with the results obtained from the replicon assay for each 
compound.
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Table 3.2 Comparison of Active Compounds in the Enzymatic and Replicon Assays
Enzymatic Replicon 
Activity ActivityStructure Name
MeOOC
' Q j u j u a
COOMe
MeOOC
HN
NH
Me0 0 GN ^ X
COOMe
CF-AB 14
CF-AB 16
CF-AB 18
3.2%
(lOmM)
NO
NO
COOMe
HN
COOMe
COOMe
NH NO
CF-AB 19
COOMe
COOMe
HN
COOMe O
HN
NH
O
M eOOC
CF-AB 20
CF-AB 21
NO
8.4%
(lOmM)
a  .COOMe MeOOC.Ha  .COO Me
CF-AB 22 NO
COOMe
O
M eOOC.UUUIV
r  ii o
MeOOC^^^
CF-AB 23
CF-AB 24
16.2%
(lOmM)
NO
YES
NO
NO
NO
NO
YES
NO
YES
NO
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HN' CF-AB 17
COOHHOOC.
HN CF-AB 25
COOH
NH
HN
CF-AB 26
HOOC
.COOH
NH
HN
CF-AB-27HOOC
NO
36.1%
(lOmM)
47%
(lOmM)
57%
(lOmM)
NO
YES
3.3.3 Discussion
Altogether 13 different compounds were tested in this assay. Even though the 
number of compounds does not allow positive conclusions to be drawn and is only a 
limited basis for SAR analysis, they are satisfactory for some basic observations.
R R
Figure 3.17. The structural scaffold of the family of compounds tested is shown here. 
Side Group (R) -  linker (L) -  Side Group (R). Given the symmetry Rleft=Rright. 
Multiple substitutions have not been tested.
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All of the above compounds belong to the same family of compounds described by the 
symmetry: side group -  linker -  side group. Looking at the linker it was found that all 
three aliphatic chain combinations that were used, carrying single bonds gave both 
active and non-active results. In this experiment the linkers that were used were the 
C2, C3, C4 and once a C2 double bond. The latter was not active and that may be an 
indication that rigid compounds are not favourable for the helicase. CF-AB24 with 
the double bond is not very different to CF-AB23 compound, which was found to be 
active (16.2% at 10 mM). That is something that was expected from the docking of 
the compounds from previous in silico experiments. The supposed site of interaction 
of this family of compounds on the helicase seems to be very sensitive in efficiently 
accommodating a more restrained compound such as CF-AB24 (due to its double 
bond in the linker region). Enough flexibility must be allowed to the linker region of 
all helicase potential inhibitor compounds. The linker region must be capable of full 
rotation, giving the compound optimal geometries that would optimize the 
interactions established with the enzyme.
It was also observed that the substitution on the phenyl ring of the side-groups should 
not contain a CONH2. That is demonstrated from the comparison between CF-AB 17, 
CF-AB25 and CF-AB 14, where the only structural difference is the CONH2 
substitution instead of the COOH or COOMe and this is responsible for the loss of 
activity in the assay (generally: CO2H > C0 2 Me > CONH2).
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It is difficult to interpret a comparison of CF-AB21, CF-AB22 and CF-AB23. These 
compounds have the same side groups and different linkers. Although, both C2 and 
C4 linkers produced active compounds C3 did not. CF-AB23 is twice as active as CF- 
AB21, and it was expected that C3 would be even more active (based on the C3 
compounds CF-AB25 and CF-AB27 that are all active). The assay was repeated again, 
and the same results were obtained. Finally, it was found that the acids of the active 
esters (CF-AB21 and CF-AB23) increased activity. Docking results favoured acids 
anyway, but since esters were easier to be chemically synthesised they were tested 
first. The conversion of the CF-AB23 to CF-AB27 (from ester to acid) increased the 
activity of the compound by 3.5-fold.
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3.3.4 Conclusion
The setup of the assay makes it a very quick and efficient tool to evaluate the 
activities of novel compounds as potential inhibitors against the HCV helicase. It was 
found that the results from the above HCV assay were in full agreement with the 
results from the replicon assay, suggesting that the activities observed in the latter are 
the effect of the given compounds on the helicase proteins.
To sum up, it was confirmed that the HCV helicase enzymatic assay is reliable and is 
suitable for use as a quick testing method for the identification of novel inhibitors for 
the HCV helicase.
Figure 3.18. Up to 96 compounds can be simultaneously evaluated for their biological 
activities against the HCV helicase.
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4.1 General Conclusions & Future Work
The homology models of both the Helicase and the Polymerase family series have 
been established, tested and evaluated for the Dengue, West Nile, Japanese 
Encephalitis and Yellow Fever viruses. After the development of the protein models a 
series of compounds, derived from a single lead compound with few modifications 
(based on de novo structure-based drug design methods), were screened and tested by 
docking, molecular mechanics & molecular dynamics simulations. From this study, 
conclusions were drawn as to which moiety was more favourable that are, the type of 
substitutions that are preferred and the binding mode of these compounds. This data 
was essential for selecting compounds for synthesis. It was found in silico that long, 
flexible linkers and side-group substitutions with benzimidazole or carboxylic groups 
increased the binding affinity of the compound candidates.
The verification of the in silico experiments came from the molecular biology and 
biochemistry experiments that followed. The lead and some of the most promising 
compounds were prepared. These new compounds were then subjected to an 
enzymatic inhibition test in the biological assay for the HCV helicase that was 
developed. The genes of the Dengue helicase, NS3 domain and HCV helicase were 
cloned and expressed. The HCV helicase was purified and an enzymatic assay was 
established that would estimate the efficacy of the HCV helicase to unwind double 
stranded DNA. The compounds were tested against the enzymatic assay of the HCV
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helicase and the results compared to data from the replicon assay. Data from both 
assays was fed back into the model in an attempt to optimise the accuracy of the 
prediction of activity/inhibition of candidate compounds from the drug design 
algorithms.
Future work on both projects will involve the use of new algorithms for compound 
docking. Virtual screening of large databases is now feasible. The process of virtual 
screening has already started using the National Cancer Institute (NCI) database and 
even though there are no results available yet, it will be very interesting to see the 
results of this experiment as this will give new ideas for ligand design.
Synthesis of new leads and promising candidate compounds has been planned to start 
soon. Results from the biological assays of these compounds will provide vital 
information that can be used in molecular modelling and lead optimisation.
The proteins of the Dengue helicase and the full NS3 domains have already been 
expressed and purified. An enzymatic assay similar to the HCV helicase one should 
be established using the Dengue proteins. The data from the Dengue assays can then 
be correlated to the ones from the HCV and replicon assays, in order to provide more 
information for the molecular modelling experiments.
The ultimate future aim would be to establish a parallel in silico /  in vitro testing 
model that will be capable of accurately predicting and evaluating the activities of 
novel compounds against the above viral helicases. Moreover, another very
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interesting future modification would be to replace dsDNA with dsRNA from the 
HCV assay and repeat the test of the same compounds.
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The Hepatitis C Virus
The genom e of HCV w as first cloned in 1989. The genom e of the  
HCV is 9 .4  kb long, contains a single long open reading fram e which 
is responsible for encoding a polyprotein of 3,010 am ino acids [15]. 
There is a non-coding region (NCR) of 324-341 nucleotides a t th e  5* 
end & on the  3' end there  is a NCR of variable length including a 
poly (U) tract. The 5' NCR contains an IRES th a t is very similar in 
function (not structure) to  th a t of picornaviruses. The nucleotidic 
sequence of the  Hepatitis C virus is highly variable; the  m ost d istan t 
strains have only 60%  nucleotide sequence homology. Strains from 
around th e  world have now been classified into 6  main categories, 
each with several subtypes, based on sequencing properties. 
Categories 1, 2 and3 account for alm ost all infections in Europe. 
Category 4 is prevalent in Egypt & Zaire, category 5 is prevalent in 
South Africa finally category 6  is found in Hong Kong. It is not clear 
yet if immunity to one category autom atically defends infection with 
ano ther strain from ano ther category. There is though evidence th a t 
various genom e types are  pretty  much different in the ir biological 
properties.
The non-structural region of th e  NS3 dom ain of the  HCV 
ranges betw een 1027 and 1657 of th e  polyprotein [38]- The genom e 
of the  HCV is a positive-stranded RNA virus [133. The 3010 amino
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acid long polyprotein of the  virus is processed by cellular and virus- 
encoded p ro teases.
5'
V/
4A 4B
HNAbi ill ;> 
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Figure A p p l. Hepatitis C genom e organization, polyprotein 
processing and protein properties. On the  top th e re  is a schem atic 
representation of th e  HCV genom e, below are  the  polyprotein 
cleavage products and defined functions as described underneath
(re feren ce : ©  1 9 9 9  B lackw ell S c ie n c e  ltd. Journal of Viral Hepatitis, 6 , 1 6 5 - 1 8 1 ) .
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The W est Nile Virus
W est Nile fever is caused by a virus th a t is part of th e  Flaviviridae 
family. There are  nearly 70 different viruses in th is group, formerly 
term ed group B arboviruses, of which nearly half a re  known to 
cause illness in hum ans. The World Health Organization defines 
arboviruses (arthropod-borne viruses) as  a group a s  those  "which 
are  m aintained in nature principally, or to  an im portant ex tent, 
through biological transm ission betw een susceptible verteb rate  
hosts by hem atophagous arthropods; they  multiply and produce 
viremia in th e  vertebrates, multiply in th e  tissues of arthropods, and 
are passed on to new verteb ra tes by the  bites of arthropods after a 
period of extrinsic incubation" (Sanford, 1991). Common viruses in 
th is classification, in addition to W est Nile, include yellow fever, 
dengue, Japanese  encephalitis, St. Louis encephalitis, and tick- 
borne encephalitis viruses. These viruses a re  generally spread  by 
m osquitoes or ticks; hum an-to-hum an spread  does not occur. 
Infection with th ese  viruses does not produce a unique clinical 
picture. Therefore, travel to an endem ic area  and laboratory te s ts  
are  im portant for identifying a specific infection.
W est Nile virus is a m osquito-borne virus found m ost commonly in 
Africa, France, India, Indonesia, th e  Middle East, and Soviet 
countries. In 1999, a West-Nile-like virus w as identified in patients 
living in th e  N ortheast United S ta tes. The bird is the  primary host
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and the  principal vector is Culex univittatus. However, o ther 
m osquitoes are  known to  carry the  virus, including Culex pipiens, 
Culex antennatus, and Culex tritaeniorhynchus (Asia). O ther animal 
reservoirs a re  not part of the  virus's normal life cycle.
W est Nile fever is common in the  Middle East with m ost individuals 
exposed as  children. Children experience a nondescript viral illness 
with fever th a t is rarely diagnosed. Neighboring Israel also 
experiences infection although there , it is m ore likely the  young 
adult than the  child who becom es infected. Spread occurs primarily 
in the  sum m er m onths when th e  m osquito population increases.
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The PenqueVirus
Dengue fever is caused by a virus th a t is part of the  Flaviviridae 
family. There a re  nearly 70 different viruses in th is group, formerly 
term ed  group B arboviruses, of which nearly half a re  known to 
cause illness in hum ans. Other common viruses in th is classification 
include yellow fever, W est Nile, Japanese encephalitis, St. Louis 
encephalitis, and tick-borne encephalitis viruses. The m ost comm on 
infection in hum ans is caused by the  dengue virus, of which there  
are four types. Flaviviruses a re  generally spread  by m osquitoes or 
ticks; hum an-to-hum an spread  does not occur. Infection with these  
viruses does not produce a unique clinical picture. Therefore, travel 
to  an endem ic area and laboratory te s ts  a re  im portant for 
identifying specific infection.
Dengue and dengue hem orrhagic fever (DHF) are  caused by 
infection with one of four antigenically distinct, virus sero types 
(DEN-1, DEN-2, DEN-3, and DEN4). Once infected with one of th ese  
sero types, the  individual develops specific immunity. However, 
cross-im m unity does not develop. It is theoretically possible, 
therefore, for an individual to be infected four tim es, each tim e with 
a different serotype.
Dengue is mostly seen in tropical urban areas. As with other members of the 
Flaviviridae family, the virus is transmitted through mosquito bites, specifically 
Aedes aegypti. This mosquito, a domestic, day-biting mosquito, prefers to 
feed on humans (Gubler and Clark, 1995). In some parts of the world (mostly
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Asia and Oceania) other vectors have been implicated: A. albopictus, A. 
scutellaris, and A. polynesiensis.
Dengue is th e  m ost im portant m osquito-borne viral disease, 
affecting hum ans with a distribution com parable to  th a t of malaria. 
Approximately 2.5 billion people are  living in a reas  a t risk for 
epidem ic transm ission (Gubler and Clark, 1995). Tens of millions of 
cases  of dengue fever occur annually along with up to  hundreds of 
thousands of cases of dengue hem orrhagic fever.
Dengue hem orrhagic fever is the  m ost serious m anifestation of the  
disease. This process, an immunologic reaction, occurs for the  m ost 
part in individuals already sensitized to  the  d isease, e ither actively 
through infection or passively in infants through placental transfer 
of immunoglobulin from m other to  child. Initially, dengue 
hem orrhagic fever appears the  sam e as dengue but after several 
days the  patient deterio rates with prostration, restlessness, signs of 
circulatory collapse (diaphoresis, cold extrem ities, dyspnea, 
circumoral and peripheral cyanosis, and hem orrhagic 
m anifestations). Available laboratory te s ts  cannot identify who will 
ultimately develop th is m anifestation.
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The Yellow Fever Virus
Yellow fever Is a viral hem orrhagic fever which strikes an estim ated 
200 000 persons worldwide each year and causes an estim ated  30 
000 d ea th s . The case  fatality rate  may reach 20%  to  80% ; however, 
th ese  figures a re  based on the  m ost severe cases th a t a re  
hospitalized and the  overall case  fatality rate  is lower.
The yellow fever virus is small (35 to 45 nm ) and consists of a core 
containing single-stranded RNA surrounded by a lipid envelope. The 
genom e has been completely sequenced and found to  contain 10 862 
nucleotides (Rice et al. 1985). The envelope contains a single 
glycoprotein with type and group-specific antigenic determ inants. 
Yellow fever virus can be inactivated with lipid solvents (ether, 
chloroform), heat (56°C for 30 m inutes), and ultraviolet light 
(Monath 1990).
Antigenic differences have been shown betw een stra ins of yellow 
fever virus. Antibody-absorption techniques can distinguish betw een 
strains from South America and Africa (Clarke 1960). S trains can 
also be differentiated on the  basis of virulence characteristics for 
mice (Fitzgeorge, Bradish 1980). RNA oligonucleotide m apping has 
shown th ree  genetically distinct geographical varian ts in Africa:
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Senegal-G am bia; Ivory Coast-Burkina Faso-Nigeria; Central and East 
Africa (Deubel e t al. 1986).
The d isease yellow fever w as first distinguished from m alaria, 
dengue, and o ther tropical d iseases during th e  1647 to  1649 
epidem ics in Barbados, Cuba, Guadeloupe and Mexico (Bres 1986). 
Since th en , it has raged as periodic epidem ics in the  Americas and 
Africa. In 1900, a commission headed by W alter Reed confirmed th a t 
the  d isease w as transm itted  from hum an to hum an by the  m osquito 
Aedes aegypti, a finding earlier theorized by th e  Cuban physician 
Carlos Finlay in 1881. This information led to  efforts a t m osquito 
control in the  Americas, with excellent results in eliminating the  
disease from many areas.
There are  two epidemiologic patterns of yellow fever virus 
transm ission: the  urban cycle and the  forest cycle (also known as the  
jungle or sylvatic cycle). The two epidemiologic pa ttern s lead to  clini­
cally identical d isease, since they  are produced by the  sam e virus. In 
som e instances, sp read  from forest to urban cycles has been 
docum ented. Today, th e  yellow fever virus circulates in an endem ic, 
fo rest cycle in the  Am ericas, resulting in up to  500 reports of 
infections of unimmunized forest workers per year. In Africa, yellow 
fever virus circulates in both urban and forest cycles, and th e  d isease
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periodically explodes out of its endem ic pa ttern  to  infect large 
num ber of unimmunized persons during m ajor epidem ics.
In the  urban pattern , the  virus is tran sm itted  by m osquito from 
infected hum ans to  susceptible hum ans. For th e  urban cycle, the  
m osquito vector is usually A. aegypti, a dom estic  m osquito th a t 
breeds near houses, with the  fem ale preferring to  lay eggs in w ater 
collected in w ater jars, old tires, gu tte rs , or d iscarded tin or plastic 
containers. In 1978, it w as found th a t A. aegypti fem ales could 
transm it yellow fever virus transovarially to  a small proportion of 
their offspring and these  eggs can thus m aintain th e  virus during the  
dry season (Aitken e t at. 1979). The virus m ultiplies in th e  m osquito 
vector. About 12 to  21 days after biting an infected person or 
m onkey the  m osquito becom es infective and  it rem ains infective for 
the  rest of its life.
The d isease  in hum ans is characterized by sudden  o n se t of fever, 
headache, backache, general muscle pain, n au sea , and  vomiting. As 
the  d isease continues, album inuria, oliguria (even anuria), and 
jaundice occur. Hemorrhagic sym ptom s m ay include epistaxis, 
hem atem esis, and m elena.
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Table appl. Ramachandran Plot stats for HepC Helicase (1A1V) & Dengue Model.
Ramachandran Plot statistics for HepC Helicase (1A1 Va)
No. o f  r e s id u e s % -tage
Most favoured regions [A,B,L] 316 89.5%*
Additional allowed regions [a,b,l,p] 37 10.5%
Generously allowed regions [~a, ~b, ~1, ~p] 0 .0%
Disallowed regions [XX] 0 .0%
Non-glycine and non-proline residues 353 100.0%
End-residues (excl. Gly and Pro) 7
Glycine residues 38
Proline residues 31
Total number of residues 429
Ramachand ran Plot statistics for Dengue Virus (Model)
No. o f  r e s id u e s  % -tage
Most favoured regions [A, B, L] 296 82 .2%*
Additional allowed regions [a, b, 1, p] 50 13. 9%
Generously allowed regions [~a, ~b, -1, ~p] 9 2.5%
Disallowed regions [XX] 5 1.4%*
Non-glycine and non-proline residues 360 100.0%
End-residues (excl. Gly and Pro) 2
Glycine residues 40
Proline residues 27
Total number of residues 429
Table app2. Ramachandran Plot stats for the Dengue Model after Molecular Dynamics
Ramachandran Plot statistics for Dengue Virus (Model) after miminisation
No. o f  r e s id u e s % -tage
Most favoured regions [A,B,L] 333 92.5%
Additional allowed regions [a,b,l,p] 19 5.3%
Generously allowed regions [~a, ~b,-1, ~p] 8 2.2%
Disallowed regions [XX] 0 0%
Non-glycine and non-proline residues 360 100.0%
End-residues (excl. Gly and Pro) 2
Glycine residues 40
Proline residues 27
Total number of residues 429
Based on an analysis of 118 structures of resolution of at least 2.0 Angstroms and i?-factor no greater than 20.0 a 
good quality model would be expected to have over 90% in the most favoured regions [A,B,L].
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Table app3. Ramachandran Plot statistics for HepC Helicase (80HM) & West Nile Virus (Model)
Ramachandran Plot statistics for the HepC Helicase (80HM)
No. of residues %-tage
Most favoured regions [A, B,L] 323 88.5%*
Additional allowed regions [a,b,l,p] 39 10.7%
Generously allowed regions [~a,~b,~1,~p] 2 .5%
Disallowed regions [XX] 1 .3%*
Non-glycine and non-proline residues 365 100.0%
End-residues (excl. Gly and Pro) 1
Glycine residues 39
Proline residues 30
Total number of residues 435
Ramachandran Plot statistics for West Nile Virus (Model)
No. of residues %-tage
Most favoured regions [A,B,L] 309 80.9%*
Additional allowed regions [a,b,l,p] 52 13. 6%
Generously allowed regions [~a, ~b, ~1, ~p] 14 3.7%
Disallowed regions [XX] 7 1.8%*
Non-glycine and non-proline residues 382 100.0%
End-residues (excl. Gly and Pro) 1
Glycine residues 27
Proline residues 25
Total number of residues 435
Table app4. Ramachandran Plot statistics for the improved West Nile Virus Models
Ramachandran Plot statistics for West Nile Virus (Model)
No. of residues %-tage
Most favoured regions [A,B,L] 329 86.1%
Additional allowed regions [a,b,l,p] 43 11.3%
Generously allowed regions [~a,~b,~1,~p] 10 2.6%
Disallowed regions [XX] 0 0%
Non-glycine and non-proline residues 382 100.0%
End-residues (excl. Gly and Pro) 1
Glycine residues 27
Proline residues 25
Total number of residues 435
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Table App5a. The Yellow Fever Helicase Model's Ramachandran plot 
analysis summary.
+---------- « <  P R O  C H E C K  S U M M A R Y  » > ---------- +
I YF 2.2 435 residues |
I Ramachandran plot: 81.5% core 13.4% allow 3.2% gener 1.9% disall i
I Gly & Pro Ramach: 5 labelled residues (out of 60) I
I Chil-chi2 plots: 1 labelled residues (out of 242) I
+ -
Table App5b. The Yellow Fever Helicase Model's Ramachandran plot 
analysis summary. AFTER MOLECULAR DYNAMICS
+------ « <  P R O  C H E C K  S U M M A R Y  » > ---------------- +
I YF 2.2 435 residues |
I Ramachandran plot: 96.7% core 3.2% allow 0.1% gener 0% disall I
I Gly & Pro Ramach: 5 labelled residues (out of 60) I
I Chil-chi2 plots: 1 labelled residues (out of 242) I+----------------------------------------------------------------------------------------------------------+
Table App6a. The Japanese Encephalitis Helicase Model Ramachandran 
plot analysis summary.
+----------< «  P R O  C H E C K  S U M M A R Y  > » ----------- +
I je 2.2 435 residues I
I Ramachandran plot: 79.9% core 15.1% allow 3.3% gener 1.6% disall I
I Gly & Pro Ramach: 11 labelled residues (out of 69) I
I Chil-chi2 plots: 2 labelled residues (out of 233) I+----------------------------------------------------------------------------------------------------------+
Table App6b. The Japanese Encephalitis Helicase Model Ramachandran 
plot analysis summary. AFTER MOLECULAR DYNAMICS
+---------- « <  P R O  C H E C K  S U M M A R Y  » > ----------- +
I je 2.2 435 residues |
I Ramachandran plot: 94.2% core 5.1% allow 0.7% gener 0% disall I
I Gly & Pro Ramach: 11 labelled residues (out of 69) I
I Chil-chi2 plots: 2 labelled residues (out of 233) I+----------------------------------------------------------------------------------------------------------+
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Figure App2. Structural motifs, accessibility and PROCHECK summary. 
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Table App7a. The
analysis summary.
Dengue Polymerase Model's Ramachandran plot
+---------- < «  P R
I den 2.2 
I Ramachandran plot:
I Gly & Pro Ramach:
I Chil-chi2 plots:
+ -----------------------------------------
0 C H K U M M A
79.7% core 16.9% allow 2.0% gener 
4 labelled residues (out of 56)
0 labelled residues (out of 360)
» >  +
566 residues I 
1.4% disall !
Table App7b. The Dengue Polymerase Model's Ramachandran plot 
analysis summary. AFTER MOLECULAR DYNAMICS
---------- « <  p r o c h e c k  s u m m a r y  » > -----------+
den 2.2 566 residues |
I Ramachandran plot: 80.9% core 16.7% allow 2.4% gener 0% disall I
Gly & Pro Ramach: 4 labelled residues (out of 56) |
Chil-chi2 plots: 0 labelled residues (out of 360) |
+ -
Table App8a. The West Nile 
analysis summary.
Polymerase Model's Ramachandran plot
r o H E K U M M A
I c:\dimitris\pdbs\wnv 2.0 566 residues
I Ramachandran plot: 68.2% core 24.6% allow 6.1% gener 1.0% disall
I Gly & Pro Ramach: 4 labelled residues (out of 76)
I Chil-chi2 plots: 8 labelled residues (out of 34 6)
Table App8b. The West Nile Polymerase Model's 
analysis summary. AFTER MOLECULAR DYNAMICS
Ramachandran plot
+ -------------------- « <  P R O
I c:\dimitris\pdbs\wnv 
I Ramachandran plot:
I Gly & Pro Ramach:
I Chil-chi2 plots:
+-------------------------------
E K U M M AC H 
2 . 0
89.8% core 16.7% allow 2.4% gener 
4 labelled residues (out of 76)
8 labelled residues (out of 34 6)
» >  +
566 residues | 
0% disall i
I
I
Table App9a. The Japanese Encephalitis 
Ramachandran plot analysis summary
Polymerase Model's
+---------- « <  P R
I je 2.2
1 Ramachandran plot:
I Gly & Pro Ramach:
I Chil-chi2 plots:
+---------------------------
H E K U M M A
68.7% core 24.1% allow 6.4% gener 
6 labelled residues (out of 78)
11 labelled residues (out of 341)
» >  +
566 residues | 
.8% disall !
I
Table App9b. The Japanese Encephalitis Polymerase Model's
Ramachandran plot analysis summary AFTER MOLECULAR DYNAMICS
+---------- « <  P R O  C H E C K  S U M M A R Y  » > ---------- +
I je 2.2 566 residues |
I Ramachandran plot: 92.1% core 4.9% allow 3.0% gener 0% disall !
I Gly & Pro Ramach: 6 labelled residues (out of 78) I
I Chil-chi2 plots: 11 labelled residues (out of 341) |+ +
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Table ApplOa. The Yellow Fever Polymerase Model's Ramachandran 
plot analysis summary.
+---------- « <  P R O  C H E C K  S U M M A R Y  » > -----------+
I c:\dimitris\pdbs\yf 2.0 566 residues I
j Ramachandran plot: 67.5% core 25.3% allow 6.6% gener .6% disall I
I Gly & Pro Ramach: 5 labelled residues (out of 63) I
I Chil-chi2 plots: 4 labelled residues (out of 348) I+ +
Table ApplOb. The Yellow Fever Polymerase Model's Ramachandran 
plot analysis summary. AFTER MOLECULAR DYNAMICS
+---------- « <  P R O  C H E C K  S U M M A R Y  » > -----------+
I c:\dimitris\pdbs\yf 2.0 566 residues I
I Ramachandran plot: 89.4% core 8.5% allow 3.1% gener 0% disall !
I Gly & Pro Ramach: 5 labelled residues (out of 63) I
I Chil-chi2 plots: 4 labelled residues (out of 348) I
+  +
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Analytic Protein-DNA/RNA Contacts
The list of contacting atom pairs:
•'11 P R O  ( 2-iG j A G •135 GURA ) D C 5 D= 2.82 (0-5) 2 2 3  ALA ( 4 13 A CB A* •133 G URA ( 5 0 G P 2  D= 3 .0 3  ^s-S )
43VAL ( 2 3 2 ) A CG2 <> 435 0URA 7 B P 0= 3.97 (S-B) 238 VAL (4 3 2 A CG1 <> 431 OURA 3 B C4' D= 3.73 (S-S)
43 VAL ( 2 3 2 )  A CG2 o 435 0URA 7 B C3‘ D= 3 5 7  (S-8) 238 VAL (4 3 2 A CG2 c> 431 OURA 3 B C5' D= 3.55 (S-S)
43VAL (2 3 2 )  A CG2 <> 435 0URA 7 B 0 5 ’ D= 3.18 (S-S) 238 VAL (4 3 2 A CG2 <> 431 OURA 3 B C4' D= 3.54 (S-S)
43VAL (2 3 2 )  A CG2 <> 436 OURA 8 B P D= 3.70 (S-B) 240 GLN (4 3 4 A CG <> 432 OURA 4 B C4 D= 3.82 (S-S)
4 3  VAL ( 2 3 2 )  A C 6 2 <> 4 3 6  OURA 8 B O P1 D“  3  1 0  (S-B) 2 4 0  GLN  ( 4 3 4 A C G <> 4 3 2  O U RA 4 B CH £ >  2  72  (S-S)
66 GLY ( 2 5 5 ) A N <> 436 OURA 8 B P D= 3.60 (B-B) 240 GLN (4 3 4 A CD <> 432 OURA 4 B 0 4 D= 3.02 (S-S)
6 6 GLY ( 2 5 5 ) A N <> 436 OURA 8 B OP2 D= 3.06 (B-S) 240 GLN (4 3 4 A NE2 <> 432 OURA 4 B 0 4 D= 2.89 (S-S)
6 6  GLY ( 2 0 5 ) A CA <> 436 OURA 6 B P D - 3.93 (B-B) 254 THR (4 4 6 A CG2 <> 432 OURA 4 B C 5 D - 3.75 (S-S)
80THR ( 2 6 9 )  A CB <> 436 OURA 8 B OP2 D= 3.28 (S-S) 254 THR (4 4 8 A CG2 <> 432 OURA 4 B C4 D= 3.83 (S-S)
80 THR ( 269.) A OG1 <> 436 OURA 8 B OP2 D= 2.42 (S-S) 254 THR (4 4 8 A CG2 <> 432 OURA 4 B 0 4 D= 3.35 (S-S)
82 GLY (271 ) A CA <> 436 OURA 8 B C5' D= 3.39 (B-S) 256 THR (4 5 0 A OG1 <> 430 OURA 2 B 03' D= 2.95 (S-B)
82 GLY (271 ) A C <> 436 OURA 8 B C5' D= 3.00 (B-S) 306 TRP (501 A CG <> 436 OURA 8 B C2 D= 3.81 (S-S)
82 G! Y ( 271 ) A o <>■ 436 OURA 6 R C4‘ D= 3 59 (R-S) 306 TRP (5 0 1 . A c n ? . 436 OURA R R Ml r*= 3.67 (S-R>
83LYS (2 7 2 )  A N « 436 OURA 8 B C5‘ D= 2.94 (B-S) 306 TRP (501 A CD2 <> 436 OURA 8 B C2 D= 3.53 (S-S)
83LYS ( 2 7 2 )  A CA <> 436 OURA 8 B C5' D= 3.52 (B-S) 306 TRP (501 A NE1 <> 436 OURA 8 B N3 D= 3.45 (S-S)
86 ALA ( 2 7 5 )  A CB <> 436 OURA 8 B 03' D= 3.34 (S-B) 306 TRP (501 A CE2 <> 436 OURA 8 B C4 D= 3.55 (S-S)
179 HIS (3 6 9 )  A CD2 <> 431 OURA 3 B C5' D= 3.64 (S-S) 306 TRP (501 A CE2 <> 436 OURA 8 B N3 D= 3.33 (S-S)
179 HIS ( 3 6 9 )  A NE2 o 431 OURA 3 B P D= 3.61 (S-B) 306 TRP (501 A CE2 <> 436 OURA 8 B C2 D= 3.55 <S-S)
179 HIS (3 6 9 )  A NE2 <> 431 OURA 3 B OP2 D -  2.76 (S-S) 306 TRP (501 A CE3 <> 436 OURA 8 B C1' D= 3.73 (S-S)
179 HIS ( 3 6 9 )  A NE2 <> 431 OURA 3 B C5' D= 3.73 (S-S) 306 TRP (501 A CE3 <> 436 OURA 8 B N1 D= 3.59 (S-S)
179 HIS ( 3 6 9 )  A O <> 432 OURA 4 B C6' D= 2.96 (B-S) 306 TRP (501 A CE3 <> 436 OURA 8 B C6 D= 3.85 (S-S)
179 HIS ( 3 6 9 )  A O <> 432 OURA 4 B C4' D= 3.37 (B S ) 306 TRP (501 A CZ2 <? 436 OURA 8 B C6 D= 3.75 (S-S)
180 SER ( 3 7 0 )  A CA <> 432 OURA 4 B OP2 D= 3.17 (B S ) 306 TRP ( 501 A CZ2 <> 436 OURA 8 B C5 D= 3.35 (S-S)
180 SER ( 3 7 0 ) A CA <> 432 OURA 4 B C5' D= 3.67 (B S ) 306 TRP (501 A CZ2 <> 436 OURA 8 B C4 D= 3.21 (S-S)
180 SER ( 3 7 0 ) A CB <> 432 OURA 4 B OP2 D= 3.12 (S-S) 306 TRP (501 A CZ2 <> 436 OURA 8 B N3 D= 3.54 (S-S)
181 LYS (371 ) A N <> 432 OURA 4 B OP2 D= 2.93 (B-S) 306 TRP (501 A CZ3 <> 436 OURA 8 B N1 0= 3.75 (S-S)
203 ARG ( 3 9 3 )  A N <> 433 OURA 5 B P D= 3.90 (BB) 306 TRP (501 A CZ3 <> 436 OURA 8 B C6 D= 3.48 (S-S)
203 ARG ( 3 9 3 )  A N o 433 OURA 5 B OP2 D= 2.80 (B S ) 306 TRP (501 A CH2 <> 436 OURA 8 B C6 D= 3.44 (S-S)
203 ARG ( 3 0 3 )  A CB <> 433 OURA 5 B P D= 3.66 (B B ) 306 TRP ( 501 A CH2 <> 436 OURA 6 B 6 5 D= 3.29 (S-S)
203 ARG ( 3 9 3 )  A CB <> 433 OURA 5 B OP1 D= 3.36 (S-B) 306 TRP (501 A CH2 <> 436 OURA 8 B C4 D= 3.72 (S-S)
203 ARG ( 3 9 3 )  A CB <> 433 OURA 5 B OP2 D= 3.41 (S-S) 307 TYR (5 0 2 A OH <> 436 OURA 8 B 0 2 D= 2.93 (S-S)
203 ARG ( 3 9 3 )  A NE <> 433 OURA 5 B C2' D= 3.08 (S-S) 361 ASN (5 5 6 A OD1 <> 433 OURA 5 B 0 4 D= 2.83 (S-S)
203 ARG (3 9 3  ) A NE <> 434 OURA 6 B OP1 D= 3.06 (S-B)
203 ARG (3 9 3 )  A NE o 434 OURA 6 B C5 D= 3.68 (S-S)
203 ARG (3 9 3  ) A CZ <> 434 OURA 6 B OP1 D= 3.30 (S-B)
203 ARG ( 3 9 3 )  A CZ <> 434 OURA 6 B C6 0=  3.47 (S-S)
203 ARG (3 9 3 )  A CZ <> 434 OURA 6 B C5 D= 3.48 (S-S)
203 ARG (3 9 3 )  A NH2 <> 434 OURA 6 B P D= 3.71 (S-B)
203 ARG (3 9 3 )  A NH2 <> 434 OURA 6 B OP1 D= 2.92 (S-B) :
203 ARG (3 9 3 )  A NH2 <> 434 OURA 6 B 05' D= 3.28 ( S S )
203 ARG (3 9 3 )  A NH2 <> 434 OURA 6 B C2’ D= 3.50 (S-S)
203 ARG ( 3 9 3 )  A NH2 <> 434 OURA 6 B C6 D= 3.00 (S-S)
203 ARG ( 3 9 3 )  A NH2 <> 434 OURA 6 B C5 D= 3.52 (S-S)
221 THR ( 4 1 1 )  A CB <> 432 OURA 4 B 03 ' D= 3.43 (S-B)
221 THR (411 ) A OG1 <> 433 OURA 5 B P D= 3.46 (S-B)
221 THR (411 ) A OG1 <> 433 OURA 5 B OP2 D= 2.54 (S-S)
223 ALA ( 4 1 3 )  A N <>. 433 OURA 5 B C5‘ D= 3.48 (B S )
223 ALA ( 4 1 3 )  A CA <> 433 OURA 5 B C3' D= 3.56 (B B )
223 ALA ( 4 1 3 )  A CA <> 433 OURA 5 B C5' D= 3.76 (B S )
223 ALA ( 4 1 3 )  A CA <> 433 OURA 5 B C4' D= 3.77 (B S )
223 ALA (4 1 3 )  A CB <> 433 OURA 5 B C3' D= 3.82 (S-B)
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D. Protein -  PNA contacts bv LioPlot
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BACTERIAL TRANSFORMATION:
1. 1 pL of plasmid DNA added to cells
2. Leave on ice for 45 m inutes
3. Heat in w aterbath  a t 42 °C for 2 m inutes
4. Add 0 .5  pL of LB medium with no antibiotic
5. Leave on ice for 1  hour a t 37 °C
6 . Microcentrifuge a t 8000 rpm for lm inu te
7. Take off and discard 0 .5  mL of su p ern a tan t
8 . Re-suspend gently in rem aining volum e
9. Plate on LB agar + AMP Petri dishes
E.COLI CULTURE
1. Pick up a healthy looking (round, consistent) colony with a 
loop
2. Inoculate in a universal tu b e  with 10 mL of LB + AMP
3. Incubate in shaking centrifuge a t  37 °C for 13 to  14 hours
MINI-PREP PREPARATION
1. Add 1.5 mL of overnight culture of E.Coli in an  eppendorf and 
spin a t  13000 for 1  m inute
2. Repeat 3 tim es for each tu b e  passing a to tal of 4 .5  mL of 
cell suspension from each tu b e
3. Each tim e discard su p ern a tan t
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MINI -  PREP
using a m icrocentrifuge
This protocol is designed for purification of up to  20 pg of high-copy
plasmid DNA fro m l-5  mL overnight cultures of E. coli in LB (Luria-
Bertani) m edium .
Note: All protocol steps should be carried out a t room tem pera tu re .
Procedure
1. Resuspend pelleted bacterial cells in 250 jjL Buffer PI and 
tran sfe r to  a m icrocentrifuge tube.
2. Ensure th a t RNase A has been added to  Buffer P I. No cell 
clum ps should be visible after resuspension of th e  pellet.
3. Add 250 pL Buffer P2 and gently invert th e  tube  4 -6  tim es to  
mix.
4. Mix gently by inverting th e  tube. Do not vortex, a s  th is will 
resu lt in shearing of genom ic DNA. If necessary , continue 
inverting th e  tube  until the  solution becom es viscous and 
slightly clear. Do not allow th e  lysis reaction to  proceed for 
m ore than  5 min.
5. Add 350 pL Buffer N3 and invert th e  tu b e  im m ediately but 
gently 4 -6  tim es.
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6. To avoid localized precipitation, mix th e  solution gently but 
thoroughly, im m ediately a fte r addition of Buffer N3. The 
solution should becom e cloudy.
7. Centrifuge for 10 min a t  13.000 rpm  (~  17.900 x g) in a 
tab le-top  microcentrifuge.
8. A com pact white pellet will form.
9. Apply th e  supernatan ts from s tep  4 to  th e  QIAprep Spin 
Column by decanting or pipetting.
10. Centrifuge for 3 0 -6 0  s. Discard th e  flow -through.
1 1 .(Optional): Wash the  QIAprep Spin Column by adding 0.5 mL 
Buffer PB and centrifuging for 3 0 -6 0  s. Discard th e  flow­
through.
12 .This step  is necessary to  rem ove trace  nuc lease  activity when 
using endA+ strains such a s  th e  JM series , HB101 and its 
derivatives, or any wild-type stra in , which have  high levels of 
nuclease activity or high carbohydrate  con ten t. Host strains 
such a s  XL-1 Blue and DH5a™ do not require  th is additional 
wash step.
13. Wash QIAprep Spin Column by adding 0 .75  mL Buffer PE and 
centrifuging for 3 0 -6 0  s.
14. Discard the  flow-through, and  centrifuge for an  additional 1 
min to rem ove residual w ash buffer.
15. IMPORTANT: Residual w ash buffer will not be completely 
rem oved unless th e  flow-through is discarded before this
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additional centrifugation. Residual ethanol from Buffer PE 
m ay inhibit su b seq u en t enzym atic reactions.
16. Place the  QIAprep colum n in a clean 1.5 mL microcentrifuge 
tube. To elute DNA, add  50 pL Buffer EB (10 mM Tris-CI, pH 
8 .5 ) or w ater to  th e  cen te r o f each  QIAprep
17. Spin Column, let stand  for 1 min, and  centrifuge for 1 min.
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DNA CONCENTRATION PROTOCOL
Materials:
1. TE solution
o 10 mM Tris (pH to  7 .5) 
o 1 mM EDTA (pH to  8 .0  to  dissolve)
2. DNA sam ple
3. SYBR Green I(R) nucleic acid gel stain  (Molecular Probes)
4. Plastic wrap
5. distilled w ater
6. DNA m arker stock (10 m g/mL)
Supplies:
1. Tubes
2. Polaroid setup  (with proper filter - SYBR Green/Gold gel stain 
photographic filter) and UV light box
3. Micropipetter and tips
Procedures:
1. Prepare 6 DNA standards from DNA m arker stock:
o standard  I (5 ug/u l): 1 :2  dilution of DNA m arker stock 
o standard  II (2 .5  ug /u l): 1:2  dilution of standard  I 
o standard  III (1 .25  ug /u l): 1 :2  dilution of standard  II 
o standard  IV (0 .625  ug/u l): 1:2 dilution of standard  III
Dimitrios Vlachakis, PhD 2006 196
Chapter 5.___________________________________________________Appendix
o standard  V (0 .313  ug/ul): 1:2 dilution of standard  IV 
o standard  VI (0 .156  ug/u l): 1 :2  dilution of standard  V
2. Make a 1:5000 dilution of th e  SYBR Green I(R) with TE 
solution.
3. Mix 5 ul of the  DNA sam ple  and  each  of th e  6 standards with 
5 ul of th e  diluted SYBR G reen I(R) dye.
4. Place a sh ee t of plastic w rap sm oothly  on to  th e  UV light box.
5. Spot th e  m ixtures individually onto  p lastic wrap.
6. Spot th e  se t of 6 s tandards.
7. Turn on th e  UV light and  ta k e  a photo  (Polaroid 667 black- 
and-w hite print film).
8. Com pare the  brightness of th e  DNA sam ple  with th e  DNA 
standards and estim ate  concentra tion .
LIGATION - PCR
• Add 1 pL of the  vector
• Add 1 pL of lOx buffer
• Add PCR product (1 pL)
• Add 8 pL of SIGMA w ater
• Add 1 pL of Ligase 
LIGATION -  OVERNIGHT
• Add 0 .5  pL of th e  vector
• Add 5 pL of lOx buffer
• Add 3.5 pL In se rt DNA
• Add 1 pL of Ligase (last)
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• Incubate overnight a t  17 °C 
LIGATION -  BENCHTOP
Add 0.5  |j L of th e  vecto r 
Add 5 pL of lOx buffer 
Add 3.5 pL Insert DNA 
Add 1 pL of Ligase (last)
Leave a t room tem p era tu re  for 2 hours + 30 m inutes. 
SDS-Paoe Gel Preparation
10%  Running Gel Stacking
Solution
Acrylamide 3.3 mL 696 ul
1.5M Tris-HCI pH8.8 2 .5  mL
0.5M Tris HCI pH6.8 —  650 pi
10% SDS 100 pi 100 ul
10% APS 50 pi 50 pi
TEMED 20 pi 10 pi
W ater (D) 4 .0  mL 3.65 mL
-> The Running Buffer is made by preparing 200 mL SDS Page 
Buffer (containing 288g Glycine and 80g Tris). 20 mL of SDS 
10% buffer into 2000mL of dH20  will give the SDS buffer.
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2.1.1 Molecular weight standards
Prestained high range molecular weight protein standards were purchased from 
Bio-Rad Laboratories, Hertfordshire, U.K or New England BioLabs, Beverly, MA, 
USA. The X Hind ID and <|>X174 Hae in  DNA markers were purchased from 
PromegaLtd., Southampton, UK.
High range protein molecular weight markers (Bio-Rad)
Myosin (H chain) 200.000 Da
Phosphorylase B 97.400 Da
Bovine serum albumin 68.000 Da
Ovalbumin 43.000 Da
Carbonic Anhydrase 31.000 Da
P Lactoglobulin 18.400 Da
Lysozyme 14.300 Da
High range protein molecular weight markers -(New England Biolabs)
MBP-p-galactosidase 175.000 Da
MBP-paramyosin 83.000 Da
Glutamic dehydrogenase 62.000 Da
Aldolase 47.500 Da
Trisosephosphate isomerase 32.500 Da
p-Lactoglobulin A 25.000 Da
Ly sozy me 16.500 Da
Aprotinin 6.500 Da
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>DENGUE— NS3
a g v lw d v p s p  p p v g k a e l e d  g a y r i k q k g i  l g y s q i g a g v  y k e g t f h t m w  h v t r g a v l m h
k g k r i e p s w a  d v k k d l i s y g  g g w k le g e w k  e g e e v q v l a l  e p g k n p r a v q  t k p g l f r t n t
g t i g a v s l d f  s p g t s g s p i v  d k k g k v v g l y  g n g v v t r s g a  y v s a i a q t e k  s i e d n p e i e d
d i f r k r r l t i  m d lh p g a g k t  k r y l p a i v r e  a i k r g l r t l i  l a p t r v v a a e  m e e a l r g l p i
r y q t p a i r a e  h t g r e i v d l m  c h a t f t m r l l  s p i r v p n y n l  i i m d e a h f t d  p a s i a a r g y i
s t r v e m g e a a  g i f m t a t p p g  s r d p f p q s n a  p i m d e e r e i p  e r s w n s g h e w  v t d f k g k t v w
f v p s i k t g n d  i a a c l r k n g k  r v i q l s r k t f  d s e y v k t r t n  d w d f v v t t d i  s e m g a n f k a e
r v id p r r c m k  p v i l t d g e e r  v i l a g p m p v t  h s s a a q r r g r  i g r n p r n e n d  q y i y m g e p l e
n d e d c a h w k e  a k m L ld n in t  p e g i i p s m f e  p e r e k v d a i d  g e y r l r g e a r  k t f v d l m r r g
d l p v w l a y k v  a a e g i n y a d r  r w c f d g t r n n  q i l e e n v e v e  i w t k e g e r k k  l k p r w l d a r i
y s d p l a l k e f  a a g r k
> Y e l l o w  f e '  
s g d v l w d i p t  
v r n g k k l i p s  
r n g g e i g a v a  
lq e ip t m L k k  
h g l d v k f h t q  
a r g w a a h r a r  
r p t a w f l p s i  
n l c v e r v l d c  
p t s e n n a h h v  
v r n c d l p v w l  
c d e r v s s d q s
r e r  v i r u s — 1 
p k i i e e c e h l  
w a s v k e d l v a  
l d y p s g t s g s  
g m t t v l d f h p  
a f s a h g s g r e  
a n e s a t i l m t  
r a a n v m a a s l  
r t a f k p v l v d  
c w le a s m L ld  
s w q v a k a g lk  
a l s e f i k f a e
e d g i y g i f q s  
y g g s w k l e g r  
p i v n r n g e v i  
g a g k t r r f l p  
v i d a m c h a t l  
a t p p g t s d e f  
r k a g k s v v v l  
e g r k v a i k g p  
n m e v r g g m v a  
t n d r k w c f e g  
g r r
t f l g a s q r g v  
w d g e e e v q l i  
g l y g n g i l v g  
q i l a e c a r r r  
t y r m L e p t r v  
p h s n g e i e d v  
n r k t f e r e y p  
l r i s a s s a a q  
p l y g v e g t k t  
p e e h e i l n d s
g v a q g g v f h t  
a a v p g k n v v n  
d n s f v s a i s q  
l r t l v l a p t r  
v n w e v i i m d e  
q t d i p s e p w n  
t i k q k k p d f i  
r r g r i g r n p n  
p v s p g e m r l r  
g e t v k c r a p g
m w h v t r g a f l  
v q t k p s I f k v  
t e v k e e g k e e  
v v l s e m k e a f  
a h f l d p a s i a  
t g h d w i l a d k  
l a t d i a e m g a  
r d g d s y y y s e  
d d q r k v f r e l  
g a k k p lr p r w
> J a p a n e s e  <
g g v f w d t p s p
g e g k l t p y w g
g e v g a v s l d y
p n m L rk rq m t
v r y q t s a v q r
i a t k v e l g e a
w f  v a s v k m g n
s r v i d c r k s v
e d d s n l a h w t
a d l p v w l a y k
v y a d h q a lk w
s n c e p h a l i t i :  
k p c s k g d t t t  
s v k e d r i a y g  
p r g t s g s p i l  
v l d l h p g s g k  
e h q g n e i v d v  
a a i f m t a t p p  
e i a m c l q r a g  
k p t i l e e g e g  
e a k im L d n ih  
v a s n g i q y t d  
f k d f a a g k r
; v i r u s — NS! 
g v y r i m a r g i  
g p w r fd r k w n  
d s n g d i i g l y  
t r k i l p q i i k  
m c h a t l t h r l  
g t t d p f p d s n  
k k v i q l n r k s  
r v i l g n p s p i  
m p n g l v a q l y  
r r w c f d g p r t
l g t y q a g v g v  
g t d d v q v i v v  
g n g v e l g d g s  
d a i q q r l r t a  
m s p n r v p n y n  
a p i h d l q d e i  
y d t e y p k c k n  
t s a s a a q r r g  
g p e r e k a f t m  
n a i l e d n t e v
m y e n v f h t  l w  
e p g k a a v n i q  
y v s a i v q g d r  
v l a p t r v v a a  
l f v m d e a h f t  
p d r a w s s g y e  
g d w d f v i t t d  
r v g r n p n q v g  
d g e y r l r g e e  
e i v t r m g e r k
h t t r g a a i m s  
t k p g v f r t p f  
q e e p v p e a y t  
e m a e a l r g l p  
d p a s i a a r g y  
w i t e y a g k t v  
i s e m g a n f g a  
d e y h y g g a t s  
k k n f l e l l r t  
i l k p r w l d a r
> w e s t  n i l e  
g g v l w d t p s p  
g e g r l d p y w g  
g e i g a v t l d y  
p e m L r k k q it  
i r y q t s a v h r  
i a t k v e l g e a  
w f  v p sv k m g n  
s r v i d s r k s v  
e d d s n f a h w t  
a d l p v w l a y k  
v y s d h q a l k s
— N S3  
k e y k k g d t t t  
s v k e d r l c y g  
p t g t s g s p i v  
v l d l h p g a g k  
e h s g n e i v d v  
a a i f m t a t p p  
e i a l c l q r a g  
k p t i i e e g d g  
e a r im L d n in  
v a a a g i s y h d  
f k d f a s g k r
g v y r i m t r g l  
g p w k lq h k w n  
d k n g d v i g l y  
t r k i l p q i i k  
m c h a t l t h r l  
g t s d p f p e s n  
k k v i q l n r k s  
r v i l g e p s a i  
m p n g l v a q l y  
r k w c f d g p r t
l g s y q a g a g v
g h d e v q m iv v
g n g v im p n g s
e a i n k r l r t a
m s p h r v p n y n
a p i s d m q t e i
y e t e y p k c k n
t a a s a a q r r g
q p e r e k v y t m
n t i l e d n n e v
m v e g v f h t l w  
e p g k n v k n v q  
y i s a i v q g e r  
v l a p t r v v a a  
I f i m d e a h f t  
p d r a w n t g y e  
d d w d f v i t t d  
r i g r n p s q v g  
d g e y r l r g e e  
e v i t k l g e r k
h t t k g a a l m s  
t k p g v f k t p e  
m e e p a p a g f e  
e m s e a l r g l p  
d p a s i a a r g y  
w i t e y v g k t v  
i s e m g a n f k a  
d e y c y g g h t n  
r k n f l e f  l r t .  
i l r p r w a d a r
> H e p a t i t i s  C— N S3
MVDFIPVENLETTMRSPVFTDNSSPPAVPQSFQVAHLHAPTGSGKSTKVPAAYAAQGYKVLVLNPSVAA 
TLGFGAYMS KAHGVDPNIRTGVRTITTGS P IT Y  STYGKFLADGGCSGGAY D IIIC D EC H STD A TSIL G I 
GTVLDQAETAGARLVVLATATPPGSVTVPHPNIEEVALSTTGEIPFYGKAIPLEVIKGGRHLIFCHSKK  
KCDELAAKLVALGINAVAYYRGLDVSVIPTSGDWWATDALMTGFTGDFDSVIDCNTCVTQTVDFSLD 
PT FT IETTTLPQDAVSRTQRRGRTGRGKPGIY RFVAPGERPSGMFDSSVLCECYDAGCAWY ELTPAETT 
VRLRAYMNTPGLPVCQDHLE FWEGVFTGLTHIDAH FLS QT KQS GENFP YLVAY QATVCARAQAPPPSWD 
QMWKCLIRLKPTLHGPTPLLYRLGAVQNEVTLTHPITKYIMTCMSADLEWTGSGSHHHHHH
> w e s t  n i l e —N S5
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GGAKGRTLGEVWKERLNQMTKE E FT RY RKEAIIEVDRS AAKHARKEGNVTGGH PVS RGTAKLRWLVERRF 
LEPVGKVIDLGCGRGGWCYYMATQKRVQEVRGYTKGGPGHEEPQLVQSYGWNIVTMKSGVDVFYRPSECC 
DTLLCDIGESSSSAEVEEHRTIRVLEMVEDWLHRGPREFCVKVLCPYMPKVIEKMELLQRRYGGGLVRNP 
LSRNSTHEMYWSRASGNWHSVNMTSQVLLGRMEKRTWKGPQYEEDVNLGSGTRAVGKPLLNSDTSKIK 
NRIERLRREYSSTWHHDENHPYRTWNYHGSYDVKPTGSASSLVNGWRLLSKPWDTITNVTTMAMTDTTP 
FGQQRVFKEKVDTKAPEPPEGVKYVLNETTNWLWAFLAREKRPRMCSREEFIRKVNSNAALGAMFEEQNQ 
WRSAREAVEDPKFWEMVDEEREAHLRGECHTCIYNMMGKREKKPGEFGKAKGSRAIWFMWLGARFLEFEA 
LGFLNEDHWLGRKNSGGGVEGLGLQKLGYILREVGIRPGGKIYADDTAGWDTRITRADLENEAKVLELLD 
GEHRRLARAIIELTYRHKWKVMRPAADGRTVMDVISREDQRGSGQWTYALNTFTNLAVQLVRMMEGEG 
VIGPDDVEKLTKGKGPKVRTWLFENGEERLSRMAVSGDDCWKPLDDRFATSLHFLNAMSKVRKDIQEWK 
PSTGWYDWQQVPFCSNHFTELIMKDGRTLWPCRGQDELVGRARISPGAGWNVRDTACLAKSYAQMWLLL 
YFHRRDLRLMANAICSAVPVNWVPTGRTTWSIPIAGGEWMTTEDMLEVWNRVWIEENEWMEDKTPVEKWSD 
VPYSGKREDIWCGSLIGTRARATWAENIQVAINQVRAIIGDEKYVDYMSSLKRYEDTTLVEDTVL
> Y e l lo w  f e v e r  v i r u s —NS5
GT AN GKT LGEVWKRE LNLLDKQQFE LY KRT DIVEVDRDTARRH LAEGKVDTGVAV S RGTAKLRWFH ERGY 
VKLEGRVIDLGCGRGGWCYYAAAQKEVSGVKGFTLGRDGHEKPMNVQSLGWNIITFKDKTDIHRLEPVKC 
DTLLCDIGESSSSSVTEGERTVRVLDTVEKWLACGVDNFCVKVLAPYHPDVLEKLELLQRRFGGTVIRNP 
LSRNSTHEMYYVSGARSNVTFTVNQTSRLLMRRMRRPTGKVTLEADVTLPIGTRSVETDKGPLDKEAIEE 
RVERIKSE YMTSWFY DNDNPY RTWH Y CGS Y VT KTS GSAASMVNGVIKILT Y PWDKIEEVTRMAMTDTT PF 
GQQRVFKEKVDTRAKDPPAGTRKIMKWNRWLFRHLAREKNPRLCTKEEFIAKVRSHAAIGAYLEEQEQW 
KTANEAVQDPKFWELVDEERKLHQQGRCRTCVYNMMGKREKKLSEFGKAKGSRAIWYMWLGARYLEFEAL 
GFmEDHWASRENSGGGVEGIGLQYLGYVI RDLAAMDGGGFYADDTAGWDTRITEADLDDEQEILNYMSP 
HHKKLAQAVMEMTY KNKWKVLRPAPGGKAYMDVISRRDQRGS GQWTYALNTITNLKVQLIRMAEAEMV 
IHHQHVQDCDESVLTRLEAWLTEHGCNRLRRMAVSGDDCWRPIDDRFGLALSHLNAMSKVRKDISEWQP 
SKGWNDWENVPFCSHHFHELQLtCDGRRIWPCREQDELIGRGRVSPGNGWMIKETACLSKAYANMWSLMY 
FHKRDMRLLSLAVSSAVPTSWVPQGRTTWSIHGKGEWMTTEDMLEVWNRVWITNNPHMQDKTMVKEWRDV 
PY LTKRQDKLCGSLIGMTNRATWASHIHLVIHRIRTLVGQEKYTDYLTVMDRY SVDADLQPGELI
> J a p a n e s e  e n c e p h a l i t i s  v i r u s —NS5
GRPGGRTLGEQWKEKLNAMSREEFFKYRREAIIEVDRTEARRARRENNIVGGHPVSRGSAKLRWLVEKGF 
VS PIGKVIDLGCGRGGW SY Y AATLKKV QEVRGY TKGGAGH EE PMLMQS Y GF^NLV S LKS GVDVFY KP S E PS 
DT LFCDIGE S S PS PE VEEQRTLRVLEMTS DWLHRGPRE FCIKVLC PYMPKVIE KMEVLQRRFGGGLVRLP 
LSRNSNHEMYVJVSGAAGNWHAVNMTSQVLLGRMDRTVWRGPRTYEEDVNLGSGTRAVGKGEVHSNQEKIK 
KRIQKLKEEFATTWHKDPEHPYRTWTYHGSYEVKATGSASSLVNGVVKLMSKPWDAIANVTTMAMTDTTP 
FGQQRVFKEKVDTKAPE PPAGAKEVLNETTNWLWAHLS REKRPRLCTKEE FI KKVNSNAALGAVFAEQNQ 
WSTAREAVDDPRFWEMVDEERENHLRGECHTCIYNMMGKREKKPGEFGKAKGSRAIWFMWLGARYLEFEA 
LGFLNEDHWLSRENSGGGVEGSGVQKLGYILRDIAGKQGGKMYADDTAGWDTRITRTDLENEAKVLELLD 
GE HRMLARAIIELTY RHKWKVMRPAAEGKTVMDVIS REDQRGSGQWT Y ALNT FTNIAVQLVRLMEAEG 
VIGPQHLEQLPRKTKIAVRTWLFENGEERVTRMAISGDDCWKPLDDRFATALHFLNAMSKVRKDIQEWK 
PSHGWHDWQQVPFCSNHFQEIVMKDGRSIWPCRGQDELIGRARISPGAGWNVKDTACLAKAYAQMWLLL 
Y FHRRDLRLMANAICSAVPVDWVPTGRTSWSIHSKGEWMTTEDMLQVWNRVWIEENEWMMDKT PI T SWTD 
VPY VGICREDIWCGSLIGTRS RATW7\EN IY AAINQVRAVIGKENY VDYMTS LRRYE DVLIQEDRVI
> H e p a t i t i s  C— NS5
SMSYTWTGALITPCAAEESKLPINPLSNSLLRHHNMVYATTSRSASLRQKKVTFDRLQVL 
DDHY RDVLKEMKAKASTVKAKLLSIEEACKLT PPH SAKSKFGY GAKDVRNLS S RAVNHIR 
SVWEDLLEDTETPIDTTIMAKSEVFCVQPEKGGRKPARLIVFPDLGVRVCEKMALYDWS 
TLPQAVMGSSYGFQY SPKQRVEFLVNTWKSKKCPMGFSYDTRCFDSTVTESDIRVEESIY 
QCCDLAPEARQAIRS LT ERLYIGGPLTNS KGQNCGY RRCRASGVLTT S CGNTLTCYLKAT 
AACRAAKLQDCTMLVNGDDLWICESAGTQEDAAALRAFTEAMTRY SAPPGDPPQPEYDL 
ELITSCSSNVSVAHDASGKRVYYLTRDPTTPLARAAWETARHTPINSWLGNIIMYAPTLW 
ARMILMTHFFSILLAQEQLEKALDCQIYGACY S IE  PLDLPQIIERLHGLSAFT LH SY S PG 
EINRVAS CLRKLGVP PLRTWRHRARS VRAKLL S QGGRAAT CGRY L FNWAVRT KLKLT P IP  
AASQLDLSGWFVAGYSGGDIYHSLSRARPR
>BVDV — NS5
AY LKLKDFIEEEEKKPRVKDTVIREHNKWILKKIRFQGNLNTKKXLNPGKLSEQLDREGR 
KRNIYNHQIGTIXSSAGIRLEKXPIVRAQTDTKTFHEAIRDKIDKSENRQNPELHNKLLE 
IFHTIAQPTLKHTY GEVTWEQLEAGVNRKGAAGFLEKKNIGEVLDSEKHLVEQLVRDLKA 
GRKIKYYETAIPKNEKRDVS DDWQAGDLWEKRPRVIQY PEAKTRLAITKVXYNWVKQQP 
WIPGYEGKTPL FNIFDKVRKEWDS FNE PVAVS FDTKAWDTQVTS KDLQLI GE IQKY Y Y K 
KEWHKFI DT ITDHXTEVPVITADGEVYIRNGQRGSGQPDTSAGNSXLNVLTXXYAFCEST 
GVPY KS FNRVARIHVCGDDGFLITEKGLGLKFANKGXQILHEAGKPQKITEGEKXKVAY R
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FED IE FCS HT PVPVRWS DNT S S HXAGRDTAVILS KXAT RLDS S GE RGTTAY EKAVAFS FL 
LXY SWNPLVRRICLLVLSQQPETDPSKHAT Y Y Y KGDPI GAY KDVIGRNLS ELKRTGFEKL 
ANLNLSLSTLGVWTKHTSKRIIQDCVAIGKEEGNWLVKPDRLISSKTGHLYIPDKGFTLQ 
GKHY EQLQL
> D en gue -N S 5
g t g n t g e t l g  e k w k n r ln a l  g k s e f q iy k k  s g i q e v d r t l  a k e g i k r g e t  d h h a v s r g s a
k l r w f v e r n l  v t p e g k v v d l  g c g r g g w s y y  c g g lk n v k e v  k g l t k g g p g h  e e p ip m s t y g
w n lv r l q s g v  d v f f t p p e k c  d t l l c d i g e s  s p n p t v e a g r  t l r v l n l v e n  w l n n n t q f c i
k v ln p y m p sv  ie k m e a lq r k  y g g a lv r n p l  s r n s th e m y w  v s n a s g n i v s  sv n m is r m L i
n r f tm r h k k a  t y e p d v d lg s  g t r n i g i e s e  t p n l d i i g k r  i e k i k q e h e t  sw h y d q d h p y
k t w a y h g s y e  t k q t g s a s s m  v n g v v r l l t k  p w d iip m v tq  m a m t d t t p f g  q q r v f k e k v d
t r t q e p k e g t  k k lm k ita e w  lw k e lg k k k t  p r m c t r e e f t  r k v r s n a a l g  a i f t d e n k w k
s a r e a v e d s g  f w e lv d k e r n  l h l e g k c e t c  vyrunm gkrek k l g e f g k a k g  s r a iw y m w lg
a r f l e f e a l g  f l n e d h w f s r  e n s l s g v e g e  g l h k l g y i l r  d v s k k e g g a m  y a d d ta g w d t
r i t l e d l k n e  em vtn h m ege h k k l a e a i f k  l t y q n k v v r v  q r p t p r g t v m  d i i s r r d q r g
s g q v v t y g l n  t f t n m e a q l i  r q m e g e g v fk  s i q h l t v t e e  i a v k n w l v r v  g r e r l s r m a i
s g d d c v v k p l  d d r f a s a l t a  ln d m g k v rk d  iq q w e p sr g w  n d w t q v p f c s  h h f h e l im k d
g r v lv v p c r n  q d e l i g r a r i  s q g a g w s lr e  t a c l g k s y a q  m w s lm y fh r r  d l r l a a n a i c
sa v p s h w v p t  s r t t w s i h a t  hewmttediriL tv w n r v w iq e  n p w m ed k tp v  e s w e e i p y l g
k r e d q w c g s l  i g l t s r a t w a  k n iq t a in q v  r s l i g n e e y t  d y m p sm k r fr  r e e e e a g v l w
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G. Virtual screening -  lead optimisation
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The sym bols used stand for:
V picks up high interaction with the protein (H bonds) 
and hydrophobic interaction too . It has a good conformation 
on the protein as w ell.
~V  -»Does not H-bond but it estab lish es hydrophobic 
interaction and has a good docking conform ation.
X ->Was im possible to  dock th e  com pound in a successful 
way. No interaction estab lished  + th e  conformation of the  
compound is bad.
STRUCTURE Number HepC Dengue WNV
1 X X X
2 X X X
dpt 3 X X X
: i X X j  ■1
4 X X X
5 X X X
c^r
6 X X X
^ O U J O r ^
7 X X X
€ h  r p 8 X X X
9 X X X
10 X X X
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STRUCTURE Number HepC Dengue WNV
d4X ' a % 1 1 X X X
1 2 X X X
c x  ym: p
q £
13 X X X
/-CXX20
14 V X X
15 X X X
JQe x  y4 16 ~V X X
a
c V x _ 0 $ 17 ~V ~v X
<V v O * > 18 X X X
r&°Z. l0^<y 19 X X X
2 0 X X
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STRUCTURE Number HepC Dengue WNV
2 1 X X X
j ?
2 2 X X X
Q0X>^P 23 X X X
: • CP
x x x  x /~ 24 X X X
✓0
/
y 0 _€ h ^ O ^ O
25 ~V X X
_rD-0O
26 X X X
<P l1O L :2 t ' ' O 0 6 0 27 X X X
28 X X X
% 29 ~V V V
• y P b
d ^ ’ ^ 30 X X X
31 V ~v
...
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WNVHepC DengueNumberSTRUCTURE
34
37
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WNVHepCSTRUCTURE DengueNumber
44
47
48
48
49
■VX
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Evaluation of the dockings:
The above compounds have been designed by applying a variety of modifications 
to the following reported compounds by Virofarma Inc.:
CHEMICAL STRUCTURE No. ICso
1 10
2 0.7
_ r -0 -@ 0 3 0.7
4 0.7
r f r ® 1 S s 5 0.7
6 0.7
7 0.7
The Virofarma compounds were subjected to a LigBuilder run using a variety of 
user defined seeds. A seed is the part of the compound that remains unchanged. 
The final compound will contain the seed and a variety of different substitutions 
added by the genetic algorithm of LigBuilder.
The 51 modifications of the original Virofarma compounds were docked using 
MOE to the HepC X-ray solved helicase and to the Dengue and West Nile helicase 
models. The docking parameters were kept constant to all dockings (same active 
site = same aligned residue number, 8000 iterations for 6  cycles). The aim of this 
study was to generate a wide variety of compounds in  silico, dock them and look 
for a consensus pattern and behaviour in those compounds.
The only conclusion that could be drawn was the same as established by the 
enzymatic assay in chapter 3 of this work: long and flexible “linker” regions 
behave better than rigid ones. Still though, the number of compounds tested is not 
large enough to be able to draw more useful conclusions (such as different 
preferences of the three different receptors). A wider range of compounds has to 
be designed and a more sensitive and exhaustive molecular docking protocol has to 
be established in order to be able to distinct small differences in ligand preference 
between the three viral helicases.
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